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Good prescribing of drugs for treatment or prevention of diseases published by the 
World Health Organization (WHO) involves the following six steps:1
1. Define the patient’s problem
2. Specify the therapeutic objective
3. Verify the suitability of your P(ersonal)‐drug
4. Write a prescription
5. Give information, instructions and warnings
6. Monitor (or stop?) the treatment
The P‐drug in step 3 is the drug the physician has chosen to prescribe first in a 
specific situation, and with which he/she has become familiar.1 The P‐drug is 
the priority choice for a given indication and includes the dosage form, dosage 
schedule and duration of treatment.1 This thesis largely focuses on patients with 
renal impairment. The P‐drug chosen may not be suitable or needs dose adjustment 
in patients with renal impairment. The risk‐benefit ratio in patients with renal 
impairment established in this step of good prescribing might be different from 
other patient populations without renal impairment. In addition, knowledge about 
the effects, both effectiveness and adverse drug reactions (ADRs), of drugs used in 
patients with renal impairment is limited. Therefore, if a drug is started in a patient 
with renal impairment, steps 5 and 6 in good prescribing of drugs will become even 
more important.
Personalized drug therapy management 
It is generally known that the principle ‘one size fits all’ is not appropriate in 
pharmacotherapy. Personalized medicine seeks to identify the right dose of the right 
drug for the right patient at the right time.2 The goal of personalized medicine 
is to optimize benefit and to reduce risk.3 A well‐known example of personalized 
medicine is the use of genotyping for the decision‐making of choosing the right 
drug and right dose. More than a decade ago, the first area where the idea of 
genotyping was proposed was psychiatry.4‐6 Most psychiatric drugs are metabolized 
by highly polymorphic CYP2D6 and CYP2C19 enzymes.7 Drugs which are mainly 
metabolized by CYP2D6 should be prescribed with caution in patients with none 
or few CYP2D6 enzymes, called poor metabolizers. For some drugs, for example 
venlafaxine, the advice is to choose another antidepressant.8 For other drugs a 
relation between genotype and drug dose was found. 
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The main difference between genotype and renal function, usually expressed 
as glomerular filtration rate (GFR), is that GFR fluctuates over time, in some 
situations even within a day. In addition, the estimated GFR (eGFR) is also prone 
to misinterpretation of the true GFR by influencing factors, which will be discussed 
in this thesis.10 In general, the genotype is measured once and is valid for a lifetime, 
whereas the renal function changes over time. All in all, drug dose adjustment in 
patients with renal impairment is also a form of personalized medicine.
Due to interindividual variation of drug response and clearance and the variation 
over time, personalized medicine is not a straightforward one‐time only approach.7 
In addition, the way patients are informed and instructed on drug use also needs to 
be personalized, based on education level. In other words, clinicians seek to identify 
the right dose of the right drug for the right patient over time. It will be a challenge 
to identify and recognize fluctuating factors, such as renal function, timely and 
adjust drug therapy whenever necessary. In patients with renal impairment drug 
dose advices are not only about changing a drug dose, but also about discontinuation 
of a drug or instructions on how to detect ADRs timely. Therefore the title of this 
Table 1.1 Dosing advice for nortriptyline based on genotype8
Table 1.2 Dosing advice for sotalol based on renal function9
These findings have led to guidelines for drug dose advices.7 Dosing advices are 
given categorically for poor, intermediate, extensive and ultra‐rapid metabolizers. 
For example nortriptyline, see Table 1.1.8
Genotype
Extensive metabolizer
Poor metabolizer
Intermediate metabolizer
Ultra rapid metabolizer
Normal dose
40% of normal dose
60% of normal dose
Choose an alternative or 160% of normal dose
Recommended daily dose of nortriptyline
Renal function group (ml/min/1.73m2)
50 - 80
30 - 49
10 - 29
< 10
Normal dose
Maximum of 160 mg
Maximum of 80 mg
No general advice
Recommended daily dose of sotalol
Personalized medicine in patients with renal impairment is basically not any 
different. Drug dose advices are given categorically per renal function group. For 
example sotalol, see Table 1.2.9 
10
Chapter 1 | Introduction   Introduction | Chapter 1 
thesis is ‘Personalized drug therapy management’ (PDTM) in patients with renal 
impairment.
Implementation of the guidelines ‘Drug dose advices in renal 
impairment’ in The Netherlands 
In recent years the focus on renal function and pharmacotherapy has increased. An 
important contribution to this, was the Hospital Admissions Related to Medication 
(HARM) study, which showed that 16,000 HARMs are potentially avoidable 
each year in The Netherlands.11 This finding prompted the HARM‐Wrestling 
report, which proposed about 40 practicable recommendations to reduce the most 
frequently occurring and potentially avoidable HARMs.12 About half of these 
recommendations concerned appropriate prescribing (e.g. adding a protective drug), 
a quarter concerned follow‐up procedures (e.g. laboratory monitoring, such as renal 
function tests), and another quarter concerned communication (with the patient 
and other healthcare providers). Of the practical recommendations half could be 
supported by combining medicines with laboratory values in a computer decision 
support system (CDSS). Leendertse et al. showed that 10% of the HARMs were 
considered to be related to a medication error and renal impairment.13 Parallel to 
the HARM study the Royal Dutch Association for the Advancement of Pharmacy 
created a handbook with drugs that need dose adjustment in patients with renal 
impairment or cannot be given to these patients.9
Approximately at the same time the Modification of Diet in Renal Disease (MDRD) 
formula was implemented in clinical chemistry laboratories in The Netherlands. This 
means that whenever a serum creatinine level is ordered, the eGFR is also reported. 
Reporting eGFR values in addition to serum creatinine led to a better recognition 
of impaired renal function and therefore it became easier to follow the guidelines for 
drug dose advices in renal impairment in daily clinical practice.
Some pharmacists adopted the renal drug handbook quickly and requested 
access to laboratory values.14 In the beginning (the first publication of the Dutch 
handbook ‘drug dose advices in renal impairment’ was in 2008) checking the renal 
function in relation to the prescribed drug (dose) was performed manually. In 
The Netherlands the drug dose advices in renal impairment are incorporated in a 
national drug database (the G‐standard) and from there they are available in basic 
pharmacotherapy‐related CDSS. To use this content it is required to turn on the 
diagnosis ‘renal impairment’ in the CDSS if applicable. The next step was and still 
is to incorporate laboratory values, such as renal function data, into these systems 
and create algorithms which take into account specific individual data. Several 
Chapter 1 | Introduction   Introduction | Chapter 1 
11
studies have shown that combining medication information with laboratory values 
in a CDSS resulted in less prescription errors.14,15 Pharmacists were inclined at first 
to implement drug dose advices in renal impairment directly and straightforward. 
In the communication with the physicians it appeared that this approach was not 
appropriate.16 The physicians were not familiar with the recommendations. Based 
on their clinical experience they felt that these recommendations were too rigid. 
Questions that physicians may ask were: “How strong is the evidence behind the 
advice? What is the degree of the risk when my patient gets an inappropriate drug 
or drug dose?”. These questions ensured that the evidence behind the guidelines was 
further examined. It appeared that the evidence was mainly based on case reports 
and pharmacokinetic studies in controlled environments. The lack of population‐
based studies and translation of the available evidence to daily clinical practice 
became the domain of this thesis.
Objective and outline of the thesis
This thesis aims to give insight into the validity of the MDRD formula used in 
prescribing drugs in renal impairment (Section 1), to add new evidence to evaluate 
existing guidelines (Section 2), and to give practical approaches for handling renally 
excreted drugs in patients with renal impairment in daily clinical practice (Section 3). 
Overall, its objective is to contribute knowledge that facilitates personalized drug 
therapy management, with a particular focus on patients with renal impairment.
When studying the development of the MDRD formula it appeared that the 
population used, does not always reflect the population seen at the community 
pharmacy or in the hospital care setting. Therefore the question arose how valid 
the MDRD formula is in specific patient populations. First, we focused on one 
patient population, namely patients with Human Immunodeficiency Virus (HIV) 
(Chapter 2). This allowed us to fine‐tune our selection and assessment criteria. 
Which aspects of a comparative study are important in a comprehensive assessment 
of the MDRD formula in different patient populations? The results of this systematic 
review about the validity of the MDRD formula in specific patient populations are 
presented in Chapter 3.
In the second part of this thesis we looked closer to the research evidence underlying 
the drug therapy recommendations in guidelines. We were especially interested 
in the frequently prescribed drugs nitrofurantoin and metformin. Both drugs are 
the drug of choice when, respectively urinary tract infection (UTI) in women or 
diabetes mellitus type 2 are diagnosed, but both drugs are also contraindicated 
when renal function drops below a specific level. Are patients with renal impairment 
12
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falsely withheld from a first choice drug? It appeared that the contraindication of 
these drugs in renal impairment was based on pharmacokinetic studies and case 
reports. We conducted two cohort studies. In the first study we determined whether 
treatment with nitrofurantoin in women with UTI and renal impairment in primary 
care was associated with a higher risk of ineffectiveness and/or serious ADRs than in 
women without renal impairment (Chapter 4). In the second study we determined 
whether treatment with metformin in patients with renal impairment was associated 
with a higher risk of lactic acidosis or elevated lactate levels compared to users of a 
non‐insulin antidiabetic drug who had never used metformin (Chapter 5).
A specific patient population is the elderly in the hospital care setting. Guidelines 
in primary care exist with information about how often renal function should be 
measured. From our clinical experience we noticed that their renal function during 
hospital admission may fluctuate, even within one day, and we wondered whether 
this was also the case after their discharge. In the current daily clinical practice, 
medication histories and laboratory values are sent to the community pharmacy 
and general practitioner after discharge from the hospital. As it seems likely that 
these laboratory values will be used for drug dose advices in the following months 
we present a study protocol in Chapter 6 to determine the fluctuation of the renal 
function after discharge from the hospital and its potential effect on appropriate 
prescriptions of drugs. The first results of this study are presented as well.
In the third and last part, we focused on drug therapy management in patients with 
renal impairment in daily clinical practice. In Chapter 7 we show the impact of 
an advanced pharmacotherapy‐related CDSS in identifying potential medication‐
related problems. This CDSS may be helpful in recognizing and optimizing PDTM. 
In view of the uncertainties surrounding the prescribing of drugs in patients with 
renal impairment we give a practical guidance in Chapter 8 on how to cope with 
these uncertainties in daily clinical practice.
Finally, the results of the studies are summarized and put into a broader perspective 
in Chapter 9.
Chapter 1 | Introduction   Introduction | Chapter 1 
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Abstract
Rationale, aims and objectives
Renal dysfunction is highly prevalent in HIV‐infected patients and may require 
dose adjustment of renally excreted antiretroviral drugs. The Modification of Diet 
in Renal Disease (MDRD)‐4 formula is frequently used in daily practice to estimate 
patients’ renal function. The aim of this systematic review was to assess the validity 
of the MDRD‐4 formula in HIV‐infected patients.
Method
A systematic search in Pubmed and EMBASE was done to identify studies which 
compared MDRD‐4 with measured glomerular filtration rate (mGFR) in HIV-
infected patients. 
Results
Five studies were included, which provided data from 464 HIV‐infected patients 
with mean mGFR ranging from 87 to 118 ml/min/1.73m2. In all studies, 
results from the MDRD‐4 gave an underestimation of the mGFR. Mean 
bias ((MDRD‐4) - mGFR) ranged from ‐6 to ‐11 ml/min/1.73m2 across studies. 
The accuracy expressed in terms of P30 ranged from 64% to 89%.
Conclusions
The MDRD‐4 formula is as valid in HIV‐positive as in HIV‐negative patients.
Because the available studies comprised mainly HIV‐infected patients with mildly 
impaired to good renal function (GFR ≥ 60 ml/min/1.73m2), more research is 
needed to validate the MDRD‐4 formula in HIV‐infected patients with moderate 
to severe renal impairment.
Validity of the MDRD formula in HIV-infected patients | Chapter 2
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Introduction
Individuals infected with human immunodeficiency virus (HIV) have an increased 
risk of kidney disease.1 HIV infection may result in HIV‐associated nephropathy, 
immune complex kidney disease and acute renal failure.2,3 These conditions are 
associated with progression to acquired immune deficiency syndrome (AIDS) and 
death.2,4 In addition, HIV itself may influence other risk factors for kidney disease, 
such as abnormal lipid levels, insulin resistance and microalbuminuria.5 A current 
estimate indicates a 30% prevalence of kidney dysfunction in HIV‐infected patients 
in developed countries, defined as an estimated renal function < 90 ml/min and 
concomitant proteinuria. Moreover, progression to end‐stage kidney disease, which 
may require haemodialysis, is common.4,6,7 The high prevalence of impaired renal 
function in HIV‐infected patients is indirectly related to the longer life expectancy 
in the highly active antiretroviral therapy (HAART) era.5,8,9 Routine monitoring of 
patients’ renal function is therefore an important component of personalized HIV 
care.3
In daily clinical practice, the Modification of Diet in Renal Disease (MDRD) 
formula is widely used to estimate the glomerular filtration rate (eGFR). The original 
6‐variable formula (serum creatinine concentration, age, sex, ethnicity, urea nitrogen 
and albumin concentrations), MDRD‐6, was developed for a sample of ambulatory, 
predominantly white patients with chronic kidney disease (CKD).10 Several years later 
(2000), this formula was simplified to 4 variables (serum creatinine concentration, 
age, sex and ethnicity), the MDRD‐4.11 The MDRD‐4 formula is based on serum 
creatinine concentration, which is a by‐product of muscle catabolism. Hence, 
serum creatinine is influenced by a person’s muscle mass. Creatinine production 
is also affected by factors such as diet, gender and age. In HIV‐infected patients, 
muscle mass may be lower and body composition may be different because of the 
disease itself or because of fat accumulation or redistribution due to antiretroviral 
treatment. Therefore, we hypothesized that the MDRD‐4 formula could lead to an 
overestimation of the true glomerular filtration rate (GFR) in this population.6,12–14
As an alternative, the GFR can be measured (mGFR) directly as the renal clearance 
of exogenous markers such as inulin, 51chromium ethylene-diamine-tetra-acetic acid 
(51Cr‐EDTA), technetium‐labelled diethylene‐triamine-pentacetate (99mTc‐DTPA), 
iothalamate and iohexol. However, these markers are impractical for routine clinical 
use due to limited access to necessary diagnostic facilities and the high cost.15,16
Accurate assessment of the GFR is necessary in the treatment of HIV. First, for 
timely detection and management of declining renal function. Second, to adjust the 
Chapter 2 | Validity of the MDRD formula in HIV-infected patients
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dose or change the type of antiretroviral agents and co‐medications appropriately. 
Dose adjustments for antiretroviral drugs in renal impairment are described in 
international HIV treatment guidelines.17
The aim of this review was to assess the validity of the eGFR based on the MDRD‐4 
formula in HIV‐infected patients.
Method
Search strategy
We performed a systematic review of published studies focused on the validity 
of the MDRD‐4 formula in HIV-infected patients. We searched the databases 
Pubmed and EMBASE for relevant literature from January 2000 (when the 
simplified MDRD‐4 formula was introduced11) until August 2012. We chose to 
limit our search strategy to the MDRD‐4 formula, because this formula is the most 
commonly used in clinical practice.18–20 The terms used for the overall search strategy 
are listed in Appendix 2.1. Titles and abstracts were reviewed independently by two 
authors (WE and PDS). Disagreements between the two reviewers were resolved 
by consensus. Subsequently, the reference lists of the selected articles were checked 
for additional articles.
Selection criteria
Articles were selected if they met the following criteria: (1) the study population 
consisted of HIV‐infected patients, (2) the MDRD‐4 formula was compared with 
a gold standard which included: 99mTc‐DTPA, inulin, 51Cr‐EDTA, 125I-iothalamate 
and iohexol, and (3) statistical analysis and reporting focused on bias, precision and/
or accuracy (definitions are described in Table 2.1).
The MDRD‐4 equations included are presented in Box 2.1.19 Proper use of the 
MDRD‐4 formula requires standardized serum creatinine measurements.19 
Standardized creatinine measurement for Scr (mg/dl)
175 x standardized Scr‐1.154 x age‐0.203 x 1.212 (if black) x 0.742 (if female)
Standardized creatinine measurement for Scr (umol/l)
30849 x standardized Scr‐1.154 x age‐0.203 x 1.212 (if black) x 0.742 (if female)
Not standardized creatinine measurement for Scr (mg/dl)
186 x standardized Scr‐1.154 x age‐0.203 x 1.212 (if black) x 0.742 (if female)
Not standardized creatinine measurement for Scr (umol/l)
32788 x standardized Scr‐1.154 x age‐0.203 x 1.212 (if black) x 0.742 (if female)
Scr = serum creatinine
Box 2.1 MDRD-4 equations
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Bias
Precision
Accuracy
Median dierence
Median percentage dierencea
Mean dierence
Mean percentage dierenceb
Inter quartile range (IQR) dierence
IQR percentage dierencea
Limits of agreement (LOA)
Standard deviation dierence (SD)
Pkc
Median absolute percentage error (mAPE)
Mean absolute percentage error (MAPE)
md eGFR – mGFR
md ((eGFR – mGFR)/mGFR) x 100% 
1/n x Σ (eGFR – mGFR)
1/n x Σ ((eGFR – mGFR)/mGFR) x 100%
IQR of (eGFR – mGFR) 
IQR of (eGFR – mGFR)/mGFR x 100% 
Mean dierence ± 1.96 SD
σ of all the individual dierences
Percentage of estimates within k% of mGFR
md ((|eGFR – mGFR|)/mGFR) x 100%
1/n x Σ ((|eGFR – mGFR|)/mGFR) x 100% 
6, 24
6
34 
44
24
24
34, 35
24, 34
24
44
44
References
a Preferred denition because a relative scale provides a more relevant metric.24
b In some articles the mean percentage dierence was called the mean percentage error (MPE).
c Preferred denition of accuracy. We limited our search to P10, P20, P30 and P50.
eGFR, estimated glomerular ltration rate; IQR, inter quartile range; LOA, limits of agreement; mGFR, measured glomerular 
ltration rate; md, median; SD, standard deviation.
After the introduction of isotope dilution mass spectrometry (IDMS)‐traceable 
calibration of serum creatinine assays the MDRD‐4 formula was re‐expressed in 
2007.19
Studies were excluded if they consisted of a case report, abstract of conference, 
poster, if patient selection was poorly described or if an article reproduced data 
already published elsewhere.
Abstracted data and outcomes reported in the included articles were summarized 
qualitatively, paying attention to the selection of the study population (age, 
sex and other factors influencing the generation, clearance or measurement of 
creatinine16,21), the mean mGFR and the outcome measurements defined in Table 2.1.
Results
Figure 2.1 shows the inclusion process of studies in the review. The initial database 
searches identified 49 articles. Scanning for title and abstracts resulted in 8 potentially 
relevant articles. A further 2 potentially relevant articles were found by searching 
their reference lists. Of these, 5 studies fulfilled the inclusion criteria.
Table 2.1. Definitions outcome measurements
Chapter 2 | Validity of the MDRD formula in HIV-infected patients
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Figure 2.1. Results of search strategy
Pubmed
n = 22
Duplicates removed
n = 13
EMBASE
n = 27
Total
n = 49
Citations screened
n = 36
Articles
n = 8
Excluded by title and abstract review
n = 28
Articles from 
reference review
(n = +2)
n = 10
Articles included
n = 5
Articles exluded by article review
n = 5
The use of other statistic methods focused on the 
correlation, not the agreement (n = 3).
Did not fulﬁll the gold standard criteria (n = 3).
The inclusion of the HIV population was not well 
described (n = 1). 
(Articles could be excluded for more than one reason.) 
In Table 2.2 the most important information about these studies is summarized. 
They were conducted in four different countries: the United States of America, 
Canada, Thailand and The Netherlands. The studies were published between 2009 
and 2012. The number of patients included ranged from 19 to 200.8,22 The patient 
characteristics, such as age, sex and body mass index (BMI), differed among the 
studies. In the study of Praditpornsilpa et al. the mean age was approximately 
10 years lower than in the studies of Beringer et al. and Barraclough et al.6,14,23 
The percentage of men varied between 57% and 95%.8,23 In the study population 
of Barraclough et al. the majority of patients had abnormal body composition 
(lipodistrophy is common in patients with HIV). This factor did not seem to 
influence the eGFR (data not reported).14 The ethnicity of the study populations 
was also different. The study of Barraclough et al. consisted of mostly Caucasians14, 
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whereas the population of Inker et al. consisted for 52% of blacks. The gold standards 
used were iothalamate in the studies of Beringer et al.6  and Vrouenraets et al.8, 
99mTc-DTPA in the studies of Barraclough et al.14 and Praditpornsilpa et al.23 and 
iohexol in the study of Inker et al.22
Of note, the majority of patients included had mild renal impairment to normal 
renal function. mGFRs ranged from 23 to 175 ml/min/1.73m2 with mean mGFRs 
ranging from 87 to 118 ml/min/1.73m2.22,23
All five studies reported that the eGFR underestimated the mGFR. The highest 
underestimation was reported as a median bias of -11 ml/min/1.73m2 in the study 
of Inker et al.22 The underestimations in the study of Beringer et al., Barraclough et 
al. and Vrouenraets et al. were in the same range, namely -10 ml/min/1.73m2.6,8,14 
The mean bias in the study of Praditpornsilpa et al. was reported as a mean bias of 
-6 ml/min/1.73m2.23
The precision was presented in terms of interquartile ranges (IQR), limits of 
agreement (LOA) and standard deviation (SD) of the mean difference. The precision 
(presented as the preferred IQR percentage difference24) seemed better in the study 
by Barraclough et al.14 (-21 to 2 ml/min/1.73m2) than in the study by Beringer et al.6 
(-31% to 19%). The LOA in the study of Praditpornsilpa et al.23 was very wide, namely 
-63 to 50 ml/min/1.73m2, whereas the SD reported in the study of Vrouenraets 
et al.8 seemed smaller, namely 17 ml/min/1.73m2. The accuracy presented as the 
proportion of the eGFR values falling within a predefined percentage of the mGFR 
values (30% expressed as P30 and 50% expressed as P50) ranged in 4 out of 5 studies 
from 80% to 89%.8,14,22,23 Only the study of Beringer et al. reported a substantially 
lower P30 of 64%.6 The P50 reported by Beringer et al. and Barraclough et al. were 
similar, about 100%.6,14
For 27 patients with renal impairment (< 60 ml/min/1.73m2) the study of Inker et al. 
reported a bias, precision and accuracy of -12 ml/min/1.73m2, 19 ml/min/1.73m2 
and 67%, respectively.22
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Table 2.2 Patient characteristics and outcomes of the included studies
Article Sampling procedure AgeDiagnosis
Beringer et al., 
2010, United 
States6
Barraclough et 
al., 2009, 
Canada14
51.0 
range: 
41.5-60.3
52 ± 9
43.6 ± 7.8
HIV (n = 22)
HIV (n = 27)
Praditpornsilpa 
et al., 2012, 
ailand23
HIV (n = 196)
HIV clinic;
Inclusion criteria: age > 18, HIV, stable HIV treatment and stable 
kidney function over 3 months before study entry.
Exclusion criteria: allergy to iodine or contrast media, anemia or 
pregnancy. Fluid restricted or receiving drugs known to alter 
excretion of creatinine.
March 2007 to August 2008.
Inclusion criteria: HIV-infected adults over 18 years of age 
followed in the HIV clinic.
Exclusion criteria: acute illness, unstable renal function (variation 
Scr > 27 umol/l) in the previous 6 weeks, pregnancy and refusal to 
provide inform consent.
Inclusion criteria: stable HIV-infected adults over 18 years of age. 
Exclusion criteria: acute renal failure, amputation, malnutrition 
(BMI < 18 kg/m2), in a bed ridden state, with infection, 
edematous, gastrointestinal bleeding, heart failure or hospitalized.
Vrouenraets et 
al., 2012, e 
Netherlands8
Inker et al., 
2012, United 
States22
46 ± 8.9
48 ± 8
HIV (n = 19)
HIV (n = 200)
Inclusion criteria: HIV-1 infected, age ≥ 18, males or non-preg-
nant non-lactating females, and other criteria as part of a 
multinational randomized trial. Exclusion criteria: renal 
impairment (eGFR < 50 ml/min), concomitant therapy with 
nephrotoxic or investigational drugs, chronic active viral hepatitis, 
or other chronic liver disease and other criteria as part of a 
multinational randomized trial.
Inclusion criteria: age > 18 years, stable on ART for at least three 
months, conrmed HIV status, HIV viral load and CD4 count 
within 6 months of recruitment.
Exclusion criteria: pregnancy, allergy or contraindication for 
iohexol or iodine, recent acute kidney injury, cognitive or physical 
impairments, use of cimetidine.
(n = number
of patients)
(years)
a the glomerular ltration rate was measured with one of the following gold standards: [1] (125I-) iothalamate, [2] technecium-labelled 
diethylenetriaminepentacetate (99mTc-DTPA), [3] inulin, [4] 51chromium ethylenediaminetetraacetic acid (51Cr-EDTA) or [5] iohexol.
b the population consisted of ai ethnicity, therefore the results of the re-expressed MDRD-4 formula with ai racial correction 
factor were presented. 
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Sex Inuencing 
factors
Mean mGFRa Bias Precision Accuracy
72.7 111[1]
range: 50.4-145
median(%): -9.56 IQR(%): 
-30.5 to 18.7
P30: 64 
P50: 95
BMI (kg/m2) = 
27.1 (21.9-30.4) 
African-American: 
36%
85 91[2]
range: 84-114
median: -10 IQR: 
-21 to 2
P10: 22 
P20: 59
P30: 89 
P50: 100
BMI (kg/m2) = 
24.6 (21.7-26.0) 
Diabetes: 7% 
Hypertension: 26%
57 117.7 ± 29.2[2] mean: -6.2b LOA:
-62.7 to 50.4b
P30: 84b BMI (kg/m2) = 
22.3 ± 3.2
Diabetes: 7% 
Hypertension: 15%
95 102 ± 19[1] mean:  -10 SD: 17 P30: 89 BMI (kg/m2) = 
23.9 ± 3.0
73 87 ± 26[5] median: -10.9 IQR: 21.7 P30: 80 BMI (kg/m2) = 
27 ± 6
Blacks: 52% 
Diabetes: 8% 
Hypertension: 31%
(% men) (ml/min/1.73m2) (ml/min/1.73m2) (ml/min/1.73m2) (%)
ART, antiretroviral therapy; AZT, zidovudine; BMI, body mass index; eGFR, estimated glomerular ltration rate; HIV, human 
immunodeciency virus; IQR, inter quartile range; LOA, limits of agreement; mGFR, measured glomerular ltration rate; RNA, 
ribonucleic acid; Scr, serum creatinine; SD, standard deviation; 3TC, lamivudine.
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Discussion
Although the MDRD-4 formula is widely used in clinical practice to estimate the 
GFR in HIV-infected patients, we found few studies which had investigated the 
validity of the MDRD-4 formula in this specific group of patients. The five studies 
found reported a systematic underestimation of the GFR when using the MDRD-4 
formula compared to the mGFR using gold standards (bias ranging from -6 to -11 ml/
min/1.73m2).6,8,14,22,23 This small underestimation of the GFR is similar to that in 
HIV-negative adults.5,25 It should be noted that the majority of HIV-infected patients 
included had mildly impaired to good renal function (GFR ≥ 60 ml/min/1.73m2). 
The study of Inker et al. included 27 patients with a mGFR < 60 ml/min/1.73m2. 
The underestimation reported for this subpopulation was -12 ml/min/1.73m2.22
Untreated HIV infection increases energy requirements while it decreases appetite 
and, in more advanced stages, it limits the intake and absorption of nutrients.26 
Therefore we hypothesized beforehand that some of the HIV-infected patients 
would have a lower muscle mass, which should result in an overestimation of the 
renal function using the MDRD-4 formula.6,12–14 However, the findings of the 
included studies present an underestimation. An explanation might be that the 
majority of the included patients had a normal BMI. The overall well-nourished 
HIV-infected patient population might partially be explained by the post-HAART 
era.14 However, physicians should remain aware of the possibility that the eGFR 
can be overestimated in HIV-infected patients, for example, when there is HIV-
associated wasting or a late presentation of the disease. More research is needed in 
this specific HIV-infected subpopulation.
In studies with black African HIV-infected patients, lower body weight 
(BMI < 20 kg/m2) was represented to a greater extent.12,15 Both studies suggested 
a small overestimation of the renal function using the MDRD-4 formula in these 
patients.12,15 Remarkably, these latter studies found that the correction factor of 
1.212 which has been included in the MDRD-4 formula for Black Americans is not 
applicable to the Black African population.12,15 The study of Praditpornsilpa et al. 
showed that the addition of the correction factor of 1.129 for Thai ethnicity resulted 
in a more accurate estimation of the GFR.23 However, this correction factor is not 
generalizable to other Asian ethnicities, as the correction factors for Japanese and 
Chinese populations are different, namely 1.23 and 0.88 respectively.23
The validity of the MDRD formula has also been determined in various other 
patient populations, with specific diseases.27–29 For example, in liver diseases the 
production of creatinine is low. A low serum creatinine level leads to a higher 
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eGFR calculated with the MDRD formula. In patients with cirrhosis the MDRD 
substantially overestimated the measured renal function.27,30 Bilo et al. found an 
overestimation of the renal function using the MDRD formula in patients with 
diabetes mellitus.29 In patients with various types of cancers the MDRD formula 
was not reliable at all.31–33 Further validation of the MDRD formula in specific 
patient populations is recommended, because it is widely used to personalize 
pharmacotherapy in renal impairment and to recognize decline in renal function.
This systematic review had several limitations. The studies were conducted in 
developed countries and mainly concerned patients with mildly impaired or good 
renal function. Since patients with a GFR < 60 ml/min/1.73m2 were poorly 
represented in the studies, further research is needed to validate the MDRD-4 
formula in HIV-infected patients with moderate to severe CKD.
We excluded studies which did not fulfil our criteria concerning statistical analysis. 
A frequently used method to compare different formulas to estimate the GFR is the 
correlation coefficient.3,7 However, the most informative method to assess diagnostic 
tests is the Bland-Altman plot as this identifies the direction and the magnitude of 
the bias.24,34,35 Apparently there is no consensus on how to present the agreement 
between two diagnostic tests. This is needed to interpret studies with the aim to 
compare diagnostic tests easily and in the same way.
Another limitation is the lack of details concerning other potentially influential factors. 
Many factors can influence the generation, clearance or measurement of creatinine, 
such as diabetes, liver disease, obesity, malnutrition, muscle wasting, amputation, 
hospitalization, vegetarian diet, ingestion of cooked meat, neuromuscular diseases, 
inflammation, ethnicity and medication (such as trimethoprim, cimetidine, some 
cephalosporins).16,21 The studies included did not adequately specify to which extent 
these factors were present or absent in their patient population.
The results of this review do not suggest a correction factor for HIV-infected 
patients with normal BMI in the MDRD-4 formula. Although more evidence 
is needed, especially in moderate to severe renal impairment, physicians may use 
the MDRD-4 formula in clinical practice to personalize pharmacotherapy. The 
use of the MDRD-4 formula instead of the Cockcroft-Gault (CG) formula in 
drug dosing has been debated in general in the literature. Hudson et al. found 
that the MDRD estimate results in higher doses compared to the CG formula.36 
Conversely, Stevens et al. found a high concordance rate between the MDRD and 
CG formula compared to mGFR (determined with 125I-iothalamate), namely 88% 
and 85%, respectively (p < 0.001).37 The Food and Drug Administration now allows 
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manufacturers to provide drug dosing advice based on CG or MDRD formulas.36,38 
The applicability of the Chronic Kidney Disease EPIdemiology (CKD-EPI) 
formula is also discussed. The CKD-EPI formula exhibits more or less similar 
accuracy as the MDRD formula in non-HIV and HIV-infected patients for the 
lower ranges of the GFR (< 60 ml/min/1.73m2) where dose adjustment usually 
should take place.39–41 In the higher ranges of the GFR (≥ 60 ml/min/1.73m2) 
the CKD-EPI performs better than the MDRD-4 formula.18 Further research 
should include the CKD-EPI formula in addition to the MDRD formula.
In patients with renal impairment the first step is adjusting the dosage of antiretroviral 
agents according to international HIV treatment guidelines. For some antiretroviral 
agents therapeutic drug monitoring might be considered.42 Switching to another 
antiretroviral drug which is not renally excreted needs to be considered in renal 
impairment, although possibilities may be limited in some patients, for instance, 
because of drug resistance. Physicians should always be aware that personalizing 
pharmacotherapy is a consideration between efficacy and toxicity, especially in HIV-
infected patients where drug resistance is of major concern.43
In addition the clinical relevance of the potential inaccuracy of the eGFR in HIV-
infected patients needs to be considered. The reliability of a formula depends on 
bias and precision. Both measurements are combined in the term ‘accuracy’. The 
K/DOQI guidelines state that a deviation of 30% from the true GFR is acceptable. 
Ideally, when the accuracy is defined as P30 this measurement should reach 
100%.6,14 However, the included studies showed a P30 beneath 100%. The studies of 
Barraclough et al.14 and Vrouenraets et al.8 with a P30 of 89% and 89%, respectively, 
came nearby, but in the population of Beringer et al.6 P30 was only 64%, meaning 
that the eGFR will deviate by more than 30% from the true GFR in almost 1/3 of 
cases.
An accurate eGFR is increasingly important because of the longer life-expectancy of 
HIV-infected patients with associated co-morbidities such as diabetes mellitus and 
hypertension. Although the median bias has a negative direction, the range of the 
precision shows that the MDRD-4 formula can also overestimate the true GFR in 
HIV-infected patients. This may lead to an early or late start of the management of 
impaired renal function, but also to incorrect dosing of antiretroviral drugs or co-
medication, because the GFR may point at an incorrect category of CKD.
Based on the available information we found no indication that in good to mild 
impaired renal function (GFR ≥ 60 ml/min/1.73m2) the MDRD-4 formula is less 
valid in HIV-positive patients compared to HIV-negative patients. Since patients with 
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a GFR < 60 ml/min/1.73m2 were poorly represented by the studies, further research 
is needed to validate the MDRD-4 formula in HIV-infected patients with moderate 
to severe CKD. In selected situations, such as in patients with severe renal impairment 
or in patients who suffer from the HIV-wasting syndrome, measurement of the GFR 
with a gold standard rather than using the MDRD formula should be considered.
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Appendix 2.1 Search terms
“Predictive Value of Tests”[Mesh Terms] OR “Reference Values”[Mesh Terms] OR predictive value* OR 
reference value*
limitation OR limitations
pitfalls OR pitfall
overestimated OR underestimated OR underestimation OR overestimation OR overestimating OR underestimating
disturbance OR interference 
“diagnostic errors”[MeSH Terms] OR (diagnostic AND errors)
“sensitivity and speci­city”[MeSH Terms] OR sensitivity OR speci­city
marker OR markers OR “Biological Markers”[Mesh Terms]
accurate OR inaccurate OR inaccuracy OR accuracy
Assessment of the renal function 
Reliability
Glomerular ­ltration rate and creatinine
Creatinine-based formulas
(cockcroft AND gault) OR cockcroft-gault OR MDRD OR (modi­cation AND diet) OR 
“kidney diseases”[MeSH Terms] OR (kidney AND diseases) OR renal disease
Date of publication
2000 – current (August 2012)
Diagnosis
Human immunode­ciency virus OR “HIV”[MeSH Terms] OR HIV
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Abstract
Background
The Modification of Diet in Renal Disease (MDRD) formula is widely used in 
clinical practice to assess the correct drug dose. This formula is based on serum 
creatinine levels which might be influenced by chronic diseases itself or the effects of 
the chronic diseases. We conducted a systematic review to determine the validity of 
the MDRD formula in specific patient populations with renal impairment: elderly, 
hospitalized and obese patients, patients with cardiovascular diseases, cancer, chronic 
respiratory diseases, diabetes mellitus, liver cirrhosis and human immunodeficiency 
virus.
Methods and findings
We searched for articles in Pubmed published from January 1999 through January 
2014. Selection criteria were (1) patients with a glomerular filtration rate (GFR) 
< 60 ml/min(/1.73m2), (2) MDRD formula compared with a gold standard, and 
(3) statistical analysis focused on bias, precision and/or accuracy. Data extraction 
was done by the first author and checked by a second author. A bias of 20% or less, 
a precision of 30% or less and an accuracy expressed as P30 of 80% or higher were 
indicators of the validity of the MDRD formula. In total we included 27 studies. 
The number of patients included ranged from 8 to 1831. The gold standard and 
measurement method used varied across the studies. For none of the specific patient 
populations the studies provided sufficient evidence of validity of the MDRD 
formula regarding the three parameters. For patients with diabetes mellitus and liver 
cirrhosis, hospitalized patients and elderly with moderate to severe renal impairment 
we concluded that the MDRD formula is not valid. Limitations of the review are 
the lack of considering the method of measuring serum creatinine levels and the 
type of gold standard used.
Conclusion
In several specific patient populations with renal impairment the use of the MDRD 
formula is not valid or has uncertain validity.
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Introduction
Chronic kidney disease (CKD) is a common condition and affects up to 13% of 
the population.1 CKD is defined as a glomerular filtration rate (GFR) < 60 ml/
min/1.73m2 or evidence of kidney damage (proteinuria, haematuria and/or 
abnormalities of the kidney) for at least 3 months regardless of underlying cause.2,3 
CKD is associated with adverse outcomes, such as kidney failure, cardiovascular 
diseases and death.2,4,5 Since laboratories routinely report the estimated GFR 
(eGFR) if serum creatinine testing is ordered, the awareness of impaired renal 
function among physicians has increased in recent years.6-8
The eGFR is not only used to diagnose CKD or to monitor its course in patients with 
kidney disease, but also to guide decisions in pharmacotherapy. Potential uses of the 
eGFR in drug therapy are: (1) signal that treatment of CKD is warranted, (2) signal 
that a drug may be contraindicated, (3) signal that renal drug toxicity is developing, 
(4) signal that the risk of an adverse drug reaction or drug-drug interaction may be 
increased or (5) signal that a drug may be less effective. Approximately 20-30% of 
adverse drug reactions (ADRs) leading to hospital admission of elderly patients are 
related to impaired renal function.9,10 This was mainly due to excessive doses of drugs 
and could have been avoided by close monitoring of renal function and adjustment of 
pharmacotherapy in terms of the prescribed agent(s) and/or the prescribed dosage(s).9
Drug dosing recommendations traditionally have used the Cockcroft and Gault 
(CG) formula to estimate creatinine clearance and therefore the ability of the kidney 
to excrete drugs.6,11 This formula was developed in 249 adult men by using the mean 
24-h urine creatinine excretion from two urine collections.12,13 The adjustment factor 
for women was based on a theoretical 15% lower muscle mass.13,14 Approximately 
15 years ago a new formula was developed that provided a more accurate estimation 
of GFR.15,16 The original six variable Modification of Diet in Renal Disease (MDRD) 
formula, MDRD-6, was developed in a sample of 1070 ambulatory, predominantly 
white patients with CKD.15 The six variables were serum creatinine concentration, 
age, sex, ethnicity, serum urea nitrogen concentration and albumin concentration.15 
Several years later (in the year 2000), this formula was simplified to 4 variables 
(serum creatinine concentration, age, sex and ethnicity), MDRD-4.16 The latter is 
now routinely used by many clinical laboratories worldwide.17-20 Variability in the use 
of different creatinine assays among clinical laboratories led to the introduction of 
isotope dilution mass spectrometry (IDMS) calibration of the creatinine assays.17,21,22 
This led to the re-expression of the MDRD formulas. The MDRD formulas are 
presented in Box 3.1.
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MDRD-615
170 x Scr -0.999 x age-0.176 x BUN-0.170 x albumin+0.318 x 1.180 (if black) x 0.762 (if female) 
Re-expressed after IDMS calibration21
161.5 x Scr-0.999 x age-0.176 x BUN-0.170 x albumin+0.318 x 1.180 (if black) x 0.762 (if female)
MDRD-416
186 x Scr-1.154 x age-0.203 x 1.212 (if black) x 0.742 (if female)
Re-expressed after IDMS calibration21
175 x Scr-1.154 x age-0.203 x 1.212 (if black) x 0.742 (if female)
Scr = serum creatinine (mg/dl)
BUN = blood urea nitrogen (mg/dl)
Albumin (g/dl)
Although there is an ongoing debate on whether the MDRD formula can safely 
replace the CG formula in drug dosing20,23, the MDRD formula is now widely used 
in clinical practice for drug dosing in various patient populations.19,24,25 The aim of 
this article is to review systematically the validity and limitations of the MDRD 
formula in specific patient populations with a known glomerular filtration rate below 
60 ml/min where adjustment of the pharmacotherapy usually should take place.
Background
The MDRD formula is an estimation of the true GFR. The true GFR is the 
product of the filtration rate in single nephrons and the number of nephrons in both 
kidneys.4 The ideal filtration marker to determine the true GFR is freely filtered 
across capillary walls, unhindered by its size, charge or binding to plasma proteins 
and neither secreted nor reabsorbed.4 Inulin fulfils these criteria, but is not widely 
used for this purpose in clinical practice, because of the necessity for intravenous 
infusion and the difficult chemical assay required for inulin measurement.26 The 
true GFR can also be measured using other markers such as 51chromium ethylene-
diamine-tetra-acetic acid (51Cr-EDTA), technetium-labelled diethylene-triamine-
pentacetate (99mTc-DTPA), iohexol and iothalamate.27 However, these markers are 
also impractical for routine clinical use due to limited access to necessary diagnostic 
facilities and high costs.3,28
Creatinine is generally considered a good filtration marker to estimate the renal 
function in routine clinical practice. Serum creatinine level is a function of endogenous 
creatinine production, exogenous creatinine supply and renal elimination (glomerular 
filtration and tubular secretion).29 There is a clear inverse correlation between serum 
creatinine levels and the true GFR. However there are several factors which may 
influence serum creatinine levels without affecting GFR itself, which potentially 
distort the interpretation of values for clinical use (see Figure 3.1).3,4,27,30,31
Box 3.1 MDRD equations
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Figure 3.1. Determinants of serum creatinine level
Endogenous creatinine production
Creatinine is formed primarily in skeletal muscles from creatine and creatine 
phosphate.29 Muscle mass is the most important determinant of total body creatine 
content and therefore of the creatinine production.26 Muscle mass is related to age, 
sex and race.4,26,32 Although the MDRD formula corrects for age, sex and race, the 
formula assumes an average muscle mass. However, muscle mass can deviate across 
individuals in anabolic or catabolic conditions. Thus, muscle-waisting conditions, 
e.g. due to neuromuscular disease, chronic glucocorticoid therapy, hyperthyroidism, 
amputation or progressive muscular dystrophy are associated with decreased 
creatinine production, whereas exercise and body building are associated with 
increased creatinine generation.4,26,32 In diseases with abnormally low muscle mass, 
serum creatinine levels will be relatively low, leading to an overestimation of the 
GFR, whereas the opposite will occur when the muscle mass is abnormally high.
In addition, the liver plays a major role in the biosynthesis of creatine. The rate of 
creatine formation and therefore the rate of creatinine production in the muscles is 
reduced in certain types of hepatic diseases.33
Laboratory
assay
Renal elimination by
tubular secretion
Renal elimination by
glomerular ﬁltration rate
Extrarenal elimination by
gastrointestinal degradation
(     by broad spectre antibiotics)
Endogenous supply 
by muscle mass
Serum
creatinine
Estimated 
glomerular
ﬁltration rate
Exogenous supply
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Exogenous creatinine supply
Dietary intake of creatinine and creatine can be either unusually high (ingestion of 
cooked meat, creatine supplementation) or unusually low (vegetarian diet).4,26 This 
may lead to underestimation and overestimation of the GFR, respectively.
Laboratory assay of serum creatinine
Two assays are now mostly used in clinical practice to measure serum creatinine levels, 
namely the alkaline picrate assay (Jaffe) and the enzymatic assay. The Jaffe assay is 
known to have more interfering substances than the enzymatic method, which may 
result in a deviation of the true serum creatinine level up to 20%.3,34 Substances 
which interfere with the Jaffe assay and may lead to an overestimation of serum 
creatinine levels include bilirubine, 5-aminolevulic acid, and high dose of lactulose. 
High doses of furosemide may lead to an underestimation of serum creatinine levels 
and cephalosporins may lead to both over- and underestimation of serum creatinine 
levels.35-39 Substances which interfere with the enzymatic assay include dopamine, 
dobutamine, glucose and flucytosine.26,35,36 These interferences may lead to an 
underestimation of serum creatinine levels and therefore an overestimation of the 
GFR, except for flucytosine. Flucytosine may overestimate serum creatinine levels 
with more than 100% and therefore underestimate the GFR.36
In addition to interferences of certain drugs in the creatinine assays, there are also 
differences in creatinine values between clinical laboratories due to differences in the 
creatinine assays and their calibration. Therefore an uniform creatinine measurement 
and an universal known calibration of the serum creatinine assays has led to the 
introduction of IDMS calibration.18,40
Creatinine secretion
Creatinine is not only excreted by glomerular filtration, but also by the renal tubules. 
In addition, in patients with severe renal impairment a substantial fraction of the 
daily creatinine production is eliminated via extrarenal routes.26 This might lead to 
relatively low serum creatinine levels, leading to an overestimation of the GFR. The 
creatinine secretion might also be altered in situations such as trauma, prolonged 
immobilization and hepatic disease.26 The etiology of these changes is unknown. 
Some drugs, such as cimetidine, trimethoprim and fibrates (except gemfibrozil) also 
alter the secretion of creatinine due to inhibition of the tubular secretion.4,36,41 As 
a result serum creatinine levels will increase, independent of the GFR, and the use 
of serum creatinine based formulas will thus cause an underestimation of GFR. Of 
note, blocking creatinine secretion ensures a better reflection of the true GFR with 
creatinine-based formulas.42,43
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Serum creatinine levels thus provide only a rough guide to the true GFR.26 While 
the dependence of serum creatinine on muscle mass is partially accounted for in 
the MDRD formula (age, sex and race), various other factors influencing both 
production and secretion of creatinine can be present. Awareness of these limitations 
of creatinine-based formulas which estimate GFR is therefore necessary. In addition, 
variability in eGFRs also includes underlying biological intraindividual and 
interindividual variation of serum creatinine values ranging from 6.3% to 17%.12,22,44
Of note, serum creatinine levels and creatinine based formulas should only be 
used in patients with stable renal function. In cases of rapidly changing GFR, the 
actual serum creatinine levels will not reflect the GFR until steady-state has been 
reached.45 A diagnosis of a low GFR must therefore rely on multiple measures of 
serum creatinine levels.46
Methods
Search strategy
We performed a systematic search in the Pubmed database for published studies 
about the validity of the MDRD formula in diverse patient populations. The 
search focused on publications between January 1999 (the introduction of the 
MDRD formula15) and January 2014. We searched for both the MDRD-4 and 
MDRD-6 formulas. The terms used for the overall search strategy have been listed 
in Appendix 3.1.
Selection criteria
We focused on studies in patients with a measured GFR (mGFR) or estimated GFR 
(eGFR) < 60 ml/min(/1.73m2). Other selection criteria were: (1) MDRD formula 
compared with a gold standard (defined as: 99mTc-DTPA, inulin (including the 
analogue sinistrin47), 51Cr-EDTA, 125I- iothalamate and iohexol) and (2) statistical 
analysis and reporting focused on bias, precision and/or accuracy (see Table 3.1 for 
definitions).
We excluded case reports, abstracts, and posters. Articles which reproduced data 
already published elsewhere were carefully reviewed. Only if newer data added 
information to our review, the article was included.
Selection of patient populations
In this review we will first discuss three more general patient groups, which were 
inadequately represented in the development of the MDRD formula, namely (1) 
elderly patients, (2) hospitalized patients and (3) obese patients.
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The MDRD formula was developed in a relatively young patient population (mean 
age: 51 ± 13 years) with CKD.15,48 The mean body weight was 79.6 ± 16.8 kg and 
the mean body surface area (BSA) was 1.91 ± 0.23 m2.15 The body mass index 
(BMI) calculated from the mean weight and BSA is approximately 28 kg/m2, so the 
population was not obese (> 30 kg/m2) as a whole. Creatinine production decreases 
Table 3.1 Definitions outcome measurements
Bias
Precision
Accuracy
Median dierence
Median percentage dierencea
Mean dierence
Mean percentage dierenceb
Inter quartile range (IQR) dierence
IQR percentage dierencea
Limits of agreement (LOA)
Standard deviation dierence (SD)
Pkc
Median absolute percentage error (mAPE)
Mean absolute percentage error (MAPE)
md eGFR – mGFR
md ((eGFR – mGFR)/mGFR) x 100% 
1/n x Σ (eGFR – mGFR)
1/n x Σ ((eGFR – mGFR)/mGFR) x 100%
IQR of (eGFR – mGFR) 
IQR of (eGFR – mGFR)/mGFR x 100% 
Mean dierence ± 1.96 SD
σ of all the individual dierences
Percentage of estimates within k% of mGFR
md ((|eGFR – mGFR|)/mGFR) x 100%
1/n x Σ ((|eGFR – mGFR|)/mGFR) x 100% 
67, 120
120
135
142
67
67
135, 136
67,135
67
142
142
References
a Preferred denition because a relative scale provides a more relevant metric.24
b In some articles the mean percentage dierence was called the mean percentage error (MPE).
c Preferred denition of accuracy. We limited our search to P10, P20, P30 and P50.
eGFR, estimated glomerular ltration rate; IQR, inter quartile range; LOA, limits of agreement; mGFR, measured glomerular 
ltration rate; md, median; SD, standard deviation.
as muscle mass decreases with age or due to immobility, which is common in 
hospitalized patients.49 When this results in low serum creatinine levels creatinine-
based formulas may overestimate the GFR.50 In addition, elderly, malnourished, 
and immobilized patients are at special risk of having depressed GFR but normal 
serum creatinine levels, so normal serum creatinine concentration cannot exclude 
significant renal impairment.51-53 Because of these considerations we found elderly 
patients (≥ 65 years), hospitalized patients and obese patients (> 30 kg/m2) of interest 
for further evaluation.
Second, we will discuss four common categories of chronic diseases, which are 
the leading cause of death in the developed world: (4) cardiovascular diseases (e.g. 
myocardial infarction, heart failure and stroke), (5) cancer, (6) chronic respiratory 
diseases (like chronic obstructed pulmonary disease (COPD) and asthma), and (7) 
diabetes mellitus.54 These diseases are associated with the use of multiple drugs of 
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which a substantial part is renally excreted. The chronic diseases itself or the effects 
of the chronic diseases may alter serum creatinine levels without affecting GFR 
itself. In patients with chronic heart failure, a cardiovascular disease, the effective 
circulating volume is reduced, blood pressure is low and therefore renal perfusion 
pressure is reduced, leading to reduced filtration rate in viable nephrons and probably 
also to reduced excretion of creatinine.55,56 The tubuli, however, are still capable of 
secreting creatinine actively.55 In addition, the cornerstone in heart failure therapy 
are renin-angiotensin-aldosterone-system (RAAS)-inhibitors, which also may 
reduce glomerular filtration pressure and therefore excretion of creatinine.56 These 
different mechanisms may influence serum creatinine levels. In addition, patients 
with heart failure are often immobile and therefore at risk for having lower serum 
creatinine levels.
In cancer and COPD unknown mechanisms may influence creatinine levels without 
affecting GFR, but reduced muscle mass and malnourishment may also be present. 
This latter may result in low serum creatinine levels and therefore in overestimation 
of the GFR. In diabetes mellitus, the choice of drugs or dosages is influenced by 
GFR.57
Finally, we searched for articles about (8) other chronic diseases in which reduced 
muscle mass (mainly due to immobility and malnutrition) can be present, which 
may render the MDRD formula less valid. Such diseases include neuromuscular 
diseases, rheumatoid arthritis, cystic fibrosis, human immunodeficiency virus (HIV) 
and liver diseases.58-62 In certain liver diseases the production of serum creatinine is 
also reduced to approximately one half of the rate of patients with normal hepatic 
function.58,60,63 Hyperbilirubinemia is also common among patients with liver 
diseases. Elevated serum bilirubine levels interfere with the Jaffe method to measure 
creatinine, which might lead to misleadingly low serum creatinine levels.35,58,64
Extraction of studies
The data and outcomes reported in the selected articles were summarized, specifically 
focusing on the selection of the study population, age, mean mGFR, type of 
creatinine assay used, type of gold standard used, mean eGFR and the outcome 
measures as defined in Table 3.1. Data extraction was done by the first author (WE) 
and checked by a second author (MW). 
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Description of the findings focused on:
a. number of patients included;
b. outcome measures;
c. method of measuring true GFR.27,65
Ad (a) number of patients included
Preferably more than 100 patients should be included.5,17 Studies with more than 
100 patients included were considered of higher value in the interpretation than 
studies with less than 100 patients.
Ad (b) outcome measures
One of our inclusion criteria concerned the presence of outcome measures: bias, 
precision and accuracy. Bias represents systematic error, precision represents random 
error and accuracy represents both (see Figure 3.2).
1 2 3 4
unbiased
imprecise
inaccurate
biased
imprecise
inaccurate
biased
precise
inaccurate
unbiased
precise
accurate
Figure 3.2. Bias, precision and accuracy
In developing a model or formula, bias can to some extent be corrected by means of a 
correction factor. An example is the correction factor of 1.212 for Black-Americans 
in the MDRD formula.15 Remaining bias refers to confounding factors for which 
corrections have not been included. It is not possible to completely correct for lack of 
precision (random error) in a model or formula. Precision is therefore an important 
indicator for the evaluation of the reliability of a clinical measure. Precision has been 
defined as the variance of the bias. The wider the variance of the bias, the higher the 
number that represents the precision, or in other words a wide imprecision. Accuracy 
is a validity indicator, which represents both precision and bias, thus systematic and 
random error. Accuracy is often expressed as a percentage of estimates within k% 
of mGFR (Pk). This outcome measure is probably most easily to interpret from a 
clinical perspective. For example, if P30 is 50%, it means that in half of the cases the 
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eGFR falls within ± 30% of the mGFR. Due to intraindividual and interindividual 
variation of serum creatinine levels and analytical variation of the measurement 
of serum creatinine levels and other influencing factors a P30 of 100% will hardly 
be achievable.5,12,22 In line with other authors we considered a bias of 20% or less, 
a precision of 30% or less and an accuracy expressed as P30 of 80% or higher as 
indicator of sufficient validity.14,66,67
Ad (c) method of measuring true GFR
Several methods for true GFR measurement are available, including urinary 
clearance, plasma clearance or a combination of both from exogenous markers, such 
as 99mTc-DTPA, 51Cr-EDTA, 125I-iothalamate and iohexol.68,69 
With urinary clearance, two to four 20 to 30 minutes urine collections are obtained, 
after administration of the exogenous marker. Urinary clearance is computed as the 
urine concentration of the exogenous marker multiplied by the volume of the timed 
urine sample, and divided by the average plasma concentration during the same time 
period.27 Plasma clearance is computed from the amount of the exogenous marker 
administered divided by the area under the curve of plasma concentration over time. 
The best estimate is a two-compartment model that requires blood sampling two to 
three time points until 60 minutes and one to three time points from 120 minutes 
forward.27
The clearance of inulin is determined by collecting three sets of 30 minutes urinary 
clearance periods during a continuous intravenous infusion with 1% of inulin. Blood 
samples should be collected at least three times at the midpoint of the urine collections. 
Bladder catheterization is necessary to assure complete urine collection.27,70 Tests 
containing sinistrin, an analogue of inulin and also a fructan, is frequently used as a 
gold standard for the measurement of GFR and therefore included in our review.47,71
Results and interpretation
We identified 1179 citations with the search terms listed in Appendix 3.1. In total 
we included 27 studies. The flow of study selection is reported in Figure 3.3. In 
Table 3.2 the most important information from the selected studies is summarized. 
The PRISMA checklist is provided as Appendix 3.2.
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Figure 3.3. Flow of study selection
1179 citations
screened
(by WE)
258 full-text articles
assessed
(by WE and PDS) 231 articles were excluded
33 studies were excluded for the use of other 
statistic methods.
22 studies were excluded for not fulﬁlling the gold 
standard criteria.
138 studies were excluded for lack of subanalysis for 
(e)GFR < 60ml/min/1.73m2.
68 studies were excluded for not concerning a speciﬁc 
disease or another disease than selected.
(Articles could be excluded for more than one reason.)
27 articles included
Elderly patients, n = 9
Hospitalized patients, n = 3
Obese patients, n = 2
Cardiovascular diseases, n = 1
Cancer, n = 4
Diabetes mellitus,  n = 5
Liver cirrhosis, n = 2
Human inmmunodeﬁciency virus, n = 2
Of note, one article provided
data for two diseases
921 excluded by title
and abstract review
Elderly patients
Background
CKD is common in elderly and is associated with a high risk of cardiovascular 
complications.66,69 Early recognition, intervention and management of patients with 
CKD by physicians has been shown to slow progression of disease and decrease 
complications.72 Accurate estimate of GFR is important to detect elderly patients 
at risk for progressive CKD, but also in order to guide drug therapy of potentially 
Validity of the MDRD formula in specific patient populations | Chapter 3
45
nephrotoxic drugs, or to adapt therapy with renally excreted drugs which is often 
desirable in elderly patients on polypharmacy.73-75 
Summary of the selected articles 
We included nine studies, four of which were conducted in 2013. The definition of 
elderly or older patients ranged from 65 to 80 years or older. The mean bias reported 
ranged from an underestimation of 20 ml/min/1.73m2 in the study of Bevc et al. to 
an overestimation of 29% in the study of Drenth-van Maanen et al.47,76 Interpretation 
of precision is more difficult. The IQR of 11 ml/min/1.73m2 reported by Kilbride 
et al. is reasonable when considering persons with higher ranges of mGFR (around 
60 ml/min/1.73m2), but would be less acceptable in the lower ranges of the mGFR. 
The accuracy reported as P30 was almost 80% which implies that the variance of the 
bias, the precision, is too large over the total range from 7 to 60 ml/min/1.73m2.77 
Although, four studies reported a bias within our 20% criteria71,77,78,79, only two 
studies reported an accuracy above 80%, namely Stevens et al. and the subanalysis 
of the Kidney Disease: Improving Global Outcomes (KDIGO) CKD stage 3A in 
the study of Koppe et al.71,79 In five studies (56%) the number of patients included 
exceeded 100.71,76,77,79,80 Six out of nine studies described the method for measuring 
GFR adequately. The gold standards were reasonably performed, but only the studies 
of Drenth-van Maanen et al. and Froissart et al. met the number of blood samples 
taken over time as described above.47,78
Interpretation and conclusion
The nine included studies were performed reasonably. There was only one study 
in which the MDRD formula appeared to be valid.79 Earlier Pottelbergh et al. 
conducted a systematic review with broader selection criteria and reported both 
over- and underestimation of the mGFR.69 They concluded that there is no accurate 
creatinine-based formula to evaluate renal function in elderly patients.69 With the 
more recently published studies presented here, we can confirm the conclusion that 
the creatinine-based MDRD formula is not valid in elderly patients.
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Article
Elderly patients
Mean ± SD
age (years)
Mean ± SD
mGFR
Gold standardStudy population
Lopes et al., 
2013, Brasil143
Evans et al., 
2013, Sweden80
-*
-*
-* -*
-* -*
-*
Iohexol;
Blood samples were 
withdrawn 2, 3, 4 and 5 
h after infusion.
Iohexol; 
Blood samples were 
withdrawn at baseline 
and after 6-8 h or 48 h 
after injection for 
patients with eGFR 
between 15-30 
ml/min/1.73m2 and 
≤ 15 ml/min/1.73m2, 
respectively.
Sinistrin; 
Loading dose followed 
by continuous infusion. 
Urine and plasma 
collection (time and 
numbers not described).
Koppe et al., 
2013, France71
n = 56
Subanalysis: mGFR < 60 
ml/min/1.73m2. 
Inclusion criteria: age ≥ 80 years, 
clinically stable, independent in 
activities. 
Exclusion criteria: to be institutionali-
zed, unable or willing to give consent, 
acute infection, moderate or severe 
cognitive impairment, heart failure, 
cirrhosis, previously received dialysis, 
unstable COPD, previous immunosup-
pressive therapy within 6 months, 
previous chemotherapy for cancer, 
known HIV infection, and previously 
reported allergic reaction to iodine.
n = 1831
Subanalysis: age ≥ 65 years.
Inclusion criteria: patients with an 
iohexol measurement ≤ 30 
ml/min/1.73m2, a registered plasma 
creatinine on the same date, between 
1999 and 2010.
Exclusion criteria: renal transplants, 
dialysis, patients from the Lund-
Malmö region.
n = 53, KDIGO CKD stage 3A
n = 68, KDIGO CKD stage 3B
n = 66, KDIGO CKD stage 4-5
Inclusion criteria: age > 70 years, 
white (Caucasian), underwent inulin 
clearance for suspected or established 
renal dysfunction.
Drenth-van 
Maanen et al., 
2013, £e 
Netherlands47
82 
range: 71-87
39.6 ± 14.9‡
ml/min/1.73m2
median (IQR): 
15 (12-20)
ml/min/1.73m2
Sinistrin; 
Bolus injection, blood 
samples were withdrawn 
at 10, 20, 30, 60, 90, 120, 
240 and 480 min after 
infusion.
Iohexol; 
Bolus injection, blood 
samples were withdrawn 
at 120, 180 and 240 min.
Kilbride et al., 
2012, United 
Kingdom77
n = 16
Inclusion criteria: patients with 
eGFR(MDRD) ≤ 60 ml/min/1.73m2, 
age ≥ 70 years, stable medical 
condition and cognitively able to give 
informed consent at acute care and 
outpatient geriatric ward.
n = 234
Subanalysis: mGFR < 60 
ml/min/1.73m2. 
Inclusion criteria: ≥ 74 years
Exclusion criteria: iodinated contrast 
media allergy, active malignancy, life 
expectancy less than 3 months, 
cognitive impairment, recent episode 
(within 3 months) of AKI, dialysis.
(n = number of patients)
Table 3.2 Validity of the MDRD formula in specific patient populations
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Creatinine
measurement
BiasMean ± SD
eGFR(MDRD)
Precision Accuracy 
Re‐expressed MDRD‐4
mean: 
5.9 ml/min/1.73m2
Re‐expressed MDRD‐4‡
Stage 3A 
median: 2 ml/min/1.73m2 
Stage 3B 
median: 6.7 ml/min/1.73m2 
Stage 4-5 
median: 5.95 ml/min/1.73m2
Re‐expressed MDRD‐4‡
Stage 3A
SD: 13.53 ml/min/1.73m2 
Stage 3B
SD: 11.69 ml/min/1.73m2 
Stage 4-5
SD: 8.6 ml/min/1.73m2
Re‐expressed MDRD‐4‡ 
Stage 3A
P10: 41.51%; P30: 84.91% Stage 3B
P10: 28.99%; P30: 73.91% Stage 4-5
P10: 19.7%; P30: 59.09%
MDRD‐4
mean: 29.1%
MDRD‐4
LOA:
-16 to 34 ml/min/1.73m2
MDRD‐4
P30: 62.5%
Re‐expressed MDRD‐4
SD: 
14.1 ml/min/1.73m2
Re‐expressed MDRD‐4
P30: 64.3%
Re‐expressed MDRD‐4
P30: 64.6%
Re‐expressed MDRD‐4 
IQR: 
11.4 ml/min/1.73m2
Re‐expressed MDRD‐4 
P30: 78%
Re‐expressed MDRD‐4
median: 2.0 ml/min/1.73m2
Jae
Enzymatic 
or Jae
Enzymatic
Enzymatic
Jae
-*
-* -* -*
-*
-*
MDRD‐4
48.6 ± 13.8‡ 
ml/min/1.73m2
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Article Mean ± SD
age (years)
Mean ± SD
mGFR
Gold standardStudy population
(n = number of patients)
Hospitalized patients
Bevc et al., 2011, 
Slovenia 76
Stevens et al., 
2007, United 
States79
-*
-* -*
-* -*
-*
51Cr-EDTA; 
After single injection 
blood samples were 
withdrawn at 120, 180 
and 240 min.
Iothalamate; 
Withdrawing of samples 
was not described.
51Cr-EDTA;
Collection of urine
1 h after injection and 
then 5 consecutive 
30-min clearances. 
Blood was withdrawn at 
midpoint of each 
clearance period up to 
300 min after injection.
Froissart et al., 
2005, France78
n = 266
Subanalysis: mGFR < 60 
ml/min/1.73m2. 
Inclusion criteria: age > 65 years, 
Caucasian.
n = 580
Subanalysis: age > 65 years and eGFR 
< 60 ml/min/1.73m2.
e results have been compiled from 
data from dierent studies.
n = -*
Subanalysis: age > 65 years and 
mGFR < 60 ml/min/1.73m2.
Exclusion criteria: renal transplant 
patients and age < 18 years, black 
patients.
-*
51Cr-EDTA; 
Withdrawing of samples 
was not described.
Fontsere et al., 
2006, Spain144
n = 43
Subanalysis: age ≥ 65 years. 
Inclusion criteria: Caucasian adult 
patients with CKD stages 4-5.
Frank et al., 
2012, Switzer-
land 145
median 
(IQR): 80
(73-83)
median 
(IQR): 30.9 
(22.0-43.3) 
ml/min
22.9 ± 6.8 
ml/min/1.73m2
Inulin; 
Blood samples were 
withdrawn at baseline, 
90, 180, 270 and 360 
min.
Inulin; 
After equilibrium phase 
(60 min), urine 
collection during 60-90 
min by 
spontaneous urination
Schuck et al., 
2005, Czech 
Republic86
n = 69
Inclusion criteria: Caucasian patients, 
age > 70 years, with CKD stage 3-4 
according to KDOQI guidelines of 
the internal medicine ward. Stable 
weight for 4 days. 
Exclusion criteria: unstable renal 
function in the last two weeks.
Poggio et al.,
2005, Califor-
nia85
65 ± 15 17.1 ± 17.9
ml/min/1.73m2
range: 20-65 19.1 ± 10.1
ml/min/1.73m2
Iothalamate; 
Bolus injection, blood 
samples were withdrawn 
at 5, 10, 15, 300, 330 and 
360 min. In case of 
expected GFR < 30, age 
> 65, or creatinine level 
> 2.5mg/dl, a sample at 
24 h was also collected.
n = 107
Inclusion criteria: patients who had 
mGFR performed with varying 
degrees of kidney dysfunction. 
Exclusion criteria: incomplete data, 
dialysis, serum creatinine level < 0.3 
mg/dl (< 27 umol/l), unstable renal 
function.
n = 79
Nephrology Department; 
Inclusion criteria: GFR < 50 
ml/min/1.73m2.
Exclusion criteria: cachexia
Validity of the MDRD formula in specific patient populations | Chapter 3
49
Creatinine
measurement
BiasMean ± SD
eGFR(MDRD)
Precision Accuracy 
MDRD‐4
mean: 
-20.2 ml/min/1.73m2
MDRD‐4
mean: 
-4.1 ml/min/1.73m2
MDRD‐4
Male 
mean: 5.6% 
Female 
mean: 7.6% 
MDRD‐4
Male 
SD: 31.4% 
Female 
SD: 34.1% 
MDRD‐4
median: -1.2%
MDRD‐4
P30: 82%
Re-expressed MDRD-4 
median: 16.3 ml/min
Re-expressed MDRD-4 
IQR: 6.4 to 27.5 ml/min
MDRD-4 
median: 53% 
MDRD-6 
median: 46%
MDRD-4 
MAPE: 53%
P30: 31%
P50: 49% 
MDRD-6
MAPE: 47%
P30: 36%
P50: 55%
MDRD‐4
SD: 14.9 ml/min/1.73m2
MDRD-4
30-59 ml/min/1.73m2 
P30: 77.9% 15-29 ml/min/1.73m2
P30: 56.6% < 15 ml/min/1.73m2
P30: 55.2%
MDRD‐6
LOA: 
-5.7 to 12.2 ml/min/1.73m2
MDRD‐6
mean: 
3.26  ml/min/1.73m2
Jae
Jae
Jae
Jae
Jae
Jae
-*
-*
-*
-*
-* -*
-*
-* -*
-*
-*
-*
MDRD-4  
23.9 ± 16.3 
ml/min/1.73m2 
MDRD-6  
22.5 ± 17.4 
ml/min/1.73m2
Re-expressed 
MDRD-4 
median: 47.9 
ml/min
MDRD‐6
22.1 ± 8.3 
ml/min/1.73m2
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Article Mean ± SD
age (years)
Mean ± SD
mGFR
Gold standardStudy population
(n = number of patients)
Obese patients
Cardiovascular diseases
Cancer
Bouquegneau., 
2013, Belgium89
Stevens et al., 
2007, United 
States79
-*
-* -*
51Cr-EDTA; 
After single injection 
blood samples were 
withdrawn at 120 and 
240 min.
Iothalamate; 
Withdrawing of samples 
was not described.
n = 207
Subanalysis: mGFR < 60 
ml/min/1.73m2. 
Inclusion criteria: > 18 years and 
BMI > 30 kg/m2. 
Exclusion criteria: patients treated with 
steroids, cimetidine or trimethoprim.
n = 1039
Subanalysis: BMI > 30 kg/m2 and 
eGFR < 60 ml/min/1.73m2.
e results have been compiled from 
data from dierent studies.
-* -*
-* -*
-*
-*
-*
125I-iothalamate; 
Constant infusion. 2 h 
stabilization period.
Valente et al., 
2014, e 
Netherlands146
n = 40
Subanalysis: mGFR < 60 
ml/min/1.73m2. 
Inclusion criteria: age ≥ 18 years, 
LVEF < 0.45, clinically stable, use of 
renin-angiotensin-system inhibitors.
Exclusion criteria: myocardial infarction 
within the last 3 months, cardiac surgery 
or angioplasty within the last 3 months 
or scheduled, unstable angina pectoris, 
primary renal disease, prior organ 
transplantation, chronic use of renal 
function-compromising medication.
Craig et al., 
2012, United 
Kingdom147
51Cr-EDTA; 
After single injection 
blood samples were 
withdrawn at 120 and 
240 min.
51Cr-EDTA; 
Bolus injection, four 
blood samples between 
120 and 300 min after 
injection.
Bolke et al.,
2011, 
Germany104
n = -*
Subanalysis: 30 < mGFR < 59 ml/min/ 
1.73m2, mGFR < 30 ml/min/1.73m2.
Inclusion criteria: patients treated with 
chemotherapy following their mGFR, 
serum creatinine measured within 7 days 
of mGFR, serum creatinine ≥ 60 umol/l, 
age > 20 years. 
Exclusion criteria: patients with missing 
information, serum creatinine < 60 umol/l
Ainsworth et al., 
2012, United 
Kingdom106
46.8 ± 7.9‡
ml/min/1.73m2
51Cr-EDTA; 
Single-sample method 
until 2005, thereafter 
three-sample method.
n = 45
Inclusion criteria: patients who had 
mGFR < 50 ml/min at the Department 
of Nuclear Medicine.
n = 8
Subanalysis: mGFR ≤ 60 ml/min/1.73m2. 
8 patients with head and neck cancer 
presenting for combined radiochemothe-
rapy and with known CKD stage 3-5. 
Exclusion criteria: high dose steroid 
treatment.
99mTc-DTPA; 
Bolus injection, blood 
samples withdrawn after 
2 and 5 h.
Faluyi et al., 
2011, United 
Kingdom105
68.3 ± 11.2n = 62
Inclusion criteria: patients with mGFR 
≤ 60 ml/min with stable renal function at 
a Cancer Centre. 
Exclusion criteria: unstable renal function.
36 ± 13
ml/min/1.73m2
-*
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Creatinine
measurement
BiasMean ± SD
eGFR(MDRD)
Precision Accuracy 
Re‐expressed MDRD‐4
mean: -0.8%
MDRD‐4
median: 4.1%
MDRD‐4 
P30: 82%
Re‐expressed MDRD‐4 
30 < mGFR < 59 
mean:
15.7 ml/min/1.73m2 
mGFR < 30
mean:
7.0 ml/min/1.73m2
MDRD-4 
median: 17.5% 
MDRD-4 
median APE: 20.5%
Re‐expressed MDRD‐4
SD: 32%
Re‐expressed 
MDRD‐4
36 ± 17 
ml/min/1.73m2
Re‐expressed MDRD‐4
mean: 
-2 ml/min/1.73m2
Re‐expressed MDRD‐4
SD: 
9 ml/min/1.73m2
Re‐expressed MDRD‐4
P30: 80%
Jae
Jae
Jae
Jae
Enzymatic
Enzymatic
-*
-*
-*
-*
-*
-*
-*
-*-*
-*
Re-expressed 
MDRD-4
55.2 ± 13.2‡ 
ml/min/1.73m2
-* -* -*
Re-expressed MDRD-4
median: 18.4%‡ 
Re-expressed MDRD-4
SD: 19.1%‡ 
Re-expressed MDRD-4
P30: 75%‡
P50: 100%‡
Re-expressed MDRD-4
P10: 40.3%
P30: 80.6%
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Article Mean ± SD 
age (years)
Mean ± SD
mGFR
Gold standardStudy population
(n = number of patients)
Diabetes mellitus
Liver cirrhosis
Iliadis et al., 
2011, Greece57
Rognant et al., 
2011, France148 -*
51Cr-EDTA; 
Bolus injection, blood 
samples withdrawn after 
2 and 4 h.
71 ± 9 48.1 ± 8.1
ml/min/1.73 m2
64 ± 8.0 31.2 ± 10.8
ml/min/1.73 m2
36.4 ± 13
ml/min/1.73 m2
Inulin; 
Continuous infusion, 
both blood and urine 
samples were withdrawn.
n = 145
Inclusion criteria: consecutive type 2 
diabetic outpatients with mGFR 
between 30-59 ml/min/1.73m2.
n = 149
Inclusion criteria: nondialyzed diabetic 
adult patients with mGFR < 60 
ml/min/1.73m2.
-* -*
-*
125I-iothalamate; 
Withdrawing of samples 
was not described.
Fontsere et al., 
2008, Spain149
n = 36
Subanalysis: 15 < mGFR < 59 
ml/min/1.73m2.
Caucasian type 2 diabetic patients.
Normo- 
albuminuric
68 ± 9 
Albuminuric
64 ± 12 
45.6 ± 29.7
ml/min/1.73 m2
51Cr-EDTA; 
Bolus injection, four 
blood samples were 
withdrawn at 75, 105, 
135 and 165 min and 
urine samples were 
collected at 90, 120, 150 
and 180 min.
Rigalleau et al., 
2007, France150
n = 89
Inclusion criteria: diabetes and an eGFR 
< 60 ml/min/1.73m2.
Exclusion criteria: renal replacement 
therapy.
33.7 ± 14.7
ml/min/1.73 m2
51Cr-EDTA; 
Bolus injection, four 
blood samples were 
withdrawn at 75, 105, 
135 and 165 min and 
urine samples were 
collected at 90, 120, 150 
and 180 min.
Rigalleau et al., 
2005, France110
n = 87
Inclusion criteria: diabetic patients with 
mGFR < 60 ml/min/1.73m2
Exclusion criteria: nephrotic proteinuria 
(> 3 g/24h), edema and dialysis.
Mindikoglu et 
al., 2014, United 
States115
Iothalamate; 
Blood samples were 
withdrawn at baseline, 5, 
15, 30, 45, 60, 120, 240 
and 360 min after 
iothalamate administra-
tion.
n = 21
Subanalysis: mGFR < 60 
ml/min/1.73m2. 
Inclusion criteria: cirrhosis, age ≥ 18 
years. 
Exclusion criteria: pregnancy or 
breast-feeding, iothalamate or iodine 
allergy, not treated hepatocellular 
carcinoma, hyperthyroidism, inability to 
provide informed consent or to collect or 
void urine, dialysis or eGFR < 15 
ml/min/1.73m2, treatment with NSAIDs, 
ACE-inhibitors 1 week prior. Onset or 
change in diuretics 1 week prior. Acute 
infection, exacerbation of encephalopathy, 
gastrointestinal bleeding, kidney injury 1 
week prior, acute cardiovascular or 
cerebrovascular event 3 weeks prior, and 
cognitive impairment.
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Creatinine
measurement
BiasMean ± SD
eGFR(MDRD)
Precision Accuracy 
Re‐expressed MDRD‐4
mean: 
7.5 ml/min/1.73m2
Re‐expressed MDRD‐4
SD: 9.5 ml/min/1.73m2
MDRD‐4
P10: 36.2%P30: 75.3%
Re-expressed 
MDRD-6≠
mean:
-10.4 ml/min/1.73m2
Re-expressed 
MDRD-6≠
SD:
13.65 ml/min/1.73m2
Re-expressed 
MDRD-6≠
P20: 52.38%
P30: 61.90%
Re‐expressed 
MDRD‐4
56 ± 13.0 
ml/min/1.73m2
MDRD‐4
mean: 
-5.3 ml/min/1.73m2
41.3 ± 13.1 
ml/min/1.73m2
MDRD-4
38.4 ± 14.0 
ml/min/1.73m2
MDRD-4
mean:
4.7 ml/min/1.73m2
MDRD-4
2SD:
20.6 ml/min/1.73m2
MDRD-?
(not mentioned) 
Normoalbuminuric 
P10: 26%
P30: 73%
P50: 86% 
Albuminuric: 
P10:24%
P30: 60%
P50: 79%
Re‐expressed MDRD‐4
P10: 26.3%P30: 69.3%
Jae
Jae
Jae
Jae
Jae
-* -* -*
-* -*
-*-*
-*-*
-*
-*
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Mean ± SD
mGFR
Gold standard
Human immunodeciency virus
Rognant et al., 
2010, France114
-*
-* -*
-*
Inulin; 
Continuous infusion (2 
to 2.5 h), collection of 
three to four urine 
samples and a blood 
sample midway through 
each collection period.
n = 45
Inclusion criteria: consecutive candidates 
for liver transplantation with decompen-
sated alcoholic cirrhosis with mGFR 
< 60 ml/min/1.73m2.
-* -*
Iohexol; 
Bolus injection, blood 
samples withdrawn after 
120 and 240 min.
Gagneux et al.,
2013, France126
n = 18
Subanalysis: mGFR < 60 
ml/min/1.73m2. 
Inclusion criteria: age ≥ 18 years, 
conrmed HIV status.
Exclusion criteria: pregnancy, history of 
allergy, thyroid dysfunction, recent AKI, 
and treatment by metformin, steroids, 
trimethoprim, or cimetidine.
Iohexol; 
Bolus injection, blood 
samples withdrawn after 
10, 30, 120 and 240 min.
For participants with 
serum creatinine > 1.5 
mg/dl, a sample at 360 
min was withdrawn.
Not all parameters were reported in the included articles. Especially when it came to subanalysis of patients with an eGFR < 60 
ml/min/1.73m2.
When individual data were available we calculated missing parameters ourselves.
e MDRD-formula used was not reported. Given the time at which the study was conducted, we assume that the re-expressed 
MDRD-formula was used.
* 
‡ 
≠ 
Inker et al., 
2012, United 
States127
n = 27
Subanalysis: eGFR < 60 ml/min/1.73m2 
Inclusion criteria: age > 18 years, stable 
on antiretroviral therapy for at least 
three months, conrmed HIV status, 
HIV viral load and CD4 count within 6 
months of recruitment.
Exclusion criteria: pregnancy, allergy or 
contraindication for iohexol or iodine, 
recent AKI, cognitive or physical 
impairments, use of cimetidine.
Article Mean ± SD
age (years)
Study population
(n = number of patients)
Hospitalized patients
Background
Reduced GFR is one of the most important complications in critically ill patients and 
is associated with increased morbidity and mortality in the intensive care unit (ICU) 
population.81,82 In addition, acute renal failure (ARF) is also associated with high 
mortality.83 Early detection of renal dysfunction and subsequent adequate treatment 
is therefore necessary in the hospital care setting.84 Estimation of the GFR is also 
necessary for appropriate treatment of critically ill and other hospitalized patients 
with renally excreted drugs.85
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Creatinine
measurement
BiasMean ± SD
eGFR(MDRD)
Precision Accuracy 
MDRD‐4
mean: 
19 ml/min/1.73m2
MDRD‐4
SD: 25 ml/min/1.73m2
MDRD‐4
P10: 11%P30: 40%
Re‐expressed MDRD‐4
mean: 61%
Re‐expressed MDRD‐4
SD: 58%
Re‐expressed MDRD‐4
P30: 22%
Re‐expressed MDRD‐4
median:
-11.9 ml/min/1.73m2
Re‐expressed MDRD‐4
IQR:
19.4 ml/min/1.73m2
Re‐expressed MDRD‐4
P30: 66.7%
Enzymatic
-* -*
-*
-*-*
SD, standard deviation; mGFR, measured glomerular ltration rate; HIV, human immunodeciency virus; BMI, body mass index; 
IQR, inter quartile range; LOA, limits of agreement; eGFR, estimated glomerular ltration rate; MDRD, modication of diet in 
renal disease; CKD, chronic kidney disease; KDIGO, kidney disease: improving global outcomes; KDOQI, kidney disease
outcomes quality initiative; h, hour(s); min, minute(s); COPD, chronic obstructive pulmonary disease; LVEF, left ventricular 
ejection fraction; AKI, acute kidney injury; 51Cr-EDTA, 51chromium ethylenediaminetetraacetic acid; 99mTc‐DTPA, technetium‐
labelled diethylene‐triaminepentacetate; NSAID, non-steroidal anti-in¢ammatory drug; ACE-inhibitor, angiotensin-converting-
enzym inhibitor.
Summary of the selected articles
In Table 3.2 three studies are presented, which fulfilled our inclusion criteria. All 
three studies reported an overestimation of the true GFR, ranging from a mean 
bias of 3.26 ml/min/1.73m2 in the study of Schuck et al. to a median relative bias 
of 53% in the study of Poggio et al.85,86 In the study of Poggio et al. the MDRD-6 
formula seemed to perform slightly better than the MDRD-4 formula with a 
median bias of 46%.85 Although the bias in the study of Schuck et al. seems low, the 
precision exceeded our criteria of 30%.86 Only the study of Poggio et al. reported 
accuracy, which appeared to be inadequate. P30 was 36% for the MDRD-6 formula 
and 31% for the MDRD-4 formula.85 The measurement of the GFR with a gold 
standard was performed reasonably, although the spontaneous urination instead of 
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catheterization in the study of Schuck et al. is questionable.86 The number of patients 
only exceeded 100 in the study of Poggio et al.85
Interpretation and conclusion
The MDRD formula is invalid in hospitalized patients on the internal medicine and 
nephrology ward. In the study of Poggio et al. selection bias was introduced, because 
the selection of patients was based on an individual nephrologist’s perception of 
laboratory values not reflecting actual GFR.85 In the other two studies the study 
was conducted only on the internal medicine and nephrology ward. The study 
population may therefore not reflect the average hospitalized patient population. In 
conclusion, the eGFR may largely overestimate true GFR in hospitalized patients, 
but the impact of this effect in different populations of hospitalized patients is still 
insufficiently known.
Obese patients
Background
Obesity is a well-recognized global health problem.87 Obesity is associated with 
cardiovascular complications, type 2 diabetes mellitus, osteoarthritis, major 
depression and some cancers.7,87 Obesity itself and its combination with these 
chronic diseases predispose individuals to develop CKD.7,88 Considering the 
increasing number of obese patients the accuracy of the MDRD formula in obesity 
is of increasing importance. 
Summary of the selected articles 
Two articles met our selection criteria. Both studies had a study population 
exceeding 100 patients. One study was compiled with data from different studies, 
so the measurement of the GFR was not described.79 In the study of Bouquegneau 
et al. the measurement of the GFR was not adequately performed.89 In both studies 
the true GFR and eGFR were normalized to ml/min/1.73m2. The bias was for both 
studies within our 20% criteria. The precision reported in the study of Bouquegnea 
et al. was slightly higher than 30%, but the accuracy was sufficient, P30 was 80%.89 
Stevens et al. reported also a sufficient accuracy, P30 of 82%.79  
Interpretation and conclusion
We found two studies, which conducted a subanalysis about the validity of the 
MDRD-4 formula in obese patients (BMI > 30 kg/m2). The performance of the 
MDRD-4 formula seemed valid, but the measurement of the gold standard could 
have been performed better. In conclusion, we were not able to draw conclusions 
about the validity of the MDRD formula in obese patients.
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Cardiovascular diseases
Background
Numerous studies about the prognostic value of the eGFR(MDRD) in cardiovascular 
diseases for clinical outcomes, such as mortality, have been published.56,90-94 In patients 
with end-stage heart failure, irreversibly impaired renal function precludes eligibility 
for heart transplantation.95 In addition, patients with cardiovascular diseases are at 
risk for polypharmacy and the use of drugs that require dose adjustment in renal 
impairment.96,97 Thus an accurate method to estimate GFR is essential.98
Summary of the selected articles
One article met our selection criteria. The mean bias of -2 ml/min/1.73m2 with a 
precision of 9 ml/min/1.73m2 were within our criteria of 20% and 30%, respectively. 
However, the number of patients included was low. The measurement of the 
true GFR was not performed with a common method, a continuous infusion of 
125I-iothalamate instead of a bolus injection. 
Interpretation and conclusion
In conclusion, we were not able to draw conclusions about the validity of the MDRD 
formula in patients with heart failure (or other cardiovascular diseases).
Cancer
Background
Both cancer and its drug therapies can lead to renal impairment.99 Renal impairment 
in patients with cancer is highly prevalent and has major clinical implications.99,100 
In the Belgian Renal Insufficiency and Anticancer Medication (BIRMA) study, 
the prevalence of renal impairment (eGFR < 90 ml/min/1.73m2) in patients with a 
range of cancer diagnosis was 64%.101 80% of the patients treated for cancer received 
at least one nephrotoxic drug and/or drugs for which dosage had to be adjusted in 
renal impairment.101 In our ageing societies oncologists are likely to be faced with 
increasing numbers of patients with both cancer and renal impairment.102,103
Summary of the selected articles
Four studies were selected and are presented in Table 3.2. None of these studies 
reported precision. Although the bias reported in the studies of Ainsworth et al. 
and Bolke et al. were within 20%, only the study of Faluyi et al. reported an accuracy 
> 80% expressed as P30.104-106 The low accuracy in the other studies implies a wide 
imprecision. The number of patients included in all three studies together exceeded 
100. The measurement of GFR with a gold standard was not adequately performed 
in any of the studies. The best performed measurement of the GFR was in the 
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study of Bolke et al. where 4 blood samples were withdrawn over a time period 
of 5 hours.104   
Interpretation and conclusion
Precision was not reported, the numbers of patients in the selected separate studies 
were low and only the measurement of the GFR in the study of Bolke et al. seemed 
robust. Yet, these studies suggest that the eGFR calculated with the MDRD formula 
in cancer patients with moderate to severe renal impairment may be substantially 
different from the mGFR for a substantial number of patients. There is no evidence 
that the use of the MDRD formula in drug dosing in patients with cancer and renal 
impairment is valid.
Chronic respiratory diseases
Background
The most frequent chronic respiratory disease is chronic obstructive pulmonary 
disease (COPD), which is associated with several comorbidities, such as 
hypertension, heart failure and diabetes.107 Renal impairment is a significant risk 
factor for cardiovascular diseases for which COPD patients are at risk.108 In addition, 
polypharmacy is frequent in patients with COPD.108 An accurate estimation of the 
GFR seems therefore important. 
Summary of the included articles
No articles met our selection criteria. 
Interpretation and conclusion
When searching for articles about the validity of the MDRD formula in patients 
with COPD, we found some recently published articles on the prevalence of 
renal impairment in patients with COPD, which discussed the advantages of 
using creatinine-based formulas for estimating GFR rather than serum creatinine 
levels.107,108 The prevalence of undiagnosed renal impairment (eGFR < 60 ml/min 
and normal serum creatinine levels) varied between 7% and 22%, and was higher 
in patients with cachexia and older age (> 64 years).107,108 This implies that the issue 
of the validity of the MDRD formula in COPD patients is still far from settled. In 
conclusion, we were not able to draw conclusions about the validity of the MDRD 
formula in patients with chronic respiratory diseases and moderate to severe renal 
impairment. 
Validity of the MDRD formula in specific patient populations | Chapter 3
59
Diabetes mellitus
Background
Diabetes mellitus is the leading cause of CKD.109 Diabetic nephropathy affects 
around one-third of patients with diabetes and is the primary cause of end-stage 
renal disease worldwide.57,109 Moreover, diabetic patients, especially those with 
impaired renal function, are at increased risk of cardiovascular events.57,110 There 
is strong evidence that early detection of diabetic nephropathy leading to timely 
intervention improves long-term outcome.111
Summary of the selected articles
Several studies have been published about the validity of the MDRD-4 formula 
in patients with diabetes mellitus. We included five studies. The bias reported in 
three out of five studies were within 20%. The precision (only reported by Iliadis et 
al. and Rigalleau et al.) was in the same range, namely a standard deviation (SD) 
of approximately 10 ml/min/1.73m2, and within our criterion of 30%.57,110 Despite 
the fact that both bias and precision reported met our criteria, the accuracy was not 
sufficient, which implies a relatively wide imprecision throughout the mGFR range. 
In two out of five studies the included number of patients exceeded 100. The findings 
of two other studies which included nearly 90 patients were in the same range. With 
respect to the method for measuring GFR, the number of blood samples withdrawn 
in the study of Iliadis et al. (two blood samples) was probably marginal.57 In the 
other four studies the method for GFR measurement was sufficient.  
Interpretation and conclusion
In four studies the MDRD-4 formula overestimated the mGFR. The overestimation 
of the GFR might lead to higher drug doses than necessary or to a late discontinuation 
of, for example, metformin use and therefore to a greater risk of ADRs. Although 
bias pointed in the same direction in four studies, the precision (= random error), 
which was not adequately reported, was probably too wide, which led to low accuracy. 
In conclusion, the MDRD formula is not valid in patients with diabetes mellitus 
and renal impairment.
Other chronic diseases
From various chronic diseases of interest, we decided to present the diseases of 
which we could include at least two studies. These diseases were liver cirrhosis and 
HIV-infection. 
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Liver cirrhosis
Background
Renal dysfunction often accompanies later stages of chronic liver diseases and is 
strongly associated with increased mortality in both acute liver failure and liver 
cirrhosis.58,112 Pretransplant serum creatinine level is a predictor of posttransplant 
mortality and posttransplant renal function.63,113 Other risk factors to develop chronic 
kidney disease, such as diabetes mellitus, coronary heart disease, and hepatitis C, are 
common among patient with liver diseases.113,114 It is therefore important to identify 
which patients with liver disease truly have renal impairment.60 
Summary of the selected articles
Two studies were included. The mean bias ranged from -10 ml/min/1.73m2 with the 
MDRD-6 formula in the study of Mindikoglu et al. to 19 ml/min/1.73m2 with the 
MDRD-4 formula in the study of Rognant et al.114,115 The corresponding imprecision 
expressed as SD were 14 and 25 ml/min/1.73m2, respectively.113,115 Both bias and 
imprecision were very wide for patients with a mGFR < 60 ml/min/1.73m2. Both 
over- and underestimation were reported, which resulted in an accuracy expressed as 
P30 of 40% and 62%.113,115 The number of patients in the separate studies were below 
100, but the measurements of the GFR were adequately performed. 
Interpretation and conclusion
The imprecision of the MDRD formula in the studies was very wide. Cholongitas 
et al. already reported that the MDRD overestimates the GFR to a great extent in a 
review in 2007.112 The two more recently published articles confirm this conclusion. 
Remarkably, the study in which the MDRD-6 formula was used, reported an 
underestimation of the mGFR.115 Despite the fact that only two studies met our 
selection criteria and per study less than 100 patients were included, the degree of 
over- and underestimation and precision is too large to justify the use of the MDRD 
formula in patients with liver cirrhosis and moderate to severe renal impairment.
Human immunodeficiency virus
Background
Individuals with HIV-infection have an increased risk of kidney disease.116 HIV 
infection may result in HIV-associated nephropathy, immune complex kidney 
disease and ARF.117,118 Moreover, progression to end-stage kidney disease, which 
may require hemodialysis, is common.119-121 These conditions are associated with 
progression to acquired immune deficiency syndrome (AIDS) and death.118,119 In 
addition, HIV itself may influence other risk factors for kidney disease, such as 
lipid levels, insulin resistance and microalbuminuria.122 Aging, comorbidities and 
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the use of nephrotoxic antiretroviral drugs might lead to a higher risk for developing 
impaired renal function.122-124 In addition, the use of renally excreted drugs is 
prevalent, therefore accurate estimation of renal function is an important component 
of personalized HIV care.117,125
Summary of the selected articles
We selected two subanalysis including only 45 patients with HIV and mGFR 
< 60 ml/min/1.73m2. The imprecision reported was very wide, namely an IQR of 
20 ml/min/1.73m2 in the study of Inker et al. and a mean relative bias of 61% in the 
study of Gagneux et al.126,127 This resulted in an accuracy, expressed as P30 of 67% 
and 22%, respectively.126,127 The measurement of GFR with the gold standard iohexol 
was adequately performed in the study of Inker et al. and reasonably performed in 
the study of Gagneux et al.126,127
Interpretation and conclusion
We were not able to draw conclusions about the validity of the MDRD formula in 
patients with HIV and moderate to severe renal impairment, because of the small 
number of patients. The wide imprecision reported in the small subanalysis does not 
support the validity of the MDRD formula. 
Of note, in our previously published review about the validity of the MDRD 
formula in HIV-infected patients we suggested that the MDRD-4 formula is as 
valid in HIV-positive as in HIV-negative patients.128 The results in this review do 
not confirm that hypothesis for patients with moderate to severe renal impairment. 
Discussion
To our knowledge this is the first systematic review, which evaluates the validity 
of the MDRD formula in a range of specific patient populations with moderate to 
severe renal impairment in a more quantitative way. We focused on studies, which 
compared the MDRD formula with a gold standard and which provided statistical 
outcome information about the degree of deviation from the true GFR. Our selection 
criteria were thus more stringent than previously published reviews.3,11,129 
This review showed that the validity of the MDRD formula has not yet been tested 
properly in patients with cardiovascular diseases and chronic respiratory diseases. In 
obese patients, patients with cancer and HIV the validity of the MDRD formula has 
been poorly tested. The number of studies and/or the number of patients included 
were very low and/or the measurement of GFR was not performed adequately. 
Therefore the validity of the MDRD formula in these patient populations remains 
unclear. For patients with diabetes mellitus and liver cirrhosis, hospitalized patients 
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on the internal medicine and nephrology ward and elderly with moderate to severe 
renal impairment we concluded that the MDRD formula is not valid. A summary 
is given in Table 3.3. 
Table 3.3 Summary of the systematic review about the validity of the MDRD formula in specific 
patient populations
Patient population
Elderly patients
Hospitalized patients*
Obese patients
Cardiovascular diseases
Cancer
Chronic respiratory diseases
Diabetes mellitus
Liver cirrhosis
Human immunodeciency virus
Not valid 
Not valid
Unclear
Not tested
Unclear
Not tested
Not valid
Not valid
Unclear
Validity of the MDRD formula
* e MDRD formula is not valid in patients on the internal medicine and nephrology ward.
 For other hospitalized patients it was not tested. 
Overall, we may conclude that the application of the MDRD formula in clinical 
practice is not supported by available research evidence for a range of specific patient 
populations. The application of the MDRD formula in drug dosing may become 
even more difficult with the knowledge that most of these chronic diseases are 
present in various combinations in the individual patient, especially in elderly.130 The 
variability of the eGFR in daily practice might thus be larger.
At the time this research was conducted the Chronic Kidney Disease EPIdemiology 
Collaboration (CKD-EPI) formulas were developed. These formulas are based on 
serum creatinine value, cystatine C value and a combination of both.131,132 Overall, 
the CKD-EPI formula performs better than the MDRD-4 formula. However, the 
differences in the eGFR range < 60 ml/min/1.73m2 are small and not clinically 
relevant.17,133 In Australia, France and a few large laboratories in the United States, 
the eGFR is already calculated with the CKD-EPI formulas.134 Although the 
CKD-EPI formulas may replace the MDRD formula, we still think that our review 
is of great interest. First, the limitations of the MDRD formula are due to the 
variable serum creatinine level. This variable still exists in the CKD-EPI formulas. 
Second, this review shows the importance of validating a formula in specific patient 
populations. Especially, populations who are at risk of having impaired renal function. 
This review is not without limitations. First, we excluded studies which did not fulfill 
our criteria concerning statistical analysis. A frequently used method to compare 
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different formulas to estimate the GFR is the correlation coefficient, which has 
major limitations when used for this purpose.117,121 The most informative method to 
assess diagnostic tests is the Bland-Altman plot, as this identifies the direction and 
the magnitude of the bias.67,135,136 Secondly, the gold standards used in the presented 
studies were diverse. The gold standard in the development of the MDRD formula 
was 125I-iothalamate.15 Use of other filtration markers may introduce a systematic bias, 
mostly an overestimation.4,17,44 We did not consider this variable in the interpretation 
of the included studies. This would have been difficult because the measurement of 
the GFR was often not well described and/or not adequately performed. Another 
limitation is the lack of taking into account the differences between the MDRD en 
re-expressed MDRD formulas, in other words, between IDMS calibrated creatinine 
measurements and uncalibrated creatinine measurements. In addition, the use of 
an enzymatic method or the Jaffe method also introduces variable variations in 
serum creatinine levels.2,137 We did not consider such additional variables in the 
interpretations of the selected studies. Instead, we choose to focus on the variables 
explained in the method section, which in our opinion have the greatest influence 
on the eGFR(MDRD). Finally, we did not discuss all different patient populations. 
Examples of patient characteristics which may also affect the validity of the MDRD 
formula, but which were not reviewed here, are pregnancy and ethnicity.138-141
Conclusion
In summary, the use of the MDRD formula in different specific patient populations 
for the fine-tuning of drug therapy management is not without limitations. There is 
no hard evidence that the MDRD formula is valid in patients with several chronic 
diseases combined with renal impairment. Clinical judgment remains necessary. 
Instead of searching for the ideal formula for estimating GFR, we should search 
for practical approaches to optimize the pharmacotherapy in patients with renal 
impairment.
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Appendix 3.1 Search terms
“Predictive Value of Tests”[Mesh Terms] OR “Reference Values”[Mesh Terms] OR predictive value* OR 
reference value*
limitation OR limitations
pitfalls OR pitfall
overestimated OR underestimated OR underestimation OR overestimation OR overestimating OR underestimating
disturbance OR interference 
“diagnostic errors”[MeSH Terms] OR (diagnostic AND errors)
“sensitivity and speci­city”[MeSH Terms] OR sensitivity OR speci­city
marker OR markers OR “Biological Markers”[Mesh Terms]
accurate OR inaccurate OR inaccuracy OR accuracy
performance
Assessment of the renal function 
Reliability
Glomerular ­ltration rate and creatinine
Creatinine-based formulas
(cockcroft AND gault) OR cockcroft-gault OR MDRD OR (modi­cation AND diet) OR 
“kidney diseases”[MeSH Terms] OR (kidney AND diseases) OR renal disease
Date of publication
January 1999 – January 2014
Last date the search was performed: April 30th, 2014 
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Appendix 3.2 PRISMA checklist
Section/topic
Title
Checklist item Reported 
on page #
#
Page 33, 
titlepage
Identify the report as a systematic review, meta-analysis, or 
both.
1
Abstract
Title
Structured 
summary
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key ndings; systematic review registration number.
Page 34
Introduction
Rationale 3 Describe the rationale for the review in the context of what is 
already known.
Page 35-36
Objectives 4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).
Page 36
Methods
Protocol and 
registration
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.
NA
Eligibility 
criteria
6 Specify study characteristics (e.g., PICOS, length of follow-up) 
and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving 
rationale.
Page 39
Information 
sources
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.
Page 39
Search 8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.
See 
Appendix 3.1
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, 
included in systematic review, and, if applicable, included in the 
meta-analysis).
Page 39-40
Data collection 
process
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and conrming data from investigators.
Page 41-43
Data items 11 List and dene all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and simplicati-
ons made.
Page 41-43
Risk of bias in 
individual 
studies
12 Describe methods used for assessing risk of bias of individual 
studies (including specication of whether this was done at the 
study or outcome level), and how this information is to be used 
in any data synthesis.
NA
Summary 
measures
13 State the principal summary measures (e.g., risk ratio, dierence 
in means).
NA
NADescribe the methods of handling data and combining results 
of studies, if done, including measures of consistency (e.g., I2) 
for each meta-analysis.
14Synthesis of 
results
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Section/topic
Methods (continued)
Checklist item Reported 
on page #
#
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each stage, 
ideally with a ow diagram.
Page 44
Protocol and 
registration 18
For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.
Table 3.2
Risk of bias 
within studies
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see item 12).
NA
Results of 
individual 
studies
20 For all outcomes considered (benets or harms), present, for 
each study: (a) simple summary data for each intervention 
group (b) eect estimates and condence intervals, ideally with 
a forest plot.
NA
Synthesis of 
results
21 Present results of each meta-analysis done, including 
condence intervals and measures of consistency.
NA
Risk of bias 
across studies
22 Present results of any assessment of risk of bias across studies 
(see Item 15).
NA
Additional 
analysis
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).
NA
Summary of 
evidence
24 Summarize the main ndings including the strength of 
evidence for each main outcome; consider their relevance to key 
groups (e.g., healthcare providers, users, and policy makers).
Page 61
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of identied 
research, reporting bias).
Page 62-63
Funding 27 Describe sources of funding for the systematic review and other 
support (e.g., supply of data); role of funders for the systematic 
review.
NA
NASpecify any assessment of risk of bias that may aect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies).
15Risk of bias 
across studies
NADescribe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which 
were pre-specied.
16Additional 
analyses
Discussion
Conclusions 26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.
Page 63
Funding
From: Moher D, Liberati A, Tetzla J, Altman DG, e PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: e PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097
For more information, visit: www.prisma-statement.org.
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Abstract
Purpose
To determine whether treatment with nitrofurantoin in women with urinary tract 
infection (UTI) and renal impairment in primary care is associated with a higher 
risk of ineffectiveness and/or serious adverse events than in women without renal 
impairment.
Methods
A cohort of 21,317 women treated with nitrofurantoin and a cohort of 7,926 
women treated with trimethoprim, identified from the PHARMO Record Linkage 
System, were analysed. The primary outcome was ineffectiveness of treatment of 
nitrofurantoin defined as the start of a second antibacterial within 1 month after 
the start of nitrofurantoin. The secondary outcome was the occurrence of serious 
adverse events of nitrofurantoin leading to hospitalization within 90 days. A 
cohort of trimethoprim users was used to determine if the associations found for 
nitrofurantoin were mainly related to nitrofurantoin itself. The association between 
renal impairment and the risk of these outcomes were determined with Cox 
regression and expressed as hazard ratios (HRs).
Results
Overall, the incidence density for ineffectiveness was 5.4 per 1,000 person-days, and 
moderate renal impairment was not associated with ineffective treatment (HR 1.1, 
95% confidence interval (CI) 0.74-1.51). The overall incidence density for adverse 
events was 0.02 per 1,000 person-days. In patients with renal impairment (< 50 ml/
min/1.73m2) the risk of pulmonary adverse events leading to hospitalization was 
significantly increased (HR 4.1, 95% CI 1.31-13.09).
Conclusions
Nitrofurantoin treatment was not associated with a higher risk of ineffectiveness 
in women with UTI and moderate renal impairment (30-50 ml/min/1.73m2). 
However, we did find a significant association between renal impairment (< 50 ml/
min/1.73m2) and pulmonary adverse events leading to hospitalization.
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Introduction
Acute uncomplicated urinary tract infection (UTI) is common in otherwise healthy, 
non-pregnant women of all ages. More than 30% of all women will experience at 
least one UTI during their lifetime.1 Nitrofurantoin is considered a first choice for 
the treatment of uncomplicated UTI in different guidelines.2–4 A recently published 
Cochrane review suggests that nitrofurantoin is a good choice because nitrofurantoin 
carries a lower risk of patients developing rash than treatment with trimethoprim-
sulfamethoxazole and does not share cross-resistance with other commonly prescribed 
antibacterials.1 However, there is concern about the effectiveness of nitrofurantoin 
in patients with renal impairment. According to the drug label, nitrofurantoin is 
contraindicated when the creatinine clearance is < 60 ml/min.5,6 In patients with 
normal renal function nitrofurantoin is concentrated many-fold in the urine, and 
urine concentrations reach a much higher level than the minimum inhibitory 
concentration.7 In patients with renal impairment, the excretion of nitrofurantoin 
is decreased, and effective antibacterial levels in the urine might not be achieved.8–10
Another clinical concern is that nitrofurantoin entails a greater risk of adverse events 
in patients with renal impairment, such as peripheral neuropathy. Serum levels 
of nitrofurantoin increase in these patients due to its decreased renal excretion. 
Evidence from clinical research to support the recommendations for its use in renal 
impairment is limited to pharmacokinetic studies and reports in which the duration 
of nitrofurantoin use was much longer than the recommended 5-10 days.8
Bains et al. recently conducted a retrospective observational study in 356 hospitalized 
patients in which the effectiveness and safety of the use of nitrofurantoin was 
compared between patients with an estimated glomerular filtration rate (eGFR) 
of ≤ 50 ml/min (renal impairment group) and those with an eGFR > 50 ml/min 
(control group).11 This study showed that in hospitalized patients with an eGFR of 
≤ 50 ml/min, nitrofurantoin appeared to achieve acceptable clinical recovery and 
was well tolerated. However, the number of patients included in this study was 
not sufficient to detect rare but serious adverse events. The aim of our study was 
therefore to determine whether ineffectiveness and the occurrence of serious adverse 
events during treatment with nitrofurantoin in women with uncomplicated UTI are 
dependent upon renal function.
Methods
Setting
An epidemiological study was conducted in a large outpatient population. Data were 
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obtained from the Dutch PHARMO Record Linkage System (RLS), a database 
with linked drug dispensing records from community pharmacies to general 
practitioner data, hospitalization records and clinical laboratory data from individual 
patients.12 This system includes the demographic details and complete medication 
history of more than three million community-dwelling residents from 1986 
onwards. For this study, drug dispensing data and hospitalization data were used. 
The computerized drug dispensing histories contain information on the dispensed 
drug, dispensing date, the prescriber, amount dispensed, prescribed dosage regimen 
and the estimated duration of use. Drugs are coded according to the Anatomical 
Therapeutic Chemical (ATC) classification.13 The hospitalization register contains 
data on all hospitalizations in The Netherlands, including detailed information on 
the primary and secondary discharge diagnoses, diagnostic, surgical and treatment 
procedures, type and frequency of consultations with medical specialists and dates of 
hospitalization and discharge. All diagnoses are coded according to the International 
Classification of Diseases, 9th edition (ICD-9-CM). All PHARMO RLS linked 
research is in accordance with Dutch privacy and ethical regulations.
Study design and population
A retrospective cohort study with two cohorts was conducted with a sample of 
the data compiled in the PHARMO RLS. One cohort (nitrofurantoin cohort) 
consisted of female nitrofurantoin users with known creatinine values (measured 
between the day nitrofurantoine treatment was started and 1 year before the start) 
and without creatinine values. In this cohort the effect of renal impairment on the 
ineffectiveness and adverse events of nitrofurantoin was determined. The second 
cohort (trimethoprim cohort) consisted of female trimethoprim users with and 
without known creatinine values. In this cohort the effect of renal impairment 
on the ineffectiveness of trimethoprim was determined. We also investigated the 
occurrence of adverse events related to nitrofurantoin compared to the trimethoprim 
cohort. We hypothesized that the degree of renal impairment would not be associated 
with ineffectiveness and/or adverse events in patients who used trimethoprim. If 
associations between renal impairment and ineffectiveness and/or adverse events 
were to be found for nitrofurantoin users, but not for trimethoprim users, the 
conclusion would be that the associations found for nitrofurantoin would be mainly 
related to nitrofurantoin itself. Patients were eligible for inclusion when they had 
received a prescription for nitrofurantoin or trimethoprim between 1 January 2005 
and 31 December 2010, were female and were at least 18 years of age (Figure 4.1). 
They should not have received any antibacterial prescription in the last half year 
prior to the starting date of nitrofurantoin or trimethoprim treatment. In addition, 
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they had to have at least 1 year of medication history prior to the starting date and 
6 months of follow-up after the starting date. Patients were excluded if the duration 
of the nitrofurantoin or trimethoprim prescription was < 3 days or > 10 days. In The 
Netherlands the recommended dosage regimen of nitrofurantoin in the treatment 
of uncomplicated UTI is 50 mg 4 times daily or 2 times daily 100 mg for extended 
release preparations14, with a recommended duration of 5 days.3 Patients to whom a 
second antibacterial had been prescribed before the course of the first antibacterial 
had been completed, or with invalid or unclear variables were also excluded from the 
study (Figure 4.1). 
Nitrofurantoin
ﬁrst prescription
n =  56827
Eligible population
n = 22214 (39.1%)
Inclusion criteria:
· Female sex n = 53215 (93.6%)
· ≥ 18 years n = 51692 (91.0%)
· No antibacterial in 182 days before n = 38305 (67.4%)
· ≥ 365 days history in PHARMO n = 27735 (48.8%)
· ≥ 182 days follow-up in PHARMO n = 22214 (39.1%)
Exclusion criteria: n = 897 (1.6%)
· Duration < 3 or > 10 days n = 202
· Second antibacterial during first antibacterial n = 522
· Invalid variables: no dosage, no creatinine unit, 
  prophylactic use, second episode n = 173
Study population 
nitrofurantoin
n = 21317 (37.5%)
Inclusion criteria:
· Female sex n = 26767 (93.5%)
· ≥ 18 years n = 25869 (90.4%)
· No antibacterial in 182 days before n = 16271 (56.9%)
· ≥ 365 days history in PHARMO n = 9934 (34.7%)
· ≥ 182 days follow-up in PHARMO n = 8498 (29.7%)
Exclusion criteria: n = 593 (2.1%)
· Duration < 3 or > 10 days n = 171
· Second antibacterial during first antibacterial n = 276
· Invalid variables: no dosage, no creatinine unit, 
  prophylactic use, second episode n = 125
Trimethoprim
ﬁrst prescription
n =  28618
Eligible population
n = 8498 (29.7%)
Study population 
trimethoprim
n = 7926 (27.7%)
Figure 4.1 Flowchart of the study population
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Outcomes
The primary outcome was ineffectiveness of treatment of nitrofurantoin defined as 
the start of a second antibacterial for treatment of UTI other than nitrofurantoin 
within 1 month after the start of a course of nitrofurantoin treatment.
The secondary outcome was the occurrence of adverse events attributable to 
nitrofurantoin leading to hospitalization.15,16 ICD-9 codes were included if serious 
adverse events were diagnosed during subsequent hospital admissions that occurred 
within 90 days after the start of nitrofurantoin treatment. These serious adverse 
events were classified as pulmonary reactions, allergic reactions, liver damage, 
blood dyscrasias or neuropathy (see Appendix 4.1).16 Because of the features of the 
database we could only retrieve ICD-9 codes at discharge from the hospital. The 
same outcomes were determined for the trimethoprim cohort.
Renal impairment
Outcome measures were computed per renal function group based on eGFRs 
calculated with creatinine levels using the original 4-variable Modification of Diet 
in Renal Disease equation.17 The predefined renal function groups were > 80 ml/
min/1.73m2 (no renal impairment), 50-80 ml/min/1.73m2 (mild renal impairment), 
30-49 ml/min/1.73m2 (moderate renal impairment), 10-29 ml/min/1.73m2 (severe 
renal impairment) and < 10 ml/min/1.73m2 (end-stage renal failure), as derived from 
the European dosing guidelines for drugs in renal impairment.18 Patients without 
creatinine values were classified as ‘renal function unknown’. Data for renal function 
groups were pooled if the number of patients with renal impairment (< 50 ml/
min/1.73m2) were too low.
Potentially confounding factors
The following factors were studied to control for potential differences between groups 
in terms of predisposition to (recurrent) UTIs: age, duration of antibacterial treatment, 
use of blood glucose-lowering drugs (diabetes mellitus)3, use of immunosuppressive 
drugs (increased susceptibility for infection)3, sodium phosphate, magnesium 
citrate, potassium citrate/phosphate, citric acid or allopurinol (urolithiasis)7, use 
of acetylsalicylic acid in combination with dipyridamole (stroke)19, use of urinary 
antispasmodics (incontinence)19, tamsulosin (kidney stones)3, rivastigmine or 
galantamine (cognitive impairment)19 and distigmine or carbachol (incomplete 
bladder emptying)3.
Data analysis
Descriptive statistics (mean, minimum, maximum, sum) were used to describe the 
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frequencies and incidence density ratios in the study population. We calculated the 
incidence density of ineffectiveness and adverse events as the incidence per 1,000 
person-days of observation. The observation period for ineffectiveness was defined 
as the number of days between the end date of nitrofurantoin or trimethoprim 
treatment and the start of a second antibacterial and was set at a maximum of 30 
days. The observation period for adverse events was defined as the number of days 
between the end date of nitrofurantoin or trimethoprim treatment and the date of 
hospital admission, with a maximum of 90 days. 
Baseline characteristicsa Nitrofurantoin
n = 21,317 (100%)
Trimethoprim 
n = 7,926 (100%)
18-29
30-45
46-64
> 64
5,115
5,488
5,610
5,104
49.2 < 0.001
  
 
(18-101) 
(24.0)
(25.7)
(26.3)
(23.9)
p-valueb
a Data are presented as the mean with the range in parenthesis, or as the number of patients, with the percentage in parenthesis.
b ­e p values were calculated using t-tests for continuous variables and chi-square tests for nominal categorical variables.
eGFR: estimated glomerular ltration rate.
Age (years)
Risk factors
Diabetes 
Immunosuppressive drugs
Urolithiasis
Stroke
Antispasmodic drugs
Kidney stones
Cognition
Incomplete bladder emptying
Duration of antibacterial treatment (days)
3
4,5
6-10
eGFR (ml/min/1.73m2)
> 80 (normal renal function)
50-80 (mild renal impairment)
30-49 (moderate renal impairment)
10-29 (severe renal impairment)
< 10 (end-stage renal disease)
Unknown
47.8 (18-103)
1,843
1,897
2,009
2,177
(23.3) 
(23.9) 
(25.3) 
(27.5)
857
87
57
144 
138
9
29 
17
(4.0)
(0.4)
(0.3)
(0.7)
(0.6)
(0.0)
(0.1) 
(0.1)
5.2
1,195
17,156
2,969
82.9
1,859
1,842 
166
20
1 
17,429
(3-10)
(5.6)
(80.5)
(13.9)
(9-200)
(8.7)
(8.6)
(0.8)
(0.1)
(0.0)
(81.8)
331
7
24
58
79
5
13
11
4.6
2,314
5,012
600
81.6
589
597
74
8 
1
6,657
(4.2) 
(0.1) 
(0.3) 
(0.7) 
(1.0)
(0.1) 
(0.2) 
(0.1) 
(3-10) 
(29.2) 
(63.2) 
(7.6) 
(7-209) 
(7.4) 
(7.5) 
(0.9)
(0.1)
(0.0) 
(84.0)
 0.115
0.548
< 0.001
   0.609
  0.606
  0.002
  0.468
  0.574
  0.147
< 0.001
  
 
Table 4.1 Baseline characteristics of the study population
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The strength of the associations between renal function and ineffective treatment and 
serious adverse events, respectively, was evaluated with multivariate Cox regression 
analysis and expressed as hazard ratios (HRs) with 95% confidence intervals (95% 
CIs). Covariates were included in the multivariate analysis if they induced a change 
in the crude regression coefficient of at least 10%. Data analysis was performed with 
IBM SPSS Statistics version 19.0 for Windows (IBM Inc., New York, NY).
Results
Of the 21,317 female nitrofurantoin users included in the study, 3,888 (18.2%) 
could be accommodated in predefined renal function groups because their creatinine 
value was known (Table 4.1). In the trimethoprim cohort, the creatinine value was 
known in 1,269 (16.0%) of the 7,926 female trimethoprim users included in the 
study. Moderate (30-49 ml/min/1.73m2) and severe renal impairment (10-29 ml/
min/1.73m2) were observed in 166 (0.8%) and 20 (0.1%) nitrofurantoin users, 
respectively, and in 74 (0.9%) and 8 (0.1%) trimethoprim users, respectively. Among 
the risk factors for UTIs, diabetes was most prevalent in both cohorts. 
Table 4.2 Association between renal impairment and ineffective antibacterial treatment
eGFR Second 
antibacterial
Follow-up time
> 80
50-80
30-49
10-29
< 10
Unknown
Overall
291
314
35
6
0
2,431
3,077
49,241
48,068
4,191
456
30
46,7318
569,304
Incidence 
density
5.91 
6.53 
8.35 
13.16 
NA
5.20 
5.40
Crude HR
1.00 reference 
1.10 (0.94-1.29) 
1.41 (0.99-2.00) 
2.12 (0.94-4.75) 
NA
0.89 (0.78-1.00)
(15.7)
(17.0)
(21.1)
(30.0)
(0)
(13.9)
(14.4)
a  Adjusted for age and use of blood glucose lowering drugs.
HR, hazard ratio; 95% CI, 95% condence interval; NA, data not available.
 (person-days)  (per 1000 person-days) (95% CI)
Adjusted HR a
1.00 reference 
0.92 (0.78-1.08) 
1.06 (0.74-1.51) 
1.57 (0.70-3.52) 
NA
0.90 (0.79-1.01)
(95% CI) (ml/min/1.73m2)  (n)  (%) 
Nitrofurantoin
Trimethoprim
> 80
50-80
30-49
10-29
< 10
Unknown
Overall
94
114
14
0
0
1,092
1,314
(16.0)
(19.1)
(18.9)
(0) 
(0)
(16.4)
(16.6)
15,537 
15,315 
1,889 
240
30 
174,811 
207,822
6.05 
7.44 
7.41 
NA 
NA 
6.25 
6.32
1.00 reference 
1.22 (0.93-1.60) 
1.20 (0.68-2.10) 
NA
NA
1.03 (0.84-1.27)
1.00 reference 
1.15 (0.87-1.51) 
1.06 (0.60-1.88) 
NA
NA
1.03 (0.83-1.27)
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Table 4.3 Association between renal impairment and serious adverse eventsa
eGFR Adverse
eventa
Follow-up time
≥ 50
< 50
Unknown
Overall
13
4
17
34
332,399
16,618
1,567,746
1,916,763
Incidence 
density
0.04
0.24
0.01
0.02
Crude HR
1.00 reference 
6.14 (2.00-18.83) 
0.28 (0.14-0.57) 
(0.35)
(2.14)
(0.10)
(0.16)
a 
b  
HR, hazard ratio; 95% CI, 95% condence interval; NA, data not available.
Adverse events during subsequent hospital admissions within 90 days after the start of a course of nitrofurantoin treatment: 
pulmonary reactions (n = 33) and blood dyscrasias (n = 1). Adverse events after start of a course of trimethoprim treatment: 
pulmonary reactions (n = 8).
Adjusted for age.
 (person-days)  (per 1000 person-days) (95% CI)
Adjusted HR b
1.00 reference 
4.13 (1.31-13.09) 
0.35 (0.17-0.73) 
(95% CI) (ml/min/1.73m2)  (n)  (%) 
Nitrofurantoin
Trimethoprim
≥ 50
< 50
Unknown
Overall
NA
NA
(0.12)
(0.10)
0
0
8
8
106,740
7,470
598,572
712,782
NA
NA
0.01
0.01
1.00 reference 
NA
NA
1.00 reference
NA
NA
Compared to trimethoprim users, the mean age of nitrofurantoin users was 
significantly lower (p < 0.001), the use of immunosuppressive drugs and urinary 
antispasmodics was significantly higher (p < 0.001 and p = 0.002, respectively) and 
the mean duration of antibacterial treatment was significantly longer (p < 0.001).
Table 4.2 shows the association between renal impairment and the risk of a second 
antibacterial (ineffective treatment) within 1 month after start of nitrofurantoin. 
Overall incidence density for ineffectiveness in nitrofurantoin users was 5.4 per 1,000 
person-days. Although a trend for higher incidence densities was observed as renal 
function declined, renal impairment was not significantly associated with ineffective 
treatment. The overall incidence density for ineffectiveness in trimethoprim users 
was 6.3 per 1,000 person-days.
There was no significant association or trend observed between ineffective treatment 
and renal impairment. Table 4.3 shows the association between renal impairment 
and the risk of an adverse event due to nitrofurantoin leading to hospitalization. 
Pulmonary reactions (unspecified chest pain [n = 28], painful respiration [n = 3] 
and pleural effusion [n = 1]) and blood dyscrasias (haemolytic anemia [n = 1]) were 
observed during the 3 months of follow-up after the start of nitrofurantoin treatment. 
Neuropathy, allergic reactions and liver damage were not reported. 
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Eight adverse events were observed in trimethoprim users with unknown renal 
function, all events were pulmonary reactions (n = 8). The overall incidence density 
for serious adverse events was 0.02 and 0.01 per 1,000 person-days for nitrofurantoin 
and trimethoprim users, respectively. The risk of an adverse event was significantly 
higher in nitrofurantoin users with renal impairment (< 50 ml/min/1.73m2 [adjusted 
HR 4.1, 95% CI 1.31–13.09]) compared to nitrofurantoin users with good renal 
function (≥ 50 ml/min/1.73m2). Due to the low incidence of adverse events in 
trimethoprim users, the HRs could not be calculated.
Discussion
Overall, nitrofurantoin treatment was not significantly associated with ineffectiveness 
in women with UTI and moderate renal impairment (30-50 ml/min/1.73m2). 
However, adverse events due to nitrofurantoin use leading to hospitalization were 
significantly associated with renal impairment < 50 ml/min/1.73m2.
The amount of nitrofurantoin excreted into the urine is directly related to renal 
function and, therefore, nitrofurantoin may be ineffective for the treatment of 
UTI in patients with impaired renal function.7,9,10 A recent review reports that 
sufficient clinical evidence for an effect of renal impairment on the effectiveness and 
adverse events of nitrofurantoin is lacking.20 In accordance, Bains et al. reported 
that nitrofurantoin is effective and well tolerated in hospitalized patients with renal 
impairment (< 50 ml/min).11 In their study, the frequencies for starting a second 
antibacterial after nitrofurantoin treatment were 29% in the renal impairment group 
versus 22% in the group without renal impairment. In our population of outpatients 
these frequencies were somewhat lower, namely 22% and 16%, respectively.
In our study, no neuropathy, allergic reactions and liver damage were diagnosed 
during the 3 months of follow-up after the start of nitrofurantoin treatment. 
Pulmonary reactions were the most frequently diagnosed adverse reactions (0.16%). 
This observation is in agreement with the results of Holmberg et al. who also 
observed pulmonary reactions to be the most frequent adverse reactions associated 
with nitrofurantoin treatment.16 In addition, several guidelines include a warning for 
pulmonary reactions due to nitrofurantoin, especially in the elderly patient.21
We observed lower point estimates for ineffective treatment and/or serious adverse 
events among patients with unknown renal function than among those with a known 
renal function. One possible explanation could be that patients with an unknown 
renal function are ‘healthy survivors’.22  
The strength of our study is that it was conducted in a very large study population 
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with a relative long follow-up time in general practice. However, there are a number 
of limitations to our study. First, the outcome second antibacterial treatment after 
an initial nitrofurantoin treatment may not have been sufficiently sensitive to classify 
ineffectiveness correctly in all cases. Although we selected only antibacterials used 
for UTI treatment, patients can receive those antibacterials for other reasons. 
Second, the registration of adverse events in the PHARMO database is limited 
to adverse events leading to hospitalization, which may only encompass the tip 
of the iceberg of all adverse events. Therefore, the occurrence of adverse events of 
nitrofurantoin use in relation to renal impairment may have been underestimated. 
A third limitation is the limited numbers of nitrofurantoin users with moderate or 
severe renal impairment (n = 166 and n = 20, respectively). An explanation for these 
small numbers could be that physicians were well aware of the contraindication 
for nitrofurantoin and mostly acted accordingly. The fourth limitation is that the 
classification of renal function groups was based on a single eGFR value of not more 
than 1 year old. This choice was for pragmatic reasons because clinical guidelines 
often recommend annual monitoring of renal function. However, variability in serum 
creatinine measurements ideally requires at least two creatinine measurements in a 
shorter period of time.23
In conclusion, this retrospective cohort study shows that nitrofurantoin treatment 
may be effective in women with UTI and renal impairment. However, we did find 
a significant association between renal impairment and pulmonary adverse events 
leading to hospitalization. Establishing the effectiveness and safety of nitrofurantoin 
use in women with renal impairment requires more sensitive outcome measurements.
What does this study add?
According to the drug label nitrofurantoin is contraindicated when the eGFR is 
< 60 ml/min because of ineffectiveness and safety problems. New evidence suggests 
that nitrofurantoin in patients with lower eGFRs may be both effective and safe. 
In our study, we found no evidence that the treatment of these women with 
nitrofurantoin is less effective; however, the number of adverse events leading to 
hospitalization was significantly increased.
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Appendix 4.1. Potentially adverse reactions of nitrofurantoin with 
corresponding ICD-9 codes
Type of adverse reaction1,2
General adverse events
ICD-9 code Description of ICD-9 code
E857Overdosing
Pulmonary reactions
Accidental poisoning by other anti-
infectives; ucytosine and nitrofurantoin 
derivatives
E931.9Adverse eects (in general) Adverse eects by other and unspecied 
anti-infectives; ucytosine and 
nitrofurantoin derivatives
519.9Common pulmonary reactions Unspecied disease of respiratory system
Respiratory Disease (chronic) NOS
516.33Acute cellular interstitial lung disease/
pneumonia
Acute interstitial pneumonitis
516.30Subacute interstitial pneumonia Idiopathic interstitial pneumonia, not 
otherwise specied. Idiopathic brosing 
alveolitis
516.32 Idiopathic non-specic interstitial 
pneumonitis
518.3Pulmonary inltrates and eosinophilia 
Eosinophilic pneumonia 
Pulmonary eosinophilia
516.8Organising pneumonia ( BOOP - 
AFOP)
Other specied alveolar and parietoalveolar 
pneumonopathies
Endogenous lipoid pneumonia; Interstitial 
pneumonia; Lymphoid interstitial pneumo-
nia due to known underlying cause; 
Lymphoid interstitial pneumonia NOS; 
Non-specic interstitial pneumonia due to 
known underlying cause; Non-specic 
interstitial pneumonia NOS; Organizing 
pneumonia due to known underlying cause; 
Organizing pneumonia NOS
516.37Desquamative interstitial pneumonia 
(DIP pattern)
Desquamative interstitial pneumonia
516.31Pulmonary brosis Idiopathic pulmonary brosis
Cryptogenic brosing alveolitis
518.82Diuse alveolar damage (DAD):
ARDS is a clinical syndrome associated 
with a variety of pathological ndings. 
ese include pneumonia, eosinophilic 
pneumonia, cryptogenic organizing 
pneumonia, acute brinous organizing 
pneumonia, and diuse alveolar damage 
(DAD). Of these, the pathology most 
commonly associated with ARDS is 
DAD.
Other pulmonary insuciency, not 
elsewhere classied
Acute respiratory distress
Acute respiratory insuciency
Adult respiratory distress syndrome 
518.4Acute severe pulmonary oedema/ARDS Acute edema of lung, unspecied
Acute pulmonary edema NOS; pulmonary 
edema postoperative
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Type of adverse reaction1,2 ICD-9 code Description of ICD-9 code
Pulmonary reactions (continued)
786 (3)Diuse alveolar haemorrhage  (ANCA) 786.3 Haemoptysis
Cough with haemorrhage
Pulmonary haemorrhage
519.11Acute bronchospasm Acute bronchospasm
Bronchospasm NOS
517.8Bronchospasm and angioedema 
(anaphylaxis)
Other anaphylactic reaction {Allergic 
shock}{Anaphylactic reaction}{Anaphylac-
tic shock}{Anaphylaxis} NOS or due to 
adverse eect of correct medicinal 
substance properly Administered; 
Anaphylactoid reaction NOS
995.0
Lung involvement in other diseases 
classied elsewhere
995.1 Angioneurotic edema, not elsewhere 
classied
Giant urticaria; Allergic angioedema
511.9Pleural eusion Unspecied pleural eusion
Pleural eusion NOS; Pleurisy: exudative, 
serobrinous, serous, with eusion NOS
417.8Pulmonary vasculitis Other specied diseases of pulmonary 
circulation: 
•Pulmonary:arteritis endarteritis
•Rupture of pulmonary vessel
•Stricture of pulmonary vessel
786.3Peritracheal/mediastinal haemorrhage 
and upper airway obstruction
Haemoptysis
518.3Skin rash, eosinophilia, and internal 
organs involvement including 
pneumonia (DRESS)
Pulmonary eosinophilia 
Eosinophilic asthma 
Löer's syndrome 
Pneumonia: allergic + eosinophilic
Tropical eosinophilia
Isolated acute chest pain 786.50 Unspecied chest pain
Painful respiration. Pain: anterior chest wall, 
pleuritic; Pleurodynia
786.52
Acute chest pain and interstitial lung 
disease
786.5 Symptoms involving respiratory system and 
other chest symptoms 
786.5 Chest pain
995.3Common Allergy unspecied, not elsewhere 
classied
Allergic reaction NOS; Hypersensitivity 
NOS; Idiosyncrasy NOS
Allergic reactions
995.20 Unspecied adverse eect of unspecied 
drug, medicinal, and biological substance
Unspecied adverse eect of unspecied 
medicinal substance properly administered
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Type of adverse reaction1,2 ICD-9 code Description of ICD-9 code
Common (continued)
Allergic reactions (continued)
995.27 Other drug allergy
Allergic reaction NEC (due) to correct 
medical substance properly administered; 
Drug allergy NOS; Drug hypersensitivity 
NOS; Hypersensitivity (due) to correct 
medical substance properly administered
Unspeci ed adverse e­ect of other drug, 
medicinal, and biological substance
Unspeci ed adverse e­ect of medicinal 
substance NEC properly administered
995.29
995.0Anaphylactic reaction Other anaphylactic reaction
{Allergic shock}{Anaphylactic 
reaction}{Anaphylactic shock}{Anaphylaxis} 
NOS or due to adverse e­ect of correct 
medicinal substance properly administered; 
Anaphylactoid reaction NOS
698.9Pruritus Unspeci ed pruritic disorder
Itch NOS; Pruritus NOS
708.0Urticaria Allergic urticaria
995.1Angioedema Angioneurotic edema, not elsewhere 
classi ed; Allergic angioedema
Erythema multiforme 695.1 Erythema multiforme
Fever, unspeci ed
Chills with fever; Fever NOS; Fever of 
unknown origin (FUO); Hyperpyrexia 
NOS; Pyrexia NOS; Pyrexia of unknown 
origin
780.60
Hepatomegaly 789.1 Hepatomegaly
Enlargement of liver
Fever
Liver damage
Jaundice 782.4 Jaundice, unspeci ed, not of newborn
Cholemia NOS; Icterus NOS
283.0Haemolytic anemia
Blood dyscrasias
Autoimmune haemolytic anemias
Autoimmune haemolytic disease (cold 
type) (warm type); Chronic cold hemag-
glutinin disease; Cold agglutinin disease or 
hemoglobinuria; Haemolytic anemia: cold 
type (secondary) (symptomatic), drug-
induced, wart type (secondary) 
(symptomatic)
283.1 Non-autoimmune haemolytic anemias
283.9 Acquired haemolytic anemia, unspeci ed
Acquired haemolytic anemia NOS; 
Chronic idiopathic haemolytic anemia
287.5rombocytopenia rombocytopenia, unspeci ed
287.30 Primary thrombocytopenia, unspeci ed
Megakaryocytic hypoplasia
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Type of adverse reaction1,2 ICD-9 code Description of ICD-9 code
Blood dyscrasias (continued)
rombocytopenia (continued)
287.9Severe haemorrhagic diathesis Unspecied haemorrhagic conditions
Haemorrhagic diathesis (familial)
288.09Allergic agranulocytosis Other neutropenia
Agranulocytosis; Neutropenia: immune, toxic
288.03Neutropenia Drug induced neutropenia
Pancytopenia 284.1 Pancytopenia
356.8 Other specied idiopathic peripheral 
neuropathy. Supranuclear paralysis
Neuropathy
Neuropathy 356.4 Idiopathic progressive polyneuropathy
287.39 Other primary thrombocytopenia
287.49 Other secondary thrombocytopenia
rombocytopenia (due to): dilutional, 
drugs, extracorporeal circulation of blood, 
massive blood transfusion, platelet 
alloimmunization, secondary NOS
Neutropenia, unspecied288.00
356.9 Unspecied idiopathic peripheral 
neuropathy
357.6 Polyneuropathy due to drugs
357.9 Unspecied inammatory and toxic 
neuropathies
357.89 Other inammatory and toxic neuropathy
1 Aronson JK. Meyler's side eects of drugs. ed. 15th: Elsevier science BV; 2006.
2 Holmberg L, Boman G, Bottiger LE, Eriksson B, Spross R, Wessling A. Adverse reactions to nitrofurantoin. Analysis of 921 
reports. Am J Med. 1980;69:733-8.
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Abstract
Objective
The objective of this study was to determine whether treatment with metformin 
in patients with renal impairment is associated with a higher risk of lactic acidosis 
or elevated lactate concentrations compared with users of a noninsulin antidiabetic 
drug (NIAD) who had never used metformin.
Research design and methods
A cohort of 223,968 metformin users and 34,571 diabetic patients who had never 
used metformin were identified from the Clinical Practice Research Datalink 
(CPRD). The primary outcome was defined as either a CPRD READ code of lactic 
acidosis or a record of a plasmalactate concentration > 5 mmol/l. The associations 
between renal impairment, dose of metformin, and the risk of lactic acidosis or 
elevated lactate concentrations were determined with time-dependent Cox models 
and expressed as hazard ratios (HRs).
Results
The crude incidence of lactic acidosis or elevated lactate concentrations in current 
metformin users was 7.4 per 100,000 person-years (versus 2.2 per 100,000 person-
years in nonusers). Compared with nonusers, risk of lactic acidosis or elevated lactate 
concentrations in current metformin users was significantly associated with a renal 
function < 60 ml/min/1.73m2 (adjusted HR 6.37, 95% CI 1.48-27.5). The increased 
risk among patients with impaired renal function was further increased in users of 
≥ 730 g of metformin in the preceding year (adjusted HR 11.8, 95% CI 2.27-61.5) 
and in users of a recent high daily dose (> 2 g) of metformin (adjusted HR 13.0, 
95% CI 2.36-72.0).
Conclusions
Our study is consistent with current recommendations that the renal function of 
metformin users should be adequately monitored and that the dose of metformin 
should be adjusted, if necessary, if renal function falls below 60 ml/min/1.73m2.
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Introduction
There is good evidence that metformin reduces the long-term incidence of 
macrovascular complications in type 2 diabetes mellitus, especially among 
overweight patients.1-3 In contrast to alternative oral noninsulin antidiabetic drugs 
(NIADs) and insulin, metformin is not associated with a risk of hypoglycemia.3-5 
The most serious adverse event that has been observed during metformin use is 
lactic acidosis, which is characterized by an elevated blood lactate concentration 
(> 5 mmol/l), decreased blood pH (< 7.35) and electrolyte disturbances with an 
increased anion gap.1,6-9 Estimated rates of lactic acidosis incidence during metformin 
use range from 1 to 47 cases per 100,000 person-years.10,11 Reported predisposing 
factors include acute kidney injury, history of lactic acidosis, hypovolemia, decreased 
tissue perfusion or hemodynamic instability due to infection or other causes, seizure, 
concurrent liver disease, alcohol abuse, acute heart failure, myocardial infarction, 
and shock.12-14 Although lactic acidosis during metformin use has a better prognosis 
than other types of severe lactic acidosis15, reported mortality rates may be as high as 
25-50%.1,4,8 Yet metformin itself has not been linked to mortality in users developing 
lactic acidosis during metformin use, which perhaps reflects a primary effect of other 
underlying causes of the acidosis.16 
According to current guidelines, the dose of metformin should be reviewed if 
the estimated glomerular filtration rate (eGFR) falls to < 45 ml/min/1.73m2, and 
the drug should be stopped in patients with an eGFR < 30 ml/min/1.73m2.3,17,18 
A decreased glomerular filtration rate may theoretically increase the risk of lactic 
acidosis during metformin use because metformin is eliminated unchanged by the 
kidneys and may therefore accumulate when kidney function becomes impaired.3,19 
However, the role of chronic renal insufficiency as a risk factor for lactic acidosis 
during metformin use remains controversial.
On the one hand, some authors argue that an association between high 
concentrations of metformin and lactic acidosis should be assumed because, for 
example, supratherapeutic plasma concentrations of metformin have frequently 
been found in patients with lactic acidosis during metformin use and because high 
metformin concentrations have been shown to increase plasma lactate in rats.4,9,20 
On the other hand, a contributory role of chronic renal insufficiency to lactic acidosis 
during metformin use was not confirmed in large epidemiological studies12,21, and a 
recent study of 56 cases of severe lactic acidosis during metformin use did not find a 
prognostic value for blood lactate.22
Duong et al.9 argue that there may be three different forms of lactic acidosis 
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during metformin use and that one of these is characterized by the accumulation 
of metformin together with acute impairment of renal function and organ 
decompensation, such as acute or chronic heart failure, induced by sepsis and/or 
dehydration. They hypothesize that this type of lactic acidosis during metformin use 
involves a positive feedback system comprising one or more of the following factors: 
vomiting and diarrhea, acute kidney injury, high doses or excessive accumulation 
of metformin, and acute disease states leading to tissue hypoxia. They suggest that 
lactic acidosis may commence with relatively small changes in hydration, kidney 
function, plasma concentrations of metformin, or tissue oxygenation, which then 
lead to positive feedback and severe lactic acidosis.
The aim of this study, therefore, was to evaluate retrospectively, in a large cohort 
of patients using a NIAD, whether treatment with metformin is associated with a 
higher risk of lactic acidosis or elevated lactate concentrations in patients with renal 
impairment compared with patients who had never used metformin. In addition, 
the risk of lactic acidosis or elevated lactate concentrations in patients with different 
metformin doses was evaluated.
Research design and methods
Data sources
We conducted a retrospective cohort study using the Clinical Practice Research 
Datalink (CPRD), previously known as the General Practice Research Database. 
The CPRD collates the computerized medical records of general practitioners 
(GPs). GPs play a key role in the U.K. health care system; they are responsible for 
primary health care and specialist referrals. Patients are semipermanently affiliated 
with a practice that centralizes the medical information from the GPs, specialist 
referrals, and hospitalizations. The data recorded in the CPRD include demographic 
information, prescription details, clinical events, preventive care provided, specialist 
referrals, hospital admissions, and major outcomes since 1987 (www.CPRD.com).
Study population
All patients with at least one prescription for a NIAD and age > 18 years during 
the period of valid CPRD data collection were enrolled. For this study, data 
collection started in April 2004, with the introduction of the Quality and Outcomes 
Framework, and ended in August 2012. The first NIAD prescription after the start 
of data collection defined the index date. Patients with a record of any renal transplant 
or dialysis during the study period were excluded (n = 152 among metformin users; 
n = 234 among nonusers).
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Exposure
Exposure to metformin and/or other NIADs was assessed in a time-dependent 
manner. For this purpose, total follow-up of each individual was divided into small 
time intervals. The length of a time interval was based on NIAD prescriptions: 
a time interval starts with a NIAD prescription and ends 1 day before the next 
NIAD prescription. If the length of a time interval exceeded 90 days, the interval 
was further divided into separate 90-day intervals. This approach minimizes 
exposure misclassification. For each time interval, the exposure to metformin was 
assessed as (1) current metformin use (at least one metformin prescription in the 
3 months before the start of a time interval); (2) recent metformin use (a most recent 
metformin prescription between 3 and 6 months before the start of a time interval); 
(3) past metformin use (the most recent metformin prescription > 6 months before 
the start of a time interval); and (4) never metformin use (no metformin prescription 
at any time before the start of a time interval). As a consequence, a patient could 
move between never, current, recent, and past metformin use. A past user could 
become a current metformin user in the event of a new metformin prescription. 
Current metformin users were stratified according to their cumulative metformin 
exposure in the previous year (< 730 g [< 365 x 2 g] and ≥ 730 g) and their most 
recent prescribed daily metformin dose (≤ 2 g and > 2 g).
Renal function
For current metformin users, we evaluated the most recently recorded renal function 
1 week to 1 year before the start of an interval. Renal function was evaluated by 
reviewing laboratory test data (eGFR(MDRD) where possible), and CPRD READ 
codes (stages of chronic kidney disease). In the event of multiple eGFR values on the 
same day, the mean value was used. CPRD READ codes were prioritized if there 
was a laboratory test on the same day as recording.
Outcomes
Patients were followed up from the index date to either the end of data collection, 
the date the patient transferred out of the practice area, the patient’s death, or an 
event of lactic acidosis or elevated lactate concentration.
Lactic acidosis or elevated lactate concentrations were evaluated either by a CPRD 
READ code for lactic acidosis or by a record of plasma lactate concentration of 
> 5 mmol/l, whichever came first. In the event of multiple laboratory tests for lactate 
concentrations on the same day, the lowest value was used. In a sensitivity analysis, 
the highest value was used instead of the lowest value. CPRD READ codes for lactic 
acidosis were prioritized if there was a laboratory test on the same day as recording.
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Potential confounders
The presence of risk factors for lactic acidosis during metformin use was assessed 
by reviewing the computerized medical records before the start of an interval. Risk 
factors that were considered in this study included age, sex, smoking status, body 
mass index (BMI), alcohol use, hemoglobin A1c (HbA1c), and a history of asthma/
chronic obstructive pulmonary disease, chronic liver disease, heart failure, and/or 
sepsis.12,23-25 We further considered a prescription in the previous 6 months for drugs 
that may have influenced renal function (including nonsteroidal anti-inflammatory 
drugs, renin-angiotensin-aldosterone-system inhibitors, loop diuretics, thiazide 
diuretics, beta blockers, statins, and systemic calcineurin inhibitors).
Data analysis
Cox regression analysis compared hazard rates of lactic acidosis or elevated lactate 
concentrations in current metformin users versus NIAD users who had never used 
metformin (SAS software version 9.2). Confounders were entered into the final 
model if they independently changed the ß-coefficient for current metformin use 
by at least 5%. The main association for possible interactions with any of the risk 
factors was tested. Current metformin users were further stratified according to 
renal function and metformin dose.
Results
Table 5.1 displays the baseline characteristics of NIAD users who were either current 
metformin users (n = 223,968) or nonusers (n = 34,571). The mean duration of 
follow-up was 4.3 years for metformin users and 4.9 years for nonusers. Metformin 
users were younger (60.1 years) than nonusers (67.8 years). No substantial difference 
in sex distribution was observed. The proportion of metformin users with stage 4 
or 5 chronic kidney disease (eGFR < 30 ml/min/1.73m2) was lower than that of 
NIAD users (0.3% and 2.8%, respectively). Heart failure was less prevalent among 
the metformin users compared with the nonusers (3.9% and 8.3%, respectively). Age 
was strongly correlated with worsening glomerular filtration rate (GFR): patients 
younger than 50 years old had a GFR of 96 ml/min/1.73m2, those aged 50-64 years 
had a GFR of 84 ml/min/1.73m2, patients aged 65-79 years had a GFR of 70 ml/
min/1.73m2, and the lowest GFR (59 ml/min/1.73m2) was seen in patients aged 
80 years and older (data not shown). Patients suffering from lactate acidosis or 
elevated lactate concentrations had a median age of 72 years (75% were older than 
60 years of age).
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Characteristic Current metformin users
NSAIDs
RAAS inhibitors
Loop diuretics

iazide diuretics
Beta blockers
Statins
Systemic calcineurin inhibitors
51,394 
49,018 
59,363 
45,689 
18,504
2,259 
25,816 
71,071 
63,622 
55,885 
5,315
(17.9)
(40.7)
(9.8)
(18.1)
(17.9)
(44.6)
(0.1)
Data are n (%) unless otherwise indicated. 
a 
b
BMI, body mass index; COPD, chronic obstructive pulmonary disease; NIAD, noninsulin antidiabetic drug; NSAID, non-steroidal 
anti-inammatory drug; RAAS, renin-angiotensin-aldosteron-system; SD, standard deviation.
Time represents valid follow-up time for patients using metformin and control patients not using metformin.
Proportion of renal function originating from READ codes: 3.6%, and 96.4% from laboratory test events.
n = 223,968  (%) 
Non-users
n = 34,571      (%) 
Follow-up time, years (mean, SD)a 
Female sex
Age, years (mean, SD)
18 – 49 
50 – 59 
60 – 69 
70 – 79≥ 80 years
Most recent renal function (ml/min/1.73m2) in the previous yearb
< 30
30 – 59≥ 60 
Unknown
Smoking status
Current smoker 
Former smoker 
Never smoker 
Unknown
BMI, kg/m2 (mean, SD)
< 20.0
20.0 – 24.9
25.0 – 29.9
30.0 – 34.9
≥ 35.0 
Unknown
Alcohol use
Yes
No 
Unknown
History of disease
Asthma/COPD 
Chronic liver disease 
Heart failure
Sepsis
Drug use within six months with potential inuence on renal function
4.3 (2.8)
105,561 
60.1 (14.8)
586 
29,742 
132,344 
61,296
45,258 
66,485 
111,137 
1,088 
31.6 (6.6) 
147,319 
64,408 
12,241
36,670 
3,511 
8,794 
2,827
40,147
91,230
21,874
40,538
40,090
99,990
316
(47.1)
(22.9) 
(21.9) 
(26.5) 
(20.4) 
(8.3)
(0.3) 
(13.3) 
(59.1) 
(27.4)
(20.2) 
(29.7) 
(49.6) 
(0.5)
(1.0) 
(11.5) 
(31.7) 
(28.4) 
(25.0) 
(2.4)
(65.8)
(28.8)
(5.5)
(16.4) 
(1.6) 
(3.9) 
(1.3)
4.9 (3.0)
15,007 
67.8 (14.5) 
4,221 
4,997 
7,899 
9,558 
7,896
955 
7,436 
14,235 
11,945
6,848 
9,706 
17,387 
630
27.6 (5.7)
1,502 
9,777 
12,205 
5,647 
3,176 
2,264
20,861 
10,363 
3,347
5,309 
733 
2,879 
488
5,435 
12,151 
5,468 
5,497 
6,534 
14,070 
255
(15.7) 
(35.1)
(15.8) 
(15.9) 
(18.9) 
(40.7) 
(0.7)
(15.4) 
(2.1) 
(8.3) 
(1.4)
(60.3) 
(30.0) 
(9.7)
(4.3) 
(28.3) 
(35.3) 
(16.3) 
(9.2) 
(6.5)
(19.8) 
(28.1) 
(50.2) 
(1.8)
(2.8) 
(21.5) 
(41.2) 
(34.6)
(12.2) 
(14.5) 
(22.8) 
(27.6) 
(22.8)
(43.4)
Table 5.1 Baseline characteristics of current metformin users and nonusers among patients using 
NIADs
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Table 5.2 shows that the incidence rate of lactic acidosis or elevated lactate 
concentrations was 7.4 events per 100,000 person-years among current metformin 
users versus 2.2 events per 100,000 person-years among nonusers. Of a total of 68 
events of lactic acidosis or elevated lactate concentrations, 50 (74%) originated from 
a READ code for lactic acidosis, whereas 18 (26%) were derived from an elevated 
plasma lactate concentration. Three events had both a READ record for lactic 
acidosis and a positive laboratory test. Current metformin users had a fourfold risk 
compared with NIAD users who had never used metformin, but this increase was 
not statistically significant (adjusted hazard ratio [AHR] 4.03, 95% CI 0.97-16.8). 
The risk among recent or past users of metformin also was nonsignificantly 
increased. None of the results were influenced by our sensitivity analysis, which 
used the highest value (instead of the lowest value) in the event of multiple lactate 
concentrations on the same day.
Never use
Past use
Recent use
Current use
91,287
212,007
40,526
743,151
2
9
2
55
1.94 (0.42-8.97)
2.25 (0.32-16.0)
3.38 (0.82-13.8)
2.25 (0.48-10.5)
2.99 (0.42-21.5)
4.03 (0.97-16.8)
Current metformin users are stratied by renal function.
a 
b
c
CI, condence interval; HR, hazard ratio.
Adjusted for age, sex, body mass index, a history of heart failure, and use of renin-angiotensin-aldosterone system inhibitors and 
other noninsulin antidiabetic drugs/insulin in the previous 6 months. Chronic liver disease and sepsis were not included in the 
nal model because there were too few exposed patients.
Renal function records in the previous week are excluded.
is substratum included 8,849 person-years, with one event that could not be subdivided further because the patients only had a 
READ code for Chronic Kidney Disease Stage 3 (30-59 ml/min/1.73m2).
Stratication of current users by most recent renal function (ml/min/1.73m2) in previous yearb
≥ 60 
< 60
   30-59 c 
     45-59 
     30-44
   < 30
≥ 45
< 45 
Unknown
547,731
126,881
124,275
89,976
25,450
2,605
644,861
29,751
68,539
29
21
19
13
5
2
43
7
5
(0.58-10.1)
(1.77-32.2)
(1.98-27.9)
(1.49-29.2)
(1.61-39.6)
(4.90-249)
(0.79-13.8)
(1.85-43.4)
(0.65-17.2)
2.42
7.56
7.09
6.60
7.98
35.1
3.30
8.97
3.33
2.87
6.37
5.94
6.06
5.47
25.7
3.16
6.74
4.51
(0.67-12.3)
(1.48-27.5)
(1.55-24.7)
(1.37-27.1)
(1.05-28.5)
(3.57-185)
(0.75-13.3)
(1.34-33.8)
(0.85-23.8)
Reference Reference
Metformin use Age/sex adjusted HR Adjusted HR
Risk of lactic acidosis or elevated lactate concentrations
(n) (n) (95% CI)a(95% CI)
EventsPerson-years
The different strata of current metformin users (compared with NIAD users who had 
never used metformin) showed the following increases in the risk of lactic acidosis or 
Table 5.2 Risk of lactic acidosis or elevated lactate concentrations in current, recent, and past 
metformin users compared with never users of metformin
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elevated lactate concentrations: (1) the risk in those with a most recent renal function 
< 60 ml/min/1.73m2 was significantly higher than the risk in never users (AHR 6.37, 
95% CI 1.48-27.5), whereas the risk in current users with renal function ≥ 60 ml/
min/1.73m2 (AHR 2.87, 95% CI 0.67-12.3) was not; (2) in an additional analysis, we 
looked at an eGFR cut-point of 45 ml/min/1.73m2. Current metformin users with 
an eGFR of ≥ 45 ml/min/1.73m2 had an AHR of lactic acidosis or elevated lactate 
concentrations of 3.16 (95% CI 0.75-13.3), whereas those with poorer renal function 
(eGFR < 45 ml/min/1.73m2) had an AHR of 6.74 (95% CI 1.34-33.8). Among 
metformin users with a recorded eGFR value, 14% of all lactic acidosis or elevated 
lactate concentrations occurred among those with an eGFR of < 45 ml/min/1.73m2; 
(3) the risk in those with a cumulative exposure to metformin of ≥ 730 g in the 
previous year (AHR 6.14, 95% CI 1.35-28.0) was significantly increased. This was 
not the case in those with an exposure < 730 g (AHR 3.69, 95% CI 0.88-15.5); 
(4) the risk in those with a recent prescribed daily dose of > 2 g of metformin 
(AHR 6.40, 95% CI 1.35-30.3) was significantly increased. This was not the case in 
those with a dose of ≤ 2 g of metformin (AHR 3.78, 95% CI 0.90-15.8). 
When the strata in analyses 3 and 4 were substratified by renal function, the risk 
in metformin users with renal function < 60 ml/min/1.73m2 consistently showed 
a significant increase. This was not seen in those with renal function ≥ 60 ml/
min/1.73m2 (Table 5.3). Compared with never users, there was an almost 12-fold 
risk in the substratum with reduced renal function and a cumulative exposure to 
≥ 730 g of metformin in the preceding year (AHR 11.8, 95% CI 2.27-61.5) and a 
13-fold increase in the substratum with reduced renal function and recent exposure 
to > 2 g of metformin/day (AHR 13.0, 95% CI 2.36-72.0).
Discussion
The risk of lactic acidosis or elevated lactate concentrations was increased sixfold 
in current metformin users with reduced renal function (Table 5.2). It increased 
further to 12- or 13-fold in substrata with high cumulative exposure to metformin 
in the preceding year or with recent high daily exposure to metformin (Table 5.3).
Our crude incidence rate of lactic acidosis or elevated lactate concentrations, 
7.4 events per 100,000 person-years among current metformin users, corresponds 
well with the range of one to nine cases of lactic acidosis per 100,000 person-years of 
metformin use that emerged from previous studies.7,10,12,26 Higher incidences of 47 to 
57 cases per 100,000 person-years also have been reported, but this is probably due 
to differences in study design.11,27 Ekström et al. assessed whether different degrees 
of renal function affect the safety of metformin use in a cohort study comprising 
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more than 51,000 patients with type 2 diabetes.21 To evaluate the occurrence of 
lactic acidosis, they used a composite end point that included a diagnosis of acidosis, 
shock, acute renal failure, and serious infections. When metformin use was compared 
with any other treatment, the risk of acidosis/serious infection was not significantly 
increased in patients with an eGFR ≤ 60 ml/min/1.73m2.21
In contrast with these negative findings, we found that reduced renal function or 
high cumulative or daily exposure to metformin (all of which can lead to higher 
concentrations of metformin) were associated with an increased risk of lactic acidosis 
or elevated lactate concentrations. That the risk was further increased when both 
reduced renal function and a high intake of metformin were present is of particular 
658,391
483,674
113,530
61,187
84,759
64,057
13,350
  7,352
46
24
17
5
9
5
4
0
3.19 (0.77‐13.1)
2.27 (0.54‐9.58)
6.84 (1.58‐29.6)
3.73 (0.72‐19.2)
4.85 (1.05‐22.4)
3.56 (0.69‐18.4)
13.7 (2.51‐74.7)
3.78 (0.90‐15.8)
2.71 (0.63‐11.7)
5.66 (1.29‐24.8)
5.19 (0.98‐27.4)
6.40 (1.35‐30.3)
4.59 (0.87‐24.3)
13.0 (2.36‐72.0)
a 
b
CI, condence interval; HR, hazard ratio.
Adjusted for age, sex, body mass index, a history of heart failure, and use of renin‐angiotensin‐aldosterone system inhibitors and 
other noninsulin antidiabetic drugs/insulin in the previous 6 months. Chronic liver disease and sepsis were not included in the 
nal model because there were too few exposed patients.
Stratication by most recent renal function in previous year. Renal function records in previous week are excluded.
Never use
Current use
Stratication of current users by cumulative exposure to metformin in previous year and renal function b
< 730 g of metformin/year 
   Renal function ≥ 60 ml/min/1.73m2 
   Renal function < 60 ml/min/1.73m2 
   Unknown 
≥ 730 g of metformin/year 
   Renal function ≥ 60 ml/min/1.73m2 
   Renal function < 60 ml/min/1.73m2 
   Unknown
Stratication of current users by most recent prescribed daily dose of metformin and renal function b
≤ 2 g of metformin/day
   Renal function ≥ 60 ml/min/1.73m2 
   Renal function < 60 ml/min/1.73m2 
   Unknown 
> 2 g of metformin/day 
   Renal function ≥ 60 ml/min/1.73m2 
   Renal function < 60 ml/min/1.73m2 
   Unknown
91,287
743,151
628,644
460,012
108,561
60,071
114,506
87,719
18,320
8,468
Reference
4.03 (0.97‐16.8)
3.69 (0.88‐15.5)
2.73 (0.63‐11.9)
5.54 (1.26‐24.4)
4.25 (0.76‐23.7)
6.14 (1.35‐28.0)
3.94 (0.78‐20.0)
11.8 (2.27‐61.5)
6.96 (0.62‐78.0)
Reference
3.38 (0.82‐13.8)
3.12 (0.76‐12.9)
2.28 (0.54‐9.65)
6.72 (1.55‐29.2)
3.03 (0.56‐16.5)
4.78 (1.07‐21.4)
3.12 (0.63‐15.4)
12.4 (2.42‐64.1)
5.38 (0.49‐59.3)
2
55
43
23
16
4
12
6
5
1
Metformin use Age/sex adjusted HR Adjusted HR
Risk of lactic acidosis or elevated lactate concentrations
(n) (n) (95% CI)a(95% CI)
EventsPerson-years
Table 5.3 Risk of lactic acidosis or elevated lactate concentrations in current metformin users 
stratified by cumulative exposure or recent daily exposure to metformin and further stratified by 
renal function
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interest. This lends support to the supposition that high concentrations of metformin 
may increase the risk of lactic acidosis during metformin use.
A major strength of our study is that it was conducted over a long observation period 
in a large database representative of the U.K. population in general practice, which 
offers the possibility to correct for smoking and BMI. The database’s information on 
drug exposure and diagnoses has been validated and proven to be of high quality.12 
Another strength is that we not only separately evaluated the influence of renal 
function and the level of metformin intake, but also did so in combination.
Like most observational studies, our study is not without limitations. First, there 
is the potential issue of the selection and inaccurate estimation of our outcome 
measure. The inclusion of patients with a lactate concentration > 5 mmol/l (26% 
of our cases) may have resulted in an overestimate compared with lactic acidosis 
during metformin use alone, since elevated lactate concentrations do not necessarily 
signify a diagnosis of lactic acidosis.28 Furthermore, in a previous study of the same 
CPRD database (General Practice Research Database) that we used, 7 of 14 patients 
with a READ code of lactic acidosis were excluded after a manual review of their 
medical record.12 This may have resulted in a nondifferential misclassification of the 
outcome, which might overestimate the incidence rates of lactic acidosis, although 
it is unlikely to affect the relative risk of lactic acidosis with metformin use among 
patients with decreased renal function. In addition, our period of observation 
(2004-2012) was different from the study period used by Bodmer et al. (1994-2005) 
and started with the year in which the so-called Quality and Outcomes Framework 
was introduced in the U.K.29 The potential risk of differential underrecording among 
nonusers should also be considered. Because of the longstanding assumption that 
metformin may be linked to lactic acidosis, the lactate concentrations of metformin 
users may have been measured and recorded more selectively, particularly in those 
with reduced renal function. Nondifferential underrecording of lactic acidosis in the 
CPRD database may also have occurred; the presenting features of lactic acidosis are 
often vague28, and GPs may not always have transferred lactic acidosis in a hospital 
discharge letter to their own records by means of the appropriate READ code. A 
counterargument against such underrecording is, of course, that lactic acidosis is a 
serious event that is likely to draw sufficient clinical attention. Mild elevations of 
lactate concentrations can be caused by a large number of pathologic conditions, 
ethanol, and drugs. Since we were not able to identify the exact cause of lactic 
acidosis, we were not able to exclude these events.
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A second limitation is that we could not retrieve adequate information about all 
potentially relevant risk factors for lactic acidosis during metformin use. We based 
our classification of renal function on a READ code or a single eGFR value; we 
pragmatically accepted this latter value so long as it was not more than 1 year old 
(based on the argument that clinical guidelines often recommend annual monitoring 
of renal function). This may have increased the risk of including outdated information. 
In spite of our liberal choice, we could not retrieve renal function data for 27.4% and 
34.6% of the current metformin users and nonusers, respectively (Table 5.1). Finally, 
we were not able to analyze the effect of acute decreases in GFR on the risk of lactic 
acidosis or elevated lactate concentrations.
In conclusion, our study suggests that the risk of lactic acidosis or elevated lactate 
concentrations is significantly increased in patients with mild to moderate renal 
insufficiency and that this risk is further increased in long-term heavy metformin 
users. Although these findings are not conclusive, they are consistent with current 
recommendations in the literature to adequately monitor the renal function of 
metformin users and to adjust the dose of metformin, if necessary, if the eGFR 
falls below 60 ml/min/1.73m2.3,17,18 This should be confirmed in future research, 
preferably in a study in which lactate concentrations, renal function, and metformin 
exposure are frequently assessed and in which all potential risk factors are accurately 
determined and recorded.
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Abstract
Background
Chronic kidney disease (CKD) is associated with an increased mortality rate, risk 
of cardiovascular events and morbidity. Impaired renal function is common in 
elderly patients, and their glomerular filtration rate (GFR) should be taken into 
account when prescribing renally excreted drugs. In a hospital care setting the 
GFR may fluctuate substantially, so that the renal function group and therefore the 
recommended dose, can change within a few days. The magnitude and prevalence of 
the fluctuation of renal function in daily clinical practice and its potential effects on 
appropriateness of drug prescriptions after discharge from the hospital is unknown.
Methods and design
This is a prospective observational study. Patients ≥ 70 years with renal impairment 
(eGFR < 60 ml/min/1.73m2) admitted to a geriatric ward are eligible to participate. 
Participants undergo blood sample collection to measure serum creatinine level at 
three time points: at discharge from hospital, 14 days, and 2 months after discharge. 
At these time points the actual medication of the participants is assessed and the 
number of incorrect prescriptions according to the Dutch guidelines in relation to 
their estimated renal function is measured. In addition, for a hypothetical selection 
of drugs, the need for drug dose adaptation in relation to renal function is measured. 
The outcome of interest is the percentage of patients that changes from renal function 
group after discharge from hospital compared to the renal function at discharge. 
In addition, the percentages of patients whose actual medications are incorrectly 
prescribed and for the hypothetical selection of drugs that would have required dose 
adaptation will be determined at discharge, 14 days, and 2 months after discharge. 
For each outcome, risk factors which may lead to increased risk for fluctuation of 
renal function and/or incorrect drug prescribing will also be identified and analysed.
Discussion
This study will provide data on changes in renal function in elderly patients after 
discharge from the hospital with a focus on the medications used. The benefits 
for healthcare professionals comprise of the creation, adjustment or confirmation 
of recommendations for the monitoring of the renal function after discharge from 
hospital of elderly patients. 
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Background
Chronic kidney disease (CKD) is associated with an increased mortality rate, as 
well as with an increased risk of cardiovascular events and morbidity.1-3 Because 
of the longer life expectancy, due to improved treatment of chronic diseases, the 
prevalence of impaired renal function increases.2-4 In addition, there is a concern 
about prescribing drugs, which need dose adjustment in impaired renal function, 
especially in the elderly who are at risk for impaired renal function.4
Up to one-third of the adverse drug reactions (ADRs) leading to hospital 
admission of elderly patients receiving outpatient care, may be related to impaired 
renal function.5,6 The ADRs were serious, because they resulted in or contributed 
to hospital admission. The problems with ADRs, including ADRs not leading 
to hospital admission, due to impaired renal function might be even greater in 
ambulatory care. Therefore, the consideration of renal function in ambulatory care 
drug therapy management (DTM) should be improved.5-7
The estimated glomerular filtration rate (eGFR) is important in the clinical 
management of patients.8 It is used for timely detection and management of declining 
renal function, to adjust the dosage of renally excreted drugs appropriately, and to 
avoid nephrotoxic drugs.1,8,9 In The Netherlands, the eGFR is usually estimated in 
daily clinical practice with the Modification of Diet in Renal Disease (MDRD) 
formula. Dose adjustment of or refraining from renally excreted drugs commonly 
takes place categorically (see Table 6.1).10
Group Description
1 
2
3 
4
5
Normal renal function
Mild renal impairment
Moderate renal impairment
Severe renal impairment
End stage renal disease (ESRD)
> 80
50‐80
30‐49
< 30
Requiring dialysis
Table 6.1 Renal function groups for drug dosing10
In a hospital care setting a patient is closely observed and (repeated) creatinine 
measurements are easy to perform. Informal clinical observations suggest that the 
renal function may fluctuate so much that the renal function group and therefore the 
recommended dose, can change within a few days. A frequent scenario is that the 
patient is dehydrated at hospital admission with impaired renal function and during 
hospital admission the fluid balance is optimized and the eGFR increases.
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The prevalence and the magnitude of fluctuations of the renal function after discharge 
from the hospital are still unknown. Since measurement of renal function is not 
routinely performed in the ambulatory care setting changes in renal function may 
remain unnoticed. It is possible that the eGFR may decrease, because of comprised 
fluid intake, or may increase because of the patient’s further recovery. Changes of 
renal function may lead to a shift to another renal function group for drug dosing and 
thereby put patients at risk for not having optimal DTM. This may have unwanted 
clinical consequences, such as ADRs or insufficient effect. However, little is known 
about the actual prevalence of such scenarios in daily practice.
The aim of this study is to describe the changes in estimated renal function in elderly 
patients 14 days and 2 months after discharge from hospital compared to the value 
at discharge. Renal function will be classified according to the categories, which 
are defined in relation to DTM (see Table 6.1). In addition, incorrectly prescribed 
drugs in the actual medications of the patient according to the Dutch guidelines 
in relation to their renal function will be determined at discharge, 14 days, and 
2 months after discharge from hospital. Finally, the percentage of patients in whom 
the fluctuation would have required another dosage regimen, if they had been taking 
a hypothetical selection of drugs that require dose adaptation, will be determined. 
For each outcome, risk factors for the fluctuation of renal function and for incorrect 
prescribing will be examined.
Methods and design
This study is conducted according to the Declaration of Helsinki. The study has 
been approved by the accredited Medical Ethical Committee of Brabant (formerly: 
METOPP). The Jeroen Bosch Hospital (JBZ) in ‘s-Hertogenbosch has provided 
local feasibility approval.
Study design and setting
This study is a prospective observational study and will be performed at the geriatric 
ward of the JBZ, which is a teaching top-clinical hospital in The Netherlands serving 
800 beds.
Study population
All consecutive patients ≥ 70 years with renal impairment (eGFR < 60 ml/
min/1.73m2) calculated with the MDRD formula at admission to the geriatric 
ward will be asked to participate in the study. Furthermore, patients must remain 
community dwelling after discharge from hospital for at least 2 months. Exclusion 
criteria are patients with an eGFR < 10 ml/min/1.73m2 and patients discharged for 
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end-of-life care.
Patients eligible for the study will be invited and informed by their geriatrician. 
Informed consent is obtained by the researcher. In case the patient is incapacitated 
the patients’ legal guardian will be informed through written information and in 
case of participation the legal guardian will sign the informed consent. Permission 
to request the medication history at the community pharmacy will be asked at the 
same time. Patients can leave the study at any time for any reason without any 
consequences for their treatment.
Study parameters
Primary study parameter
The main study parameter is the eGFR(MDRD). Serum creatinine level will be 
measured at 3 different time points (see Figure 6.1). The eGFR(MDRD) will 
automatically be calculated as follows:
175 x Scr-1.154 x age-0.203 x 1.212 (if black) x 0.742 (if female).11
t = 0
at discharge
t = 1
14 days
after discharge
t = 2
2 months
after discharge
The estimated renal function will be classified according to the categories, which 
are commonly applied in relation to DTM (see Table 6.1). The main endpoint is 
the percentages of patients in whom the eGFR improves, deteriorates and remains 
unchanged within 2 months after discharge compared to their eGFR at discharge.
Improvement is defined as a change to a better renal function group compared to the 
renal function group at discharge. Deterioration is defined as the change towards 
a worse renal function group compared to the renal function group at discharge. 
Unchanged is defined as no change in renal function group.
Secondary study parameters
At each time point the recommended dose or contraindication for each drug the 
patient uses will be determined in accordance with the eGFR of the patient and the 
Dutch guidelines for drug dose advices in renal impairment.12 A secondary endpoint 
will be the percentage of patients in whom the prescribed drugs are not in accordance 
with the Dutch guidelines at discharge, 14 days, and 2 months after discharge from 
Figure 6.1 Several time-points during follow-up 
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hospital. Possible reasons for changes in the percentage of incorrect prescribed drugs 
at the different time points will be identified. Besides fluctuation of eGFR, other 
reasons could be starting a new drug not adjusted to renal function or discontinuation 
of a drug, which needed adjustment in renal impairment. The average number of 
incorrectly prescribed drugs per patient and the type of drugs most often incorrectly 
prescribed at the three different time points will be determined.
The top 10 most frequently prescribed drugs in the elderly outpatients (≥ 70 years) 
that require dose adaptation in patients with renal impairment are selected from the 
database of the Dutch foundation for pharmaceutical statistics (see Appendix 6.1). 
The recommended doses or contraindications of this hypothetical selection of drugs 
will be determined at each time point in relation to the renal function of the patient 
and subsequently compared with the recommended doses or contraindications at 
discharge. The endpoints will be the percentages of patients in whom a change in the 
medication would be needed at 14 days and at 2 months after discharge compared to 
changes needed in the medication at discharge.
Potential risk factors at admission and during admission which may predict 
fluctuation between renal function groups will be determined. These risk factors are 
presented in Table 6.2.
Data collection
Table 6.2 shows the detailed data collection at each time-point. When patients are 
admitted to the geriatric ward a blood sample is almost always routinely taken for 
a range of tests including serum creatinine value and C-reactive protein (CRP).
Prior to discharge (max. 2 days) a blood sample will be taken to measure serum 
creatinine. At discharge the patients will be given two laboratory forms to collect 
blood samples 14 days and 2 months after discharge to measure creatinine. The 
patient will be reminded to go to the nearest general practitioners laboratory for 
blood sample collection 14 days and 2 months after discharge. Initially the blood 
samples were taken at the patient’s nearest general practitioners laboratory. This was 
changed to blood sample collection at home because patients often did not show up 
at the laboratory.
At admission the following variables will be collected as part of usual care: age, 
gender, weight, length, use of non-steroidal anti-inflammatory drugs (NSAIDs) 
in the two weeks prior to admission, nutritional status and hydration status. 
The nutritional status will be defined with the Simplified Nutritional Appetite 
Questionnaire (SNAQ )13 and the hydration status will be observed and judged by 
the physician.
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The following parameters will be collected retrospectively per patient: all creatinine 
values measured during admission, admission via emergency department or a 
planned admission, reason for admission (diagnosis), duration of admission, co-
morbidities, and medication orders during admission.
After two months the researcher will obtain the medication history (from at least 
6 months prior to discharge to 2 months after discharge) of the patient from the 
community pharmacy.
Parameter at admission at discharge 14 days after 
discharge
2 months after 
discharge
Time-points
P
P
P
P
* 
NSAID, non-steroidal anti-inflammatory drug; RAS-inhibitor, renin-angiotensin-system-inhibitor; SNAQ, simplified nutritional 
appetite questionnaire.
ese medications are: glucocorticosteroids, cimetidine, trimethoprim, fenobrate (except gembrozil), calcitriol and 
alfacalcidol.22‐24
Serum creatinine level
Medication history
Potential risk factors
Age
Gender
Weight
Length
Incapacitated patient
Admission via emergency
department or planned admission
Reason for admission (diagnosis)
C‐reactive protein (CRP)
Duration of admission
Co‐morbidities
Nutritional status (SNAQ‐score)
Hydration status
All serum creatinine values
measured during admission
Specic items in medication history:
- NSAID use 2 weeks prior to
   admission
- Polypharmacy
- Use and dose of diuretics
- Use of NSAIDs
- Use of RAS‐inhibitors
- Medications which inuences
  creatinine production*
P P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
Table 6.2 Data collection overview
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All blood samples (heparinized plasma) will be analyzed at the Clinical Chemistry 
and Hematology department of JBZ. Serum creatinine levels will be measured in 
blood samples with the isotope dilution mass spectrometry (IDMS)-traceable Jaffe 
method on a Dimension Vista 1500 system (Siemens Healthcare Diagnostics).14
The results of the creatinine measurements will be reported to the general practitioner 
and/or the geriatrician as soon as the creatinine value is available. If necessary, 
adjustment of the medication can be made according to the Dutch guidelines by the 
general practitioner and/or the geriatrician. Reporting the creatinine value will not 
have an influence on the results. We will carefully examine the medication histories 
and identify changes made after reporting the creatinine value.
Statistical power estimation
This study focuses on the fluctuation of renal function in elderly patients within 
two months after discharge from hospital. We are both interested in the percentage 
patients that change from one to another renal function group, but also in the 
direction of these changes (improvement or deterioration).
Raosoft sample size calculator (http://www.raosoft.com/samplesize.html) was used 
to estimate the number of subjects required to detect a change in renal function 
group in 15% of the population with a 95% confidence level and a 5% margin of 
error. The recommended sample size is 195 subjects.
In order to detect a difference in percentage of patients in whom the change in renal 
function group improved or deteriorated the sample size is calculated based on the 
McNemar test (https://www.statstodo.com/SSizMcNemar_Pgm.php). Assuming 
that 5% of the patients improve and 15% of the patients deteriorate after discharge 
from hospital, power (1-beta) is 0.8 and probability of type I error (alpha) is 0.05, the 
sample size calculated is 155.
A sample size of 195 subjects should be sufficient for answering both questions in 
this study. Assuming that 20% of the included patients are lost to follow-up, the 
number of patients needed to include is 195/0.8 = 244.
Statistical analysis
For each patient data will be collected and archived in a validated data file. Errors 
and missing data will be monitored during data-collection, and complemented or 
corrected whenever possible. After completion of data-sampling, data will be checked 
for logical consistency (e.g. out of reach scores) and then finalized and locked. This 
file will be the basis for all further data analyses.
Measurement of serum creatinine
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To analyse if the percentages of patients in which the renal function group improves, 
deteriorates and remains unchanged 14 days and 2 months after discharge from 
hospital compared to the renal function group at discharge are statistically significant, 
the McNemar-Bowker test will be used (categorical data with repeated measurements 
within one patient). The secondary outcome is the percentage of patients in whom 
the prescribed drugs are not in accordance with the Dutch guidelines. To test the 
differences of the concordance of the medication to Dutch guidelines at the different 
time points, the McNemar test will be used (binary data with repeated measurements 
within one patient). The same test will be used to analyse the percentage of patients in 
whom a change in the medication would be needed if they had been using the top 10 
most frequently prescribed drugs in elderly outpatients (≥ 70 years) that require dose 
adaptation in patients with renal impairment. In further explorative analyses, we 
use various analytical methods (e.g. logistic regression analysis and nominal logistic 
regression analysis) to identify potential determinants of outcomes.
Discussion
DTM in patients with renal impairment is an important issue. Efforts are being 
taken to reduce drug therapy errors in these patients, for example by introducing 
clinical decision support systems.15,16 An educational intervention providing a list 
of frequently used drugs and their dosing schedule already reduced the number 
of drug dosing errors.17 Special attention should be paid to older patients with 
renal insufficiency and polypharmacy who are using high risk medications such as 
anticoagulants (e.g. vitamin K antagonists, direct oral anticoagulants [DOAC]), 
diuretics, cardiovascular agents, analgesics, and anti-diabetic agents.18,19 All these 
studies and recently published guidelines for drug dose advices in renal impairment 
reflect on our daily clinical practice in a hospital care setting. Every time when a 
new eGFR is reported the correct drug or drug dose is reviewed by the hospital 
pharmacist. Advices may change from one day to another.
Guidelines, such as Kidney Disease: Improving Global Outcomes (KDIGO), 
do not offer advice about monitoring renal function after hospital discharge.20,21 
In addition, it is tempting for community pharmacists and general practitioners 
to rely on the latest eGFR measured in the hospital for DTM after discharge. It 
is uncertain how stable the eGFR is in elderly patients who have recently been 
admitted to the hospital. This might be especially the case when eGFR changes 
were frequent during hospital admission. This study is designed to address the gap in 
monitoring the natural course of the renal function after discharge from the hospital 
with attention to the medications used in the elderly. If fluctuation of the eGFR is 
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present at great extent this study will address whether closer monitoring of renal 
function and adaptation of renally excreted drugs after discharge will be needed. In 
addition, the benefits for healthcare professionals comprise of creation, adjustment 
or confirmation of recommendations for monitoring renal function after discharge 
from hospital of elderly patients.
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Appendix 6.1 Top 10 most frequently prescribed drugs in elderly 
patients
Drug Dose advice in renal impairment
1
2
3
4
5
6
7
8
9
10
furosemide
metformin
hydrochlorothiazide
enalapril
perindopril
digoxin
bumetanide
bisoprolol
alendronic acid
spironolacton
10‐30 ml/min
Starting dose as in normal renal function.
If necessary, increase the dose guided by eect and indication.
In case the eect is inadequate, replace furosemide by bumetanide.
30‐50 ml/min
Starting dose 2 x 500 mg metformin
­en, increase the dose gradually to a standard maintenance dose.
10‐30 ml/min
Contraindicated.
10‐30 ml/min
Avoid hydrochlorothiazide
30‐50 ml/min
Starting dose is 5 mg once daily.
If necessary, increase the dose guided by clinical eect.
If the prescriber is a general practitioner the maximum dose is 10 mg.
If the prescriber is a specialized physician the dose may be higher.
10‐30 ml/min
Starting dose is 2.5 mg once daily.
If necessary, increase the dose guided by clinical eect.
If the prescriber is a general practitioner the maximum dose is 5 mg.
If the prescriber is a specialized physician the dose may be higher.
30‐50 ml/min
If the prescriber is a general practitioner the maximum dose is 2 mg.
If the prescriber is a specialized physician the dose may be higher.
10‐30 ml/min
If the prescriber is a general practitioner the maximum dose is 2 mg every 48
hours.
If the prescriber is a specialized physician the dose may be higher.
10‐50 ml/min
After digitalization, the starting dose is 0.125 mg once daily.
­en guide dose adjustment by clinical eect.
10‐30 ml/min
Starting dose as in normal renal function.
If necessary, increase the dose to a maximum of 10 mg per day.
10‐30 ml/min
Starting dose 50% of the dose as in normal renal function
If necessary, increase the dose to a maximum of 10 mg per day.
10‐30 ml/min
Use is not recommended.
10‐50 ml/min
Monitor serum potassium levels regularly.
­ese prescription data were obtained from the Dutch “Foundation for Pharmaceutical Statistics” (SFK) in 2012.
Chapter 6 | Fluctuation of renal function after discharge in elderly patients
120
Addendum
First results of the study: Fluctuation of the renal function after discharge 
from hospital and its effects on drug dosing in elderly patients
A total of 48 patients were included. Six patients were lost to follow up; one patient 
went to another care setting after discharge, two patients decided to leave the study 
before discharge, for 1 patient we did not had a creatinine value at admission (inclusion 
was probably done with an older value), for 1 patient a creatinine value at discharge 
was missing and for 1 patient the reason was not recorded. For eleven patients we 
did not had a serum creatinine value 14 days and 2 months after discharge. There 
were several reasons: 2 patients were readmitted to the hospital, 6 patients did not go 
to a general practitioners laboratory for blood sample collection at both time points, 
1 patient left the study, 1 patient died and 1 patient went too late for blood sample 
collection.
Therefore, 31 patients were eligible for analysis of which only 19 patients had both a 
serum creatinine value at 14 days and 2 months after discharge.
Patient characteristics are presented in Table 6.3. The mean age was 84 years and 
45% was male. The mean eGFR(MDRD) at admission to the hospital was 36.7 ml/
min/1.73m2.
eGFR, estimated glomerular filtration rate; SNAQ, simplified nutritional appetite questionnaire.
Characteristic Number of 
patients
Mean (range)/% 
31
14
17
5
17
9
28
21
8
2
23
7
1
84 
45%
55%
36.7
16%
55% 
29%
1.1 
68%
26%
6%
74%
23%
3%
Age (years)
Sex
  Male
  Female
eGFR at admission (ml/min/1.73m2)
  50‐80
  30‐49
  < 30
SNAQ‐score
Hydration status
  Hydrated
  Dehydrated
  Unknown
Capacitated
  Yes
  No
  Unknown
(13-59)
(0-6)
(74‐98)
Table 6.3 Patient characteristics
Fluctuation of renal function after discharge in elderly patients | Chapter 6
121
Twelve out of 31 patients (39%) changed from renal function group after discharge 
from hospital. Table 6.4 presents the twelve patients with a change in renal function 
group over the three time points, at discharge, 14 days, and 2 months after discharge. 
The direction of the change in renal function group was in both directions, namely 
improvement and deterioration. Three patients showed a variable change in renal 
function group.
Patient
number
Renal function
group 
at discharge
Renal function
group 14 days
after discharge
Renal function
group 2 months
after discharge
Deterioration or improvement 
of renal function group 
after discharge
1
2
3
4
5
6
7
8
9
10
11
12
Deterioration
Improvement
Improvement
Deterioration
Deterioration
Deterioration
Deterioration
Improvement
Variable
Deterioration
Variable
Variable
<30
50‐80
30‐49
Dialysis
<30
<30
<30
50‐80
50‐80
<30
30‐49
30‐49
<30
50‐80
<30*
<30
30‐49
30‐49
<30
50‐80
30‐49
30‐49
50‐80
50‐80
30‐49
30‐49
<30
<30
30‐49
30‐49
30‐49
30‐49
50‐80
30‐49
30‐49
30‐49
* missing value: last observation carried forward.
Discussion
The number of patients in which a change occurred in renal function group is 
noteworthy, namely 39%. In our sample size calculation we assumed that a change 
of renal function group in 15% of the population would be of clinical relevance. As 
the first results presented, showing even a higher number of patients changing from 
one to another renal function group within 2 months after discharge, continuation 
of the study is highly recommended.
Of interest, three out of 12 patients (25%) had variable changes in renal function 
group. This proportion is noteworthy and further research is necessary to identify 
risk factors and the consequences for drug therapy management.
Table 6.4 Change of renal function group over three time points in patients with a change in renal 
function group
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Abstract
Objective
To compare the clinical relevance of medication alerts in a basic and in an advanced 
clinical decision support system (CDSS).
Design
A prospective observational study.
Materials and methods
We collected 4023 medication orders in a hospital for independent evaluation in two 
pharmacotherapy-related decision support systems. Only the more advanced system 
considered patient characteristics and laboratory test results in its algorithms. Two 
pharmacists assessed the clinical relevance of the medication alerts produced. The 
alert was considered relevant if the pharmacist would undertake action (e.g. contact 
the physician or the nurse). The primary analysis concerned the positive predictive 
value (PPV) for clinically relevant medication alerts in both systems.
Results
The PPV was significantly higher in the advanced system (5.8% versus 17.0%; 
p < 0.05). Significant differences were found in the alert categories: drug-(drug) 
interaction (9.9% versus 14.8%; p < 0.05), drug-age interaction (2.9% versus 73.3%; 
p < 0.05), and dosing guidance (5.6% versus 16.9%; p < 0.05). Including laboratory 
values and other patient characteristics resulted in a significantly higher PPV for 
the advanced CDSS compared to the basic medication alerts (12.2% versus 23.3%; 
p < 0.05).
Conclusion
The advanced CDSS produced a higher proportion of clinically relevant medication 
alerts, but the number of irrelevant alerts remained high. To improve the PPV of 
the advanced CDSS, the algorithms should be optimized by identifying additional 
risk modifiers and more data should be made electronically available to improve the 
performance of the algorithms. Our study illustrates and corroborates the need for 
cyclic testing of technical improvements in information technology in circumstances 
representative of daily clinical practice.
Comparison of a basic and advanced clinical decision support system | Chapter 7
127
Introduction
The Hospital Admissions Related to Medication (HARM) study showed that 
16,000 HARMs are potentially avoidable each year in The Netherlands.1 This 
finding prompted the HARM-Wrestling report, which proposed about 40 practical 
recommendations to reduce the most frequently occurring and potentially avoidable 
HARMs.2 About half of these recommendations concerned appropriate prescribing 
(e.g. adding a protective drug), a quarter concerned follow-up procedures (e.g. 
laboratory monitoring), and another quarter concerned communication (with the 
patient and other healthcare providers). Many of the recommended actions cannot 
be postponed until the next medication review but should be carried out as soon as 
a treatment is started or changed.3 An important general recommendation was to 
improve, innovate, and implement information and communication technology in 
the pharmacotherapy process.
The currently used clinical decision support system (CDSS) in our daily hospital 
practice (CDSS 1, a so-called basic CDSS) has several limitations. First, it does 
not include specific individual patient data, such as laboratory test results, in its 
algorithms. Second, it cannot deal with different problems simultaneously: it 
assesses the clinical risk of a drug-drug interaction and that of renal insufficiency 
separately from each other. Another limitation concerns the complexity of clinical 
rules. CDSS 1 only screens drug therapies when a medication order (start, repeat, 
change, or stop) is entered into the system and not when other individual patient 
data (such as a new laboratory test result) become available. CDSS 1 generates many 
medication alerts which are clinically irrelevant, thereby reducing actual benefit in 
daily practice through alert fatigue.4-6 All in all there is an urgent need for a more 
advanced pharmacotherapy-related CDSS (CDSS 2) which combines medication 
orders with laboratory test results and other patient characteristics and which also 
responds as soon as these types of data become available. Such a system should be 
more effective (generate more relevant alerts) and more efficient (generate fewer 
irrelevant alerts) compared to the current CDSS 1. 
Geerts et al. have shown that in 36.7% of patients with a potential drug-drug 
interaction in the community pharmacy, a laboratory test is required for the 
assessment of the clinical relevance of the potential drug-drug interaction.7 Other 
studies have shown that combining medication information with laboratory values 
in a CDSS results in better monitoring of adverse drug events (ADEs) in patients.8-12
We developed a CDSS 2 based on data from different clinical information systems. 
In this study we had access to inpatient medication and laboratory data. As in 
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other CDSS, our system generates medication alerts invoked by events (‘triggers’), 
based on available data (‘input data’), leading to a possible action (‘intervention’). 
This application of simple or complex ‘if-then’ rules is comparable to the mode of 
operation of systems used in United States (US) hospitals.13
We considered it important to test CDSS 2 in direct comparison with CDSS 1 
before it would be implemented, since technological improvements do not necessarily 
translate into improvements in clinical practice. The aim of this study was to 
compare the positive predictive value (PPV) for clinically relevant medication alerts 
in CDSS 2 with that in CDSS 1. In addition, differences between specific categories 
of medication alerts were explored with respect to their clinical relevance.
Background
In The Netherlands, the Royal Dutch Association for the Advancement of 
Pharmacy publishes a national drug database, the so-called G-standard, which is 
used by general practitioners, community pharmacies, and hospitals and provides 
digitalized safety information on all drug products registered in The Netherlands 
(e.g. concerning dosing, drug-drug interactions, drug duplication, drug-disease 
interaction, and pharmacogenetic factors).14,15 It also presents standardized alert 
texts which contain information about potential adverse drug reactions and 
recommendations on how to respond to the alert, as well as details about clinical 
consequences, the underlying mechanism, and consulted references.16 Both the basic 
and advanced pharmacotherapy-related CDSS investigated in this study were based 
on the G-standard.
The generation of specific alerts varies in different hospitals. In the Jeroen Bosch 
Hospital (JBZ), where this study was conducted, the physician initiates medication 
orders by means of a computerized physician order entry system (CPOE). If necessary, 
the CPOE will generate an alert for the physician, who can either take action or 
not. Several times each day, a pharmacist evaluates all generated medication alerts 
even though the physician may have already seen the alert. The pharmacist decides 
if further action is needed. In JBZ, the pharmacists are not allowed to cancel or 
change a medication order or to request for a laboratory value, but they contact the 
physician and advise an appropriate action.
Method
Setting
A prospective observational study was performed in the hospital pharmacy (ZANOB) 
of JBZ, which is a teaching top clinical hospital in The Netherlands with 800 beds.
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Basic pharmacotherapy-related clinical decision support system (CDSS 1)
In 1981, Centrasys (iSOFT) was implemented in the hospital pharmacy (hereafter 
called system 1). The CPOE part of this system was introduced in the hospital in 
2007. Up to 2011 the hospital pharmacy has used system 1 in daily practice. 
System 1 is based on the G-standard and cannot cope with data from other databases, 
such as laboratory values. To account for the risk that reduced renal function in elderly 
patients may remain unnoticed, system 1 assigns the attribute ‘renal impairment’ to 
every patient above 70 years of age, regardless of their actual renal function. It is also 
possible to provide individual drugs in system 1 with a maximum dose of 0 mg per 
day. This guarantees that these drugs always generate a dose alert when prescribed, 
and allows the pharmacist to manually check the dose. An example is the drug 
methotrexate because medication errors leading to overdosing can easily occur (e.g. 
a high oncolytic dose given instead of a low antirheumatic one).17
The following clinical decision support (CDS) categories, as stated by Kuperman 
et al.18, were operational in system 1: drug-allergy checking, basic dosing guidance, 
duplicate therapy checking, drug-drug interaction checking, drug-disease interaction 
checking, and drug-pregnancy checking. It should be noted that the performance 
of these categories depends on the availability of the input data. Medication control 
takes place in real-time.
The version of Centrasys used in this study was 4.31, service pack 6 with the 
G-standard update of July 2010.
Advanced pharmacotherapy-related clinical decision support system 
(CDSS 2)
Since June 2008, the hospital pharmacy has been cooperating with the software 
company Pharmaps to develop an advanced CDSS, known as ‘Pharmaps 
Medicatiebewaking PLUS’ (hereafter called system 2).
System 2 can handle data from different databases. Data from the clinical chemistry 
department and the pharmacy were available during the study period. System 2 
covers all the CDS categories in system 1 except for the basic dosing guidance. In 
addition, it also covers the categories advanced guidance on medication-associated 
laboratory testing and advanced dosing guidance in relation to renal function.18 
System 2 performs all the medication surveillance covered by the G-standard (with 
the exception of basic dosage control) similarly to system 1, as well as additional 
medication surveillance (degree of renal impairment, hyperkalemia, lack of potassium, 
and creatinine levels and other specific recommendations of the HARM-Wrestling 
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report2). In addition, the system generates medication alerts concerning thyroid 
dysfunction for two drugs (amiodarone and lithium).19 Generation of the medication 
alerts took place once a day (at 03:00 h). System 2 can generate medication alerts in 
real-time, but for practical reasons we chose to generate medication alerts once a day 
during this test phase.
Some aspects of medication surveillance could only be partially realized because: (1) 
not all patient characteristics (such as diagnosis) were electronically available and (2) 
the functionality of reasoning with time-frames was not yet available. For example, 
when a patient above 80 years of age uses a renin-angiotensin-aldosterone-system 
(RAAS)-inhibitor, renal function should be checked every 6 months.2 Consequently, 
the CDSS should check whether renal function has been determined in the preceding 
6 months and should generate an alert if this is not the case.
Pharmaps Medicatiebewaking PLUS version 3.1.2.8 was used in this study with the 
G-standard update of July 2010.
Data collection
During 5 randomly chosen consecutive days in July 2010, all prescribed drugs were 
evaluated in systems 1 and 2 on the basis of the same medication orders for all 
patients hospitalized in the JBZ. All medication alerts were assessed independently 
by two pharmacists. It was not possible to blind the pharmacists regarding the 
systems for practical reasons. A medication alert was considered ‘relevant’ when the 
evaluating pharmacist concluded that the physician or nurse should be contacted. 
An alert was considered ‘irrelevant’ when the evaluating pharmacist concluded that 
no specific action was necessary. If the two pharmacists did not agree on the same 
alert, a third pharmacist evaluated the medication alert for the final judgment. Our 
method of determining the relevance of medication alerts was similar to that of Van 
Doormaal et al.20
The 10 pharmacists involved in the study were well trained to handle basic and 
advanced medication alerts and consisted of one hospital pharmacist-toxicologist, 
two hospital pharmacists, two hospital pharmacists-clinical pharmacologists, two 
hospital pharmacist trainees, two pharmacists working in the hospital on a project 
basis and one community pharmacist. The third appraiser was a hospital pharmacist-
toxicologist or hospital pharmacist trainee.
Medication alert categories
We defined categories of medication alerts in order to explore differences between 
systems 1 and 2 regarding the clinical relevance of the medication alerts. Classification 
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of the alert categories was based on the content of the signals: drug-(drug) interaction, 
drug-age interaction, drug duplication, drug-disease interaction, dosing guidance, 
and missing laboratory value. We will give an example for each category. The category 
drug-(drug) interaction includes medication alerts caused by the combination of 
two different drugs or the presence of one drug without another, for example, the 
absence of a laxative in opioid therapy. The category drug-age interaction includes 
medication alerts caused by drugs in combination with age. For example, when a 
non-steroidal anti-inflammatory drug (NSAID) is started and the patient is over 
70 years of age a proton pump inhibitor (PPI) is recommended.21 In system 1, age 
> 70 years is a proxy for the contraindication renal impairment. Medication alerts 
in the category drug duplication are generated by the combination of two similar 
drugs. The category drug-disease interaction covers medication alerts advising 
against particular drugs in certain conditions. For example, thiazide diuretics are 
contraindicated in patients with a renal function < 30 ml/min. The category dosing 
guidance includes all types of medication alerts with dosage advice. Medication 
alerts caused by a missing laboratory value belong to the category missing laboratory 
value.
The triggers which caused a medication alert in systems 1 and 2 were different. 
System 2 is capable of applying laboratory values, other patient characteristics, a 
combination of three or more drugs, and the absence of a drug or laboratory value in 
its algorithms. We checked whether each medication alert in system 2 was generated 
by one of the advanced properties. We defined such medication alerts as ‘advanced’. 
The other system 2 medication alerts we defined as ‘basic medication alerts’. These 
medication alerts were based only on medication data and the basic properties of 
system 2, using G-standard data.
Analysis
The proportion of all medication alerts produced which were considered clinically 
relevant was expressed as the PPV and was calculated separately for each system as 
follows:
number of relevant medication alerts 
(number of relevant medication alerts + number of irrelevant medication alerts)
Positive predictive value =
Total positive predictive values (PPVs) were stratified for the different alert categories 
in both systems. PPVs were also calculated for each individual medication alert. 
Statistical tests were performed using SPSS version 16.0. The χ2-test was used to 
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calculate if the difference in PPV between both systems was statistically significant. 
A p-value ≤ 0.05 was considered to be statistically significant.
Results
A total of 619 inpatients were included in the sample. Their mean age was 53.1 years 
and 45.7% were male. The total number of medication orders was 4023. The number 
of patients with medication orders which generated a medication alert was 438 for 
system 1 and 454 for system 2. The mean age of these patients was 67.2 and 67.0 years 
in systems 1 and 2, respectively (p = 0.60), and 51.8% and 53.5% of these patients, 
respectively, were male (p = 0.57). 
The 4023 medication orders generated 2607 medication alerts in system 1 and 2256 
in system 2. Table 7.1 shows the PPVs for all the medication alerts in both systems 
and for each category of medication alert.
Table 7.1 Positive predictive values for the clinical relevance of medication alerts
nrelevant* ntotal‡ PPV§nrelevant* ntotal‡ PPV§ p-value
System 2System 1
Total of medication alerts 150 2607 5.8 384 2256 17.0 < 0.05
§
*
‡
◊ 
1
2
3
4
5
6
positive predictive value = 
the number of clinically relevant medication alerts
the total number of medication alerts
the PPV could not be calculated because this category was not operational in system 1
medication alerts caused by the combination of two dierent drugs or the combination of a drug with the
absence of another drug.
medication alerts caused by drugs in combination with age (in system 1, age was a proxy for the contraindication
renal impairment).
medication alerts caused by the combination of two similar drugs.
medication alerts with the advice not to give a certain drug in certain conditions.
medication alerts with a dosage advice.
medication alerts caused by a missing laboratory value.
number of relevant medication alerts
(number of relevant medication alerts + number of irrelevant medication alerts)
Alert category
Drug‐(drug) interaction1 
Drug‐age interaction2 
Drug duplication3 
Drug‐disease interaction4 
Dosing guidance5 
Missing laboratory value6
82
23
30
0
15
-
828
784
724
2
269
-
9.9
2.9
4.1
0
5.6
172
44
19
34
73
42
1163
60
344
139
432
118
14.8
73.3
5.5
24.5
16.9
35.6
< 0.05
< 0.05
   0.31
0.42
< 0.05
-◊             
(%) (%)
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The number of relevant medication alerts increased from 150 in system 1 to 384 
in system 2 for the same sample of medication orders. The difference between the 
PPVs of the medication alerts in system 1 and system 2 was statistically significant 
(5.8% versus 17.0%; p < 0.05). Stratification into the medication alerts categories 
showed statistically significant differences for the following categories: drug-(drug) 
interaction (9.9% versus 14.8%; p < 0.05), drug-age interaction (2.9% versus 73.3%; 
p < 0.05), and dosing guidance (5.6% versus 16.9%; p < 0.05). Remarkably, the two 
appraising pharmacists disagreed more often regarding the clinical relevance of 
medication alerts in system 2 than in system 1. The third pharmacist had to review 
8.6% of the medication alerts in system 1 versus 32.9% in system 2. This difference 
was also statistically significant (p < 0.05).
PPVs were also calculated for each type of medication alert. Table 7.2 shows the 
top five medication alerts (occurring at least 20 times) with the highest PPVs in 
system 2. The highest PPV of 30.8% in system 1 was found for the medication alert 
‘clopidogrel + omeprazole/esomeprazole’. To improve system 2 further, it would be 
helpful to investigate and then adapt or eliminate frequently occurring medication 
alerts with the lowest PPV. Table 7.3 shows the top 10 medication alerts (occurring 
at least 20 times) with the lowest PPVs in system 2.
Alert text nrelevant* ntotal‡ PPV§
Advice: give a proton pump inhibitor
Beware of induction or exacerbation of hyperkalemia
Clopidogrel + omeprazole/esomeprazole∆
is drug requires dosage adjustment in renal impairment. Determine renal
function, since the renal function is unknown in this patient.
is drug requires attention when the serum potassium level is high (> 5 mmol/l)
44
15
13
19
14
60
21
20
55
 41
73.3
71.4
65.0
34.5
34.1
§
*
‡
∆
positive predictive value = 
the number of clinically relevant medication alerts
the total number of medication alerts
at the time this study was conducted, this interaction had just been noted as relevant by various
(inter)national authorities. However, the eect of the combination of clopidogrel with omeprazole on
cardiovascular events remains controversial.22,23
number of relevant medication alerts
(number of relevant medication alerts + number of irrelevant medication alerts)
(%)
Table 7.2. The top five of medication alerts occurring at least 20 times that were generated by 
system 2 and had the highest positive predictive values
The impact of including laboratory values and other patient characteristics in the 
medication surveillance by system 2 is shown in Table 7.4. The PPV was calculated 
for both the basic medication alerts and the advanced medication alerts in each 
medication alert category. The advanced medication alerts show a significantly 
higher PPV than the basic medication alerts (12.2% versus 23.3%; p < 0.05). The 
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Table 7.3 The top ten of medication alerts occurring at least 20 times that were generated by system 2 
and had the lowest positive predictive values
Alert text nrelevant* ntotal‡ PPV§
Drug duplication: dierent strength, same mechanism of action
Selective beta‐blockers + insulin
Beta‐blockers + oral hypoglycemic drugs
Alpha‐blocking drugs (for benign prostate hyperplasia) + beta‐blockers/calcium
channel blockers
Renal function: bumetanide
Renin‐angiotensin‐aldosterone-system (RAAS)‐inhibitors + diuretics
Salicylates antithrombotic + non-steroidal anti-inammatory drugs (NSAIDs) 
(other than Ibuprophen)
RAAS‐inhibitors + potassium(‐saving diuretics)
NSAIDs + corticosteroids
Bisphosphonates + antacids/iron/calcium
0
0
0
0
0
2
74
43
25
23
 20
120
0.0
0.0
0.0
0.0
0.0
1.7
§ positive predictive value = number of relevant medication alerts(number of relevant medication alerts + number of irrelevant medication alerts)
*the number of clinically relevant medication alerts
‡the total number of medication alerts
(%)
1
1
2
2
41
61
44
51
2.4
3.3
4.5
2.0
nrelevant* ntotal‡ PPV§nrelevant* ntotal‡ PPV§ p-value
Advanced medication alertsBasic medication alerts
Drug‐(drug) interaction1 
Drug‐age interaction2 
Drug duplication3 
Drug‐disease interaction4 
Dosing guidance5 
Missing laboratory value6
155 1274 12.2 229 982 23.3 < 0.05
§ positive predictive value = number of relevant medication alerts(number of relevant medication alerts + number of irrelevant medication alerts)
*the number of clinically relevant medication alerts
‡the total number of medication alerts
◊there were no medication alerts in this category 
1medication alerts caused by the combination of two dierent drugs or the combination of a drug with the
absence of another drug.
2medication alerts caused by drugs in combination with age (in system 1, age is a proxy for the contraindication
renal impairment).
3medication alerts caused by the combination of two similar drugs.
4medication alerts with the advice not to give a certain drug in certain conditions.
5medication alerts with a dosage advice.
6medication alerts caused by a missing laboratory value.
(%)(%)
Total of medication alerts 
Alert category
136
-
19
-
-
-
930
-
344
-
-
-
14.6
-◊
5.5
-◊
-◊
-◊
36
44
-
34
73
42
233
60
-
139
432
118
15.5
73.3
-◊
24.5
16.9
35.6
0.75
-
-
-
-
-
Table 7.4 Comparison of basic and advanced medication alerts in system 2
highest PPV (73.3%) was seen in the category drug-age interaction (advanced) and 
the lowest PPV (5.5%) in the category drug duplication (basic).
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Discussion
The difference between the PPVs of systems 1 and 2 was substantial (5.8% versus 
17.0%; p < 0.05). This shows that the clinical relevance of medication alerts was 
improved by including more data on patient characteristics (especially individual 
laboratory values) in the medication surveillance. Differences between systems 1 
and 2 were mainly found in the categories drug-(drug) interaction, drug-age 
interaction, and dosing guidance. Regarding system 2, the advanced medication 
alerts showed a significantly better PPV than the basic medication alerts (12.2% 
versus 23.3%; p < 0.05). Thus, this study confirms the added value of the advanced 
pharmacotherapy-related CDSS for medication surveillance in a realistic sample of 
hospitalized patients from one hospital.
The PPVs for drug-(drug) interaction and dosage guidance in system 1 (9.9% and 
5.6%, respectively) corresponded well with the results of a previous Dutch study 
(12% and 6%, respectively) which evaluated a system based on the G-standard.20 
In a study by Murphy et al., conducted in the US with online prospective drug-use 
review systems, 73.8% of the drug-drug interactions were overridden by pharmacists 
in a community pharmacy, giving a PPV of 26.2%.24
The PPVs found for individual medication alerts in systems 1 and 2 varied from 0% 
to 73.3%. This wide variation has also been found in some previous studies which 
investigated one or more specific advanced medication alerts.25-27 Handler et al. 
conducted a systematic review of medication alerts based on pharmacy and laboratory 
data to detect ADEs such as elevated serum creatinine levels and hyperkalemia. They 
found PPVs ranging from 3% for hypokalemia to 50% for supratherapeutic quinidine 
levels.26 Raschke et al. also found a wide variation in the PPVs for detecting ADEs 
(24%-97%).27 One explanation for the broad range of PPVs is that laboratory values 
are often abnormal because of the onset or worsening of clinical conditions unrelated 
to the use of medication.26 Another explanation is that some algorithms detect rare 
but immediately life-threatening ADEs, while others detect common situations 
with a lower potential to result in injury.27
This study has several limitations. First, the local user settings in both systems were 
different. The G-standard in system 1 had already been modified following years 
of experience by the hospital pharmacists. This fine-tuning had not yet taken place 
in system 2. Adjustment of the G-standard generally leads to a higher PPV, which 
implies that the contrast in the PPV between systems 1 and 2 probably would have 
been greater if the G-standard in system 2 had been amended. In addition, not 
all features of the G-standard were fully used in both systems. Second, the PPV 
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was chosen as the primary outcome measure for comparing systems 1 and 2. The 
PPV is a useful measure for the correctness and clinical relevance of the generated 
medication alerts but does not indicate how often relevant alerts were missing, which 
requires assessment of the sensitivity of the CDSS. However, this parameter requires 
that all truly positive alerts are recognized as such (the so-called ‘gold standard’), 
which was not a goal of our study. One way to establish the sensitivity of a system 
is through the use of a set of test patients. Van der Sijs et al. and Saverno et al. 
calculated the sensitivity and specificity for a variety of medication alerts, including 
drug-drug interactions in several different CPOE and CDSS. Both groups found a 
wide variation in sensitivity (38%-79% and 23%-100%, respectively) and specificity 
(11%-84% and 83%-100%, respectively).28,29
The capabilities of CDSS differ between providers,13,30 which may have influenced 
the generalizability of our results. However, CDSS algorithms generally rely on 
literature-based evidence and practice-based experience, which is accepted worldwide 
as the best foundation for improving clinical outcomes.31 Therefore, the algorithms 
leading to medication alerts are likely very similar across countries. Consequently, 
we believe that the results of our study are also applicable to other CDSS.
We have identified several reasons why the PPV of system 2 may have been relatively 
low. First, not all information needed, such as the patient problem list (diagnosis), 
was electronically available. For example, the severity of the drug-drug interaction 
NSAIDs and RAAS-inhibitors is more important in patients with heart failure 
than in those with uncomplicated hypertension. A second limitation of system 2 was 
its inability to combine different algorithms. For example, system 2 recognized the 
combination of a RAAS-inhibitor and potassium(-saving diuretics) and generated 
a medication alert with the advice to monitor the serum potassium level. Another 
algorithm checked if the serum potassium level was available and within the range 
of 3.5-5.0 mmol/l. The first algorithm should be suppressed if the second algorithm 
does not generate a medication alert, because the potassium level is already 
monitored. Third, some of the algorithms in both systems had been incorporated 
to exclude any risk. For example, the alert ‘drug duplication’ is generated when the 
physician prescribes two medication orders for the same drug. Such a combination 
may have been ordered by accident, but may also have been intentional (e.g. two 
drug products to provide an unavailable dose strength). As the pharmacists in our 
study only contacted the physician in one out of 20 medication alerts, intentional 
combination appears to have occurred more often than accidental duplication.
Agreement between the two appraising pharmacists occurred less often for system 2. 
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The third pharmacist, who passed the final judgment, was involved significantly more 
often in system 2 (8.6% versus 32.9%; p < 0.05), probably because of the complexity 
of the advanced medication alerts. Laboratory values were manually searched with 
system 1 and so the pharmacists were familiar with advanced medication alerts, but 
in system 2 more and other triggers were involved in generating a medication alert. 
Judging a medication alert based on two drugs is easier to interpret than medication 
alerts based on a drug and a variable laboratory value or the addition of another drug, 
for example, the medication alert that a laxative should be added to an opiate. In case 
of piritramide 15 mg subcutaneous 4 times a day after surgery, some pharmacists 
will advise a laxative from day 1, whereas other pharmacists will advise a laxative 
only after 3 days. Therefore, interpretation of a medication alert requires particular 
attention when a new type of medication alert is implemented in clinical practice.
The more information is incorporated into algorithms, the more precise the 
generated medication alerts should be. Therefore, to better develop and optimize 
the algorithms, risk modifiers should be identified from evidence-based and clinical 
practice-based medicine. For instance, multivitamin supplements providing 25 µg of 
vitamin K1 have long been considered harmless for patients on warfarin. However, 
this view was seriously challenged by three cases of stabilized warfarin users in 
whom anticoagulant treatment was compromised by the initiation or cessation of 
a low-dosed multivitamin supplement.32 Subsequent research showed that 25 µg of 
vitamin K1 daily produces subtherapeutic international normalized ratios (INRs) 
in users with a low vitamin K1 level.33 In other words, vitamin K1 status is an 
important modifier of the risk that stabilized warfarin users are affected by dietary 
supplements providing a small dose of vitamin K1. Therefore, identified potentially 
interesting risk modifiers should be made electronically available in the database and 
also built into the algorithms.
The knowledge database of a CDSS should be continuously maintained by evaluating 
what effects medication alerts have in daily practice. The Plan-Do-Check-Act 
(PDCA) cycle, also known as the Deming cycle, might be helpful.25,34 Wessels-
Basten et al. improved the PPV of the lithium algorithm from 63% to 83% by using 
the PDCA cycle.25 The next step to improve the PPV of system 2 is to determine 
why the pharmacists respond to some alerts and not to others. This could be followed 
by two strategies. First, if the pharmacists do not respond correctly to medication 
alerts, education is needed. Second, the algorithm should be fine-tuned until the 
PPV has improved. It is expected that the PPV of system 2 will increase when the 
PDCA cycle is completed.
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Conclusion
The main conclusion of this study is that system 2 had a significantly higher PPV 
than system 1 (5.8% versus 17.0%; p < 0.05). The study shows that system 2 was more 
effective and more efficient than system 1 in carrying out medication surveillance. 
However, the number of irrelevant medication alerts remained relatively high.
To improve the PPV of system 2, the algorithms should be further optimized as 
follows: (1) by identifying risk modifiers from the existing scientific literature, (2) 
by making these additional risk modifiers electronically available, and (3) by cyclic 
testing of the effects of medication alerts in daily clinical practice (PDCA cycle).
Our study illustrates and corroborates the need to test technical improvements in 
information technology in circumstances representative of daily clinical practice. 
This type of research will contribute to further optimization of CDSS. It should also 
be kept in mind that maintenance of a knowledge database is a continuous process.
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Abstract
Estimated glomerular filtration rate (eGFR) is a key component in drug therapy 
management (DTM) in patients with renal impairment. eGFR is routinely reported 
by laboratories whenever a serum creatinine testing is ordered. In this paper we 
will discuss how to use eGFR knowing the limitations of serum creatinine-based 
formulas. Before starting a renally excreted drug an equally effective drug which 
can be used more safely in patients with renal impairment should be considered. 
If a renally excreted drug is needed the reliability of the eGFR should be assessed 
and when needed a 24-h urine creatinine clearance collection should be performed. 
After achieving the best approximation of the true GFR we suggest a gradually drug 
dose adaptation according to the renal function. A different approach for drugs with 
a narrow therapeutic window (NTW) is recommended compared to drugs with a 
broad therapeutic window. For practical purposes a therapeutic window of 5 or less 
was defined as a NTW and a list of NTW-drugs is presented. Considerations about 
the drug dose may be different at the start of the therapy or during the therapy and 
depending on the indication. Monitoring effectiveness and adverse drug reactions 
are important, especially for NTW-drugs. Dose adjustment should be based on an 
ongoing assessment of clinical status and risk versus the benefit of the used regimen.
In conclusion, when determining the most appropriate dosing regimen serum 
creatinine-based formulas should never be used naively but always in combination 
with clinical and pharmacological assessment of the individual patient.
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Introduction
The importance of the recognition of the renal function in drug therapy management 
(DTM) has been well documented. Ten to thirty-two percent (in elderly patients) of 
adverse drug reactions (ADRs) that necessitated hospital admission were related to 
impaired renal function.1,2 In the hospital care setting, patients with chronic kidney 
disease (CKD) are at increased risk of drug dosing errors and acute kidney injury 
(AKI).3,4 Therefore, drug therapy adjustment according to renal function is of major 
importance to improve DTM.
The glomerular filtration rate (GFR) is widely accepted as the preferred index of 
kidney function and recognized as defining CKD.5 Drug dosing recommendations 
traditionally have used the Cockcroft and Gault (CG) formula to estimate creatinine 
clearance and therefore the ability of the kidney to excrete drugs.6 Approximately 
15 years ago a new formula was developed that provided estimation of GFR (eGFR), 
the Modification of Diet in Renal Disease (MDRD) formula.7 More recently the 
Chronic Kidney Disease EPIdemiology Collaboration (CKD-EPI) formulas for 
eGFR were developed.8 Since laboratories routinely report the eGFR if serum 
creatinine testing is ordered, the awareness of impaired renal function and the use 
of eGFR in DTM among clinicians has increased in recent years.9-11
All the formulas have in common that they are based on serum creatinine levels. 
There is a clear inverse correlation between serum creatinine levels and GFR. 
However there are several factors which may influence serum creatinine levels 
and therefore eGFR without affecting true GFR itself, which potentially distorts 
the interpretation of these estimates for clinical use (see Figure 8.1).12-14 Although 
the serum creatinine-based formulas provide a better estimation of the true GFR 
than serum creatinine concentrations in the general population, none have been 
validated in diverse patient populations.15 Inaccuracy in eGFRs might lead either 
to overestimation of kidney function, leading to administration of inappropriately 
large doses and therefore possible toxicity, or, conversely, underestimation of kidney 
function, leading to subtherapeutic dosing and therefore treatment failure, and 
prolonged illness.16 The effect of the possible overestimation and underestimation of 
true GFR is illustrated in Table 8.1 and 8.2. Table 8.1 illustrates that the inaccuracy 
of the eGFR may lead to a different renal function group than the renal function 
group to which the patient actually belongs according to the mGFR. The relative 
steady state drug levels that have been theoretically calculated in Table 8.2 can 
exceed the target level by more than 200% when relying naively on eGFR. Despite 
such limitations, serum creatinine-based formulas are routinely used in daily clinical 
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practice.17-20 In this paper we will discuss approaches on how to use serum creatinine-
based formulas in daily clinical practice in a well-informed way.
Serum
creatinine
Laboratory
assay
Estimated 
glomerular
ﬁltration rate
Endogenous supply 
by muscle mass
Exogenous supply
Renal elimination by
tubular secretion
Renal elimination by
glomerular ﬁltration rate
Extrarenal elimination by
gastrointestinal degradation
(     by broad spectre antibiotics)
Liver function
Table 8.1. The effects of the inaccuracy of the eGFR in drug dosing
mGFR < 10 10-29 30-49eGFR (mGFR ± 30%)* > 8050-80
Renal function groups for drug dosing47
100
60
40
20
70-130
42-78
28-52
14-26
*
e coloured parts in the table illustrate the eects of the inaccuracy of the eGFR (mGFR ± 30%). e eGFR may lead to a 
dierent renal function group than the renal function group to which the patient actually belongs according to the mGFR.
eGFR, estimated glomerular ltration rate; mGFR, measured glomerular ltration rate.
An accuracy expressed as P30% (eGFR falls within ± 30% of the mGFR) of 80% or higher has been indicated as sucient.25,54,55
(ml/min/1.73m2) (ml/min/1.73m2)
Figure 8.1. Determinants of serum creatinine level
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Risk benefit ratio
The first question after defining the patient’s health problem is, what is the 
therapeutic objective?21 In general, the goal of DTM is to optimize the risk-benefit 
ratio and to attain an optimal therapeutic outcome.22 In the situation of patients with 
renal impairment the principals for considering the risk-benefit ratio is not different 
from any other treatment. In a lifesaving situation, for example a treatment with 
antibiotics in case of sepsis, a higher dosing regimen than generally recommended 
for patients with renal impairment may be chosen. The risk of developing ADRs is 
less important in this situation than the risk to give an insufficient drug dose which 
may lead to untimely death. In less urgent situations, such as treating hypertension, 
a more conservative drug dose can be given at the start of the therapy. This drug dose 
can be gradually increased with monitoring effect (blood pressure) and/or ADRs. In 
other words: ‘start low, go slow’.
The severity of the illness being treated determines if a specific ADR is accepted or 
not. In addition, the severity of the ADR may vary between individual patients. For 
patients with renal impairment the risk-benefit ratio should be taken into account 
when answering the following questions:
1. Can I use the eGFR reported by laboratories in DTM?
2. Is there an equally effective drug which can be used more safely in patients with 
renal impairment?
3. What are the chances and risks of dosing outside the therapeutic window?
a. Considerations at start of pharmacotherapy
b. Considerations during pharmacotherapy
4. Is it possible to monitor effectiveness and/or ADRs in order to timely intervene 
and/or to prevent serious situations?
How to apply eGFR in daily clinical practice
In daily clinical practice one should be aware of the limitations of creatinine-based 
formulas. These limitations have been described elsewhere.15 Reported eGFR values 
have a degree of inaccuracy. When there are no reasons to suspect that the true GFR 
is substantially different from the eGFR, the laboratory value eGFR can be used 
without reservations.
Serum creatinine levels and therefore creatinine based-formulas should only be 
used in patients with stable renal function.22 In cases of rapidly changing GFR, the 
serum creatinine levels will not reflect the actual GFR, until steady-state has been 
Chapter 8 | Drug therapy management in patients with renal impairment 
146
reached.23 In such situations, assessment of impaired renal function must rely on 
multiple measures of serum creatinine levels.24
In specific patients and/or clinical situations (e.g. malnourishment, low or high muscle 
mass, acute critical illness) where estimating equations are known to be inaccurate 
or clinical decision-making requires a greater accuracy than expected from eGFR, 
GFR should be measured.22,25 Measurement of GFR is ideally performed with gold 
standards such as 51chromium ethylene-diamine-tetra-acetic acid (51Cr-EDTA), 
technetium-labelled diethylene-triamine-pentacetate (99mTc-DTPA), inulin, iohexol 
and iothalamate.13 However, these markers are impractical for routine clinical 
use due to limited access to necessary diagnostic facilities and high cost.26 24-h 
urine creatinine clearance collection is easier to perform and might be helpful, 
especially in the hospital care setting. In the ambulatory care setting this method 
might be more inconvenient for the patient and prone to failure of collection of 
the entire specimen.26,27 In any case, the endogenous creatinine clearance measured 
overestimates true GFR because creatinine is excreted by glomerular filtration and 
tubular secretion.9 In specific patients, for example in situations where the renal 
function is not stable, both eGFR and 24-h urine collection are not sufficiently 
informative. In those situations choosing another drug or monitoring effectiveness 
and/or ADRs, preferably with therapeutic drug monitoring, may be appropriate 
(this will be discussed in the next paragraphs).
The difference between normalized (ml/min/1.73m2) and absolute (ml/min) eGFR 
values should also be taken into account when someone is substantially larger or 
smaller than an average person, but with a normal figure (with a body surface 
area (BSA) of 1.73m2). The best descriptor of body size in obese patients is still 
unclear.28 The GFR increases with body size but does not increase in proportion 
to the total body weight.10 Therefore, adjustment of eGFR to absolute GFR using 
BSA calculated based on actual body weight causes errors in the obese patients.10,29 
A recent study suggests the use of ideal body weight as the body size descriptor for 
GFR indexation30, although others suggest the lean body weight.29,31
In summary, the reported eGFR by laboratories may not reflect the true GFR of the 
individual patient properly. The introduction of a ‘simple’ correction factor seems not 
possible, because the direction and degree of the deviation is not predictable.15,32 To 
make it even more complex, most drug dose recommendations in patients with renal 
impairment are based on the CG formula, representing renal clearance of creatinine 
instead of eGFR. This may lead to clinically relevant problems.33 For example when 
using the new thrombin inhibitors, such as dabigatran and rivaroxaban. The use 
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of the MDRD-4 formula instead of the CG formula, which was used in clinical 
trials, would result in higher doses or incorrectly judgment if patients are eligible 
for treatment.34,35 Dabigatran would be recommended in a full dose for 33% of 
all participants when using the CG formula compared to 67% when using the 
MDRD-4 formula.34 Safety has not been established using the MDRD equation, a 
concern since the risk of major bleeding or the development of thrombosis would be 
increased in patients with renal impairment.35
All in all, there are many uncertainties when using eGFR in DTM. In the following 
paragraphs we will outline possible considerations when prescribing drugs in patients 
with renal impairment to cope with the knowledge and uncertainties we know today.
Choice of drug
Physicians should be aware of the fact that renally excreted drugs require dose 
adjustment in patients with renal impairment.1,36-38 In addition, there may not only 
be pharmacokinetic changes, but also pharmacodynamic changes which may differ 
between drugs.37 This latter and the lack of information of drug dosing in patients 
with renal impairment may lead to the advice to avoid the drug (contraindication).
There are often alternatives available for patients with renal impairment. For some 
drug classes there are several alternatives available, for example in the drug class of 
statins. Only rosuvastatin is contraindicated in severe renal impairment, whereas the 
other statins are not.39 If a 65-year old woman is diagnosed with diabetes mellitus 
type 2 with an eGFR of 35 ml/min/1.73m2 is metformin still the first choice drug? 
Metformin according to the guidelines may be started in a low dose of 500 mg two 
times daily. The risk of metformin associated lactic acidosis increases when renal 
function drops below 30 ml/min/1.73m2.40 This risk is probably already increased 
in the 65-year old women, because the eGFR is near the cut-off value of 30 ml/
min/1.73m2. Furthermore, the eGFR may overestimate true GFR and the renal 
function may decline in the near future. It might be that gliclazide is a better choice.
In patients with renal impairment alternatives for drugs that are not renally excreted 
are often available. But as in every step of prescribing drugs the benefits should 
outweigh the risk. In some clinical situations a renally excreted drug may be 
necessary. Then, the drug dose becomes important, which will be discussed in the 
next paragraph.
Therapeutic window
The therapeutic window (TW) reflects the concentration range that provides efficacy 
without unacceptable toxicity. In other words, the area between the minimum 
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efficacious dose and the maximum tolerable dose.41-43 The TW may also be thought 
of as a range of acceptable plasma levels of the drug and its active metabolite(s) in 
which positive therapeutic results are seen.42 In other words presented in a formula:
 
In the sequel of the definition of the TW, the question arises when is a TW called 
a narrow therapeutic window (NTW). Recently, Schulz et al. reported for nearly 
1,000 drugs and other xenobiotics, therapeutic (‘normal’) and, if data were available, 
toxic and comatose/fatal blood-plasma concentrations.44 The ranges reported for 
therapeutic and toxic blood plasma concentrations could be transformed to the 
presented formula above.
In Table 8.2 we illustrate the effect of overestimation and underestimation of the 
true GFR on the relative steady-state drug level (rCss) assuming that a rCss of 100% 
is reached in patients with a normal renal function of 100 ml/min/1.73m2 and 
a recommended drug dose of 100 mg per day. From our clinical experience, the 
overestimation of the eGFR, calculated with the MDRD formula, may become as 
high as 50-100% in patients who are completely bedridden for a prolonged period.
Theoretically, when the TW of a drug is 2, with a minimum relative effective plasma 
concentration of 70% and a minimum relative toxic plasma concentration of 140%, 
patients may suffer from a toxic rCss (see Table 8.2). For example, when the GFR 
is overestimated by 25%, patients suffering from impaired renal function (< 60 ml/
min/1.73m2) will reach a rCss that exceeds 140%. If the TW is assumed to be 3 
corresponding to a relative therapeutic range of 70-210%, toxic levels could also 
emerge easily. However, if the TW rises to 10 (70-700%, respectively), it becomes 
much more difficult to reach toxic levels (unless the drug level is already near the 
minimum toxic level).
We recommend a different approach for drugs with a NTW than for drugs 
with a broad therapeutic window (BTW) for drug dosing in patients with renal 
impairment.22 However, definitions for NTW-drugs are lacking in the literature.
We suggest that a drug with a TW of 5 or lower can be arbitrarily defined as a 
drug with a NTW. Table 8.3 presents examples of renally excreted drugs (or their 
active metabolites) with a TW of 5 or less. We used the Dutch guidelines ‘Drug 
dose advices in renal impairment’ to select drugs which need dose adjustment, are 
contraindicated or need therapeutic drug monitoring in renal impairment.39 
Minimum toxic plasma concentration 
Minimum effective plasma concentrationTherapeutic window (TW) =
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Table 8.2. Theoretical effects of substantial overestimation of eGFR values on relative steady-state 
drug levels of renally cleared drugs
The TW was calculated with the information summarized by Schulz et al. and 
supplemented with recent literature which indicates that toxic levels may be reached 
easily in patients with renal impairment.39,44 It appeared that for many drugs we 
could not retrieve concrete TW data. Therefore, this list should be considered as a 
starting point, which has to be updated when new information comes available.
In addition, clinicians should also be aware when a high dose (near the maximum 
recommended dose) is needed of a drug without a NTW, for example amoxicilline. 
eGFR Corresponding drug 
dose recommendation
 based on eGFRa 
Assumed degree
of overestimation
eGFR corrected 
for overestimation
Relative steady-
state drug levelb
100
60
40
20
100
60
40
20
100
60
40
20
100
60
40
20
100
100
50
25
100
100
50
25
100
100
50
25
100
100
50
25
100
60
40
20
80
48
32
16
67
40
27
13
50
30
20
10
100
167
125
125
125
208
156
156
149
250
185
154
200
333
250
250
0%
25%
50%
100%
a
b
eGFR = estimated glomerular ltration rate.
Recommended dose regimen: 100 mg if eGFR ≥ 50 ml/min/1.73m2; 50 mg if eGFR 30-49 ml/min/1.73m2; 
25 mg if eGFR 10-29 ml/min/1.73m2.
Relative steady-state drug level (rCss) has been calculated as follows:
Relative steady state drug level =
is formula is a simplication of the formula56:
Css =
by making the following assumptions56:
-   e patient has a normal body surface area of 1.73m2 
-   e drug has a bioavailability of 1 (i.e., 100%)
-   e drug has a dosing interval of 1 (i.e., once daily)
-   e drug is completely renally cleared
corresponding drug dose recommendation (mg/day)
eGFR corrected for overestimation
Bioavailability x drug dose
Dosing interval x drug clearance
(ml/min/1.73m2) (ml/min/1.73m2)(mg/day) (%)
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Drug Dose
adaptation
erapeutic
drug 
monitoring
Monitoring therapeutic
eect (TE) and/or adverse 
drug reactions (ADR)
erapeutic
window based
on Schultz et al.44
Other 
references
Type of advice in patients with renal impairment
Analgetic and 
antirheumatic drugs
Hydroxychloroquine
Antibacterial drugs
Amikacin
Ciprooxacin
Gentamicin
Tobramicin 


37,41
37,41
41
Memantine
Varenicline
a
b
e therapeutic window is based on the information of the metabolite oxypurinol.
Voriconazol by the intravenous route in patients with moderate to severe renal impairment is contraindicated due to the potential 
toxic eects of the accumulation of the solvent vehicle sulphobutyletherbetacyclo-dextrin.58
Antiepileptic drugs
Carbamazepine
Oxcarbazepine
Pregabaline
Primidone
Zonisamide
Antiglaucoma drugs
Acetazolamide
Antigout drugs
Allopurinol
Antimycotica
Flucytosine
Voriconazol intravenous
Antiparkinsonian drugs
Amantadine
Antipsychotic drugs
Lithium
Cardiac drugs
Digoxin
Disopyramide
Flecainide
Milrinon
Gastrointestinal drugs
Metoclopramide
Various



 (ADR)
 (ADR)
 (ADR)
 (ADR)
 (ADR)
 (ADR)
 (ADR)
 (ADR)
 (ADR)
 (ADR)
 (ADR)
 (TE)
 (TE, ADR)
(TE, ADR)
 (ADR)
 (TE)
 (TE)




b












 

4.6
5
3
3
3
2.5
3.3
4
2
5
2.5
4
5
5
4.5
5
4a
1.75
2.5-5
4
5
3.25
2.86
37,41,57
41,57
37,41,57
41
41
Table 8.3 Renally cleared drugs with a narrow therapeutic window
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In the situation of bacterial meningitis, for example, patients with renal impairment 
are at increased risk to reach plasma concentration above the minimum toxic plasma 
concentration, because the minimum effective dose and therefore the plasma level is 
higher. A lower dose should be considered in those situations.45
Considerations at the start of pharmacotherapy
When a renally cleared drug is needed for a patient with renal impairment, the 
starting dose should be considered. The rate at which the effect of the drug must be 
achieved (quickly or not) is of major importance. The following questions should be 
asked: “What is the risk of therapeutic failure with lower doses, and what is the risk 
of drug toxicity with higher doses?”45
If the pharmacological effect is needed quickly one should consider to start with the 
recommended dose for patients with a normal renal function and adjust the dose 
depending on ADRs and/or effectiveness. In other words, consider to not adjust 
the drug dose to renal function. Starting with a normal dose in patients with renal 
impairment may be seen as a loading dose. Moreover, the half-life time of renally 
excreted drugs will be longer and therefore it will also take longer to reach Css. For 
example antibiotics, the risk when dosing too low is insufficient efficacy, but also 
increasing risk to develop drug resistance. For most antibiotics the ADRs are easy 
to observe and may be relatively mild. Therefore, starting with a normal dose is 
preferable.
In case it is not crucial to have a quick pharmacological effect, one should preferably 
start with a low dose and gradually increase the dose over time while monitoring 
the effectiveness of the drug and ADRs. Examples are antihypertensive drugs and 
statins. This is called the ‘start low and go slow principle’.
Especially, for drugs with a NTW one should consider a more conservative 
approach.46
Considerations during pharmacotherapy
Drug dose recommendations concerning patients with impaired renal function are 
usually expressed per renal function category (50-80, 30-49, 10-29, and < 10 ml/
min/1.73m2).39,47 Therefore recommended dose changes for most drugs are crude 
(e.g. halving the dose or changing from twice-a-day regimen to a once-a-day 
regimen).17 One could argue that differences between eGFR and the true GFR will 
remain without practical consequences as long as they do not result in different renal 
function categories. However, the factors influencing the variance of the eGFR 
become more important as the eGFR approaches the nearest cut-off value for falling 
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into another renal function category. Then, a minor change in eGFR over time will 
lead to different drug dosing recommendations. It is important to keep in mind that 
different renal function categories to guide drug dosing are merely a derivative of a 
continuous function that is expressed by the following formula:
Fraction of normal dose = 1 - fe x (1-kF)
Herein, fe is the fraction of the original dose excreted as unchanged compound (or 
active metabolite) in the urine, while kF is the patient’s GFR divided by 120 ml/
min.48 If one indiscriminately applies drug dose recommendations of 50% for eGFRs 
of 30-50 ml/min and of 25% for eGFRs of 10-30 ml/min, a minor change in eGFR 
from, for example, 31 to 29 ml/min will halve the drug dose. If it is assumed that 
the fe for the particular drug equals 1, the formula above will yield a dose of 26% and 
24% for eGFRs of 31 and 29 ml/min, respectively. Alternatively, one could decide 
to replace the recommended doses of half and a quarter of the full drug dose by 
one-third for eGFRs around 30 ml/min.11 Following the calculation of the desired 
drug dose, the prescribed drug dose must be rounded off to the available strengths 
of the drug in question.49
Monitoring
Recognition of renal function as an issue to be considered when prescribing 
and dispensing drugs is probably more important than the precision of different 
estimates of renal function.37 To overcome uncertainties, drug efficacy and safety 
should preferably be monitored after the start of the therapy and dose adjustment 
should be based on ongoing assessment of clinical status and risk versus benefit 
of the current regimen.22 The Dutch guidelines for drug dosing in patients with 
renal impairment generally recommends therapeutic drug monitoring (TDM) 
and/or careful monitoring of therapeutic effects and/or ADRs for all drugs with a 
NTW (see Table 8.3).39 When it is not possible to monitor effectiveness or ADRs 
appropriately, or when it is not possible to timely detect serious ADRs, use of a 
different drug should be considered.
For a number of drugs monitoring their effectiveness and/or ADRs (when feasible 
through TDM) is more important than dose adjustment according to current 
guidelines. Digoxin, for example, is a drug that is difficult to manage, particularly 
in elderly patients who are at high risk of decreased renal function.50 An important 
limiting factor in the prediction of a digoxin dosage regimen when eGFR is 
< 60 ml/min, is the contribution of hepatic elimination. The latter increases when 
renal function decreases. This resulted in high inter-individual variation for digoxin 
plasma levels.36,51 Therapeutic drug monitoring of digoxin is then indicated. Another 
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example is allopurinol. Treat to target serum uric acid concentrations (< 0.36 mmol/l) 
rather than give a dose according to renal function has been shown to be safe and 
effective.52,53
Conclusion
DTM based naively on eGFR is not without limitations. The variation in non 
GFR determinants of serum creatinine levels cannot be overcome with existing 
formulas for estimating renal function. In addition, multimorbidity and drug-drug 
interactions can further complicate clinical decision making.44 The narrower the 
therapeutic window of a drug is, the more relevant individual patient characteristics 
are and the less satisfactory crude dose recommendations (such as halving the dose 
or doubling the dose interval) become.17 Therefore the following considerations in 
DTM in patients with renal impairment should be made: (1) is the drug renally 
excreted? If yes, is there a safer alternative available?, (2) if not, is it possible that 
the eGFR substantially deviates from the true GFR? If yes, consider 24-h urine 
creatinine clearance collection, (3) does the BSA of the patient deviates substantially 
from 1.73m2? If yes, calculate BSA and adjust eGFR to ml/min, (4) combine 
consideration 2 and 3 in order to achieve the best approximation of the true GFR, 
(5) adjust the drug dose gradually to the renal function, (6) be extra careful with 
drugs with a NTW and consider another starting dose depending on indication, (7) 
consider if it is possible to monitor effectiveness and/or ADRs with TDM and/or 
other measurements.
In conclusion, when determining most appropriate dosing regimen for patients with 
impaired renal function, the serum creatinine-based formulas should never be used 
naively but always in combination with clinical and pharmacological assessment of 
the individual patients.46
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Introduction
Chronic kidney disease (CKD) is a growing health problem and is associated with 
adverse outcomes, such as kidney failure, cardiovascular diseases and death.1-3 In 
addition, patients with renal impairment have an increased risk for developing 
adverse drug reactions and medication-related hospital admissions.4,5 Renal function 
therefore plays an important role in personalized drug therapy management 
(PDTM).
The estimated glomerular filtration rate (eGFR), mostly calculated with the 
Modification of Diet in Renal Disease (MDRD)-4 formula, is reported routinely 
by many clinical laboratories whenever a serum creatinine value has been ordered.6 
Computerized decision support systems (CDSS) facilitate appropriate dosing of 
renally cleared medications by including eGFR in its algorithms.7 The use of CDSS 
has led to fewer prescribing errors in patients with renal impairment according to 
existing guidelines.8,9 The implementation of guidelines in algorithms, which give an 
alert for an individual patient, suggests that the evidence underlying the algorithms 
are ‘black or white’. In other words the guidelines are often implemented as a rule book, 
whereas it is meant to give assessment tools based on existing evidence.10 Although it 
is widely understood that not every patient with a particular condition, for example 
patients with renal impairment, benefits from treatment adjustments that are known 
to work in an average population, clinicians may use guidelines as a rule book.11 
The introduction of the Dutch guidelines ‘Drug dose advices in renal impairment’ 
recommends pharmacists to actively advise another drug and/or another drug dose.12 
Although a group of experts with clinicians, both physicians and pharmacists, were 
involved in the development of the guidelines, the application of the guidelines in 
daily clinical practice encountered different perceptions between physicians and 
pharmacists.13 For example, nitrofurantoin initially was contraindicated when eGFR 
dropped below 50 ml/min.14 Pharmacists advised physicians to consider another 
drug when it was prescribed in patients with renal impairment. Physicians appeared 
not to be willing to do so, because they had not experienced any problems with 
nitrofurantoin in the past. Such differences between guidelines and clinical practice 
was the start of the researches presented in this thesis. To improve PDTM, it is 
important to understand the different perceptions and to investigate whether certain 
assumptions correspond with daily clinical practice.
This thesis comprises a variety of studies in which the pharmacological evidence 
of a part of the guidelines ‘Drug dose advices in renal impairment’ is examined. It 
starts with fundamental research about the validity of the MDRD formula. Then, 
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cohort studies about the risk to develop serious adverse drug reactions (ADRs), such 
as metformin induced lactic acidosis, are presented. In Chapter 8 we described a 
practical approach to cope with the uncertainties, reported in the previous chapters, 
in daily clinical practice and the role which a CDSS might play. This thesis contributes 
to knowledge that can be used for the improvement of the role of the pharmacist in 
drug therapy management in patients with renal impairment.
In the general discussion three topics will be addressed from the perspective of what 
is already known and what is added by this thesis to improve PDTM in patients 
with renal impairment. These topics are:
1. Complexity of renal function in drug dosing
2. Application of the guidelines ‘Drug dose advices in renal impairment’
3. Implications for clinical practice and future research
Complexity of renal function in drug dosing
Renal function
At the start (in 2009) of the studies described in this thesis, the MDRD-4 formula 
was used to estimate GFR. Clinical laboratories had just introduced the reporting 
of the eGFR calculated with the MDRD-4 formula. The advantage of this formula 
is that only age and serum creatinine levels are necessary to calculate eGFR. This in 
contrast to the Cockcroft and Gault (CG) formula wherein weight is also needed as 
a variable. The reporting of the eGFR by clinical laboratories stimulated pharmacists 
and other clinicians to give or apply drug dose advices when necessary.
As most of the drug dose advices are historically based on the older CG formula 
(see the next paragraph), the first question was, how valid is the MDRD formula 
in estimating the GFR in specific patient populations? The MDRD formula was 
developed in a sample of 1070 ambulatory, predominantly white patients with CKD, 
a mean age of 51 years, and 6% was diabetic.15 The population was not obese and 
without multiple comorbidities. Patients with serious medical conditions, such as 
lung disease, liver disease, and heart failure (New York Heart Association class 3 
and 4), were excluded.15 In other words, how does the patient population in daily 
clinical practice, both in the ambulatory and hospital care setting, correspond to 
the patient population used to develop the MDRD formula? Are there clinical 
conditions in which the MDRD formula is not valid?
In Chapter 3 we shortly reviewed the serum creatinine household. There are 
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numerous factors, conditions and situations that influence serum creatinine 
levels and thus eGFR calculated with the MDRD formula. Chapter 2 presented 
a systematic review for the full range of the GFR in patients with human 
immunodeficiency virus (HIV). Our conclusion was that the MDRD formula was 
as valid in HIV-positive as in HIV-negative patients with good renal function to 
mild renal impairment.16 In the meantime, from 2009 on, the Chronic Kidney 
Disease EPIdemiology Collaboration (CKD-EPI) formulas were developed. These 
formulas appeared to be more valid in the eGFR range ≥ 60 ml/min/1.73m2. The 
differences in the GFR range < 60 ml/min/1.73m2 were small and not clinically 
relevant.17,18 These results reminded us that the MDRD formula was developed in 
patients with renal impairment and was therefore by definition not properly tested in 
patients with normal renal function. For our broader systematic review we therefore 
selected only patients with a(n) (e)GFR < 60 ml/min/1.73m2. We conducted 
a systematic review to determine the validity of the MDRD formula in specific 
patient populations with renal impairment: elderly, hospitalized and obese patients, 
patients with cardiovascular diseases, cancer, chronic respiratory diseases, diabetes 
mellitus, liver cirrhosis and HIV. This selection was based on three general patient 
groups which were inadequately represented in the development of the MDRD 
formula, four common categories of chronic diseases, which are the leading cause 
of death and other chronic diseases in which reduced muscle mass can be present. 
In summary, the selection criteria we applied were an eGFR 60 < ml/min/1.73m2, 
comparison with a gold standard, and statistical analysis focussed on bias, precision, 
and accuracy. We interpreted these aspects as the most important ones, because an 
ideal comparison was not possible. In an ideal comparison, the gold standard and the 
measurement of serum creatinine levels would be exactly the same as in the study 
about the development of the MDRD formula, namely 125I-iothalamate and the 
kinetic alkaline picrate assay (Jaffe method), respectively.15
For patients with diabetes mellitus and liver cirrhosis, hospitalized patients on the 
internal medicine and nephrology ward and elderly with moderate to severe renal 
impairment we concluded that the MDRD formula is not valid.19 The conclusion of 
elderly patients, and patients with liver cirrhosis was in line with existing reviews, 
but more robust due to less methodological limitations.20,21 Our review also showed 
that the validity of the MDRD formula has not yet been tested properly or was 
tested poorly in patients with cardiovascular diseases and chronic respiratory 
diseases, obese patients, patients with cancer and HIV. In other words, the MDRD 
formula cannot be used naively in many patients both in the ambulatory and hospital 
care setting.19
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Several reviews about the validity of the MDRD formula have been published 
previously.20-23 These reviews often concerned the full range of the GFR, a diverse 
patient population, 24-hour urine collection as a ‘gold standard’, or another, to our 
opinion less appropriate, statistical analysis.
At the time the research for this thesis was conducted the CKD-EPI formulas were 
developed. These formulas are based on serum creatinine value, cystatin C value and 
a combination of both.24,25 Because these formulas are also serum creatinine based, 
the limitations discussed for the MDRD formula are probably similar. Therefore we 
assume that the results of this thesis may well be sustainable, even when the newer 
formulas will be increasingly used in the next years.
Another limitation of the studies presented in Chapter 2 and 3, but also throughout 
the thesis, is that the classification of renal function groups was based on a single 
eGFR value. This choice was for pragmatic reasons because clinical guidelines 
often recommend annual monitoring of renal function. However, variability in 
serum creatinine measurements requires at least two creatinine measurements.26 In 
addition, in certain clinical situations renal function may fluctuate substantially, so 
that the renal function group and therefore the recommended dose, can change 
within a few days. The magnitude of the fluctuation of the renal function in daily 
clinical practice and its potential effect on appropriate prescribing of medications, 
for example after discharge from the hospital, is unknown. Chapter 6 presented a 
study design about the fluctuation of eGFR around hospital admission in the elderly. 
The first results suggested that in one third of the patients the renal function group 
changed from one category to another and therefore implies that after discharge 
monitoring of renal function and (further) drug dosing adjustment may be necessary 
within the first two months. 
In summary, eGFR calculated with the MDRD formula is prone to influencing 
factors which may lead to a value that differs substantially from the true GFR. The 
MDRD formula is currently available and no alternatives are easy and forehanded 
and this will probably not the case in the near future. Therefore the next question is, 
is it possible to use the MDRD formula in drug dosing? And how should we use the 
MDRD formula in daily clinical practice?
Renal function and drug excretion of one drug
The ability to metabolize and eliminate drugs varies considerably between 
individuals.27 The two principal organs responsible for the elimination of drugs and 
their metabolites from the body are the liver and the kidney.28 In general, three 
processes can potentially contribute to the renal clearance of a drug: glomerular 
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filtration rate, tubular secretion, and tubular reabsorption.28 The CG formula has 
historically been the method applied to determine drug dose regimens in patients 
with impaired renal function, and reflects both the glomerular filtration rate and 
tubular secretion.6,22 The MDRD formula only represents the glomerular filtration 
rate. Therefore with the widespread automated reporting of the eGFR, calculated 
with the MDRD formula, the question has been raised whether eGFR can facilitate 
drug dosing decisions instead of the CG formula.6 The results of available studies 
are contradictory, but also interpreted differently. A concordance of 80% is said 
to be sufficient, whereas others suggest that a difference of 15% is unacceptable. 
According to Spruill et al. it is not surprising that the MDRD and CG formula 
perform differently, because of their mathematical differences.29 The expression of 
the age factor in the CG formula is linear, whereas the age factor in the MDRD 
formula is exponential.29 An additional difference is the way in which the units of 
both formulas are expressed. The CG formula reports results in ml/min, whereas 
the MDRD formula reports results in ml/min/1.73m2.30 For patients who are 
substantially larger or smaller than an average person (with a body surface area of 
1.73m2) and with a normal figure the outcome of both formulas may be substantially 
different, and this may lead to different drug dose advices. Hudson et al. reported that 
the eGFR estimated with the MDRD formula resulted in higher doses compared 
with the CG formula.22 Stevens et al. reported a high concordance rate between the 
MDRD and CG formula compared to mGFR (measured with 125I-iothalamaat), 
namely 88% and 85%, respectively (p < 0.001).6 However, the clinical relevance of 
the disconcordance might be high, depending on the type of drug.
In view of the foregoing, the use of the MDRD formula in drug dose advices seems 
less appropriate. In addition, renal dysfunction not only alters the renal excretion 
of unchanged drug and/or their metabolites, but it can also lead to modifications 
in plasma protein binding, distribution, transport and biotransformation of drug 
substances.28,30 The importance of these factors for each drug will differ depending 
on the metabolic process affecting that drug.30 For example, digoxin showed a 
great interindividual variability in the lower ranges of the eGFR (eGFR < 60 ml/
min).31,32 Although 80% of the digoxin dose is excreted unchanged in patients 
with normal renal function, the relative contribution of the hepatic elimination is 
increased in patients with renal impairment.31 Renal impairment can also affect the 
pharmacodynamic (PD) action of a drug, but this has not been well studied.28,33 
For example larger doses of furosemide are needed in patients with chronic renal 
impairment to achieve an adequate diuretic response compared to patients with 
normal renal function.28 Ideally integrated pharmacokinetic (PK)/PD studies are 
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needed to evaluate the necessity of drug dose adjustment in renal impairment.28,33
For newer drugs more attention should be paid to general pharmacokinetic principles 
in drug information programs.27 In 2010 the FDA published a draft update of their 
guidance for industry recommending that manufacturers provide drug dose advices 
on the basis of the CG and MDRD or CKD-EPI formula.33 The five major updates 
were 33: (1) a PK study should be conducted in subjects with renal impairment when 
the drug is likely to be used in these subgroups, both for renally and non-renally 
excreted drugs, (2) both formulas might be used, CG and MDRD, (3) conduct 
studies in hemodialysis patients on dialysis, (4) study the PK of therapeutic proteins 
in renally impaired patients when appropriate, and (5) the results should be described 
in the label/product information. The intention of the FDA is a step forward, but 
how to cope with already existing drugs remains unclear.
In Chapter 4 and 5 we described two cohort studies about patients with renal 
impairment using nitrofurantoin and metformin, respectively. Both drugs are 
considered to be contraindicated when renal function drops below a specific level. 
Nitrofurantoin and metformin are the drug of choice in urinary tract infection in 
women or diabetes mellitus type 2, respectively. Currently provided recommendations 
on drug dose are predominantly based on case reports and/or pharmacokinetic 
studies. The latter are often performed in healthy volunteers using a single dose, 
and therefore they not have to be representative for daily clinical practice. The main 
finding for both drugs, metformin and nitrofurantoin, was that the risk for adverse 
drug reactions was increased in patients with renal impairment which is in line 
with current recommendations.34,35 We showed that this type of research is useful 
in confirming drug dose advices in a large representative population over a long 
period. In the metformin study we even identified that a high metformin dose in 
combination with renal impairment further increases the risk of lactic acidosis. The 
problem is that the incidence of such ADRs are rare. One unanswered question is 
whether there are additional risk modifiers to identify patients with a higher risk.
The database studies had several limitations. First, the outcome measures may not 
classify all cases correctly. In the nitrofurantoin study the outcome measurement for 
ineffectiveness was another antibacterial treatment used for urinary tract infection, 
but these antibacterials could have been used for other reasons. In the metformin study 
one could raise the question to which extent an elevated lactate level (> 5 mmol/l) 
point in the direction of lactic acidosis. Second, the registration of adverse events, 
diagnosis and/or laboratory values in databases is limited. In other words, the events 
measured in our studies might only be the tip of the iceberg. In daily clinical practice 
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the number of less critical events (which also may be inconvenient for the patient) 
might be even greater. Third, we used a single serum creatinine level to calculate 
eGFR or the single reported eGFR only. As we explained above, the variability in 
serum creatinine measurements requires at least two creatinine measurements or 
two reported eGFRs to assess the degree of renal impairment.26
In summary, cohort studies in a large database and over a long period generated 
new evidence to existing guidelines. In future research additional risk factors should 
be identified. In addition, these cohort studies showed the importance of post 
marketing surveillance of the behaviour of drugs in large populations of patients 
with renal impairment. Especially in the case of rare ADRs, such as metformin 
induced lactic acidosis.
Renal function and the use of multiple drugs for multiple comorbidities 
and/or unstable situations.
In the previous two sections we focussed on eGFR and the impact of eGFR on 
one specific drug. In daily clinical practice clinicians are confronted with patients 
with multiple comorbidities using multiple drugs. Patients with CKD frequently 
have comorbidities, including hypertension, diabetes, cardiovascular disease, and 
metabolic bone disease.36 Polypharmacy is typical and therefore the risk of drug-
drug interactions is substantial.36
For example, the use of an angiotensin-converting enzyme (ACE)-inhibitor as an 
antihypertensive drug in patients with diabetes is recommended.37 When a patient 
with diabetes also has renal impairment, the risk for developing hyperkalaemia 
from ACE-inhibitors is approximately 5 times higher.38 This rarely leads to severe 
hyperkalaemia, because the kidney is capable of adapting potassium homeostasis. 
However, there are situations wherein the potassium level strongly increases and 
leads to the discontinuation of the ACE-inhibitor, namely with the concomitant use 
of non-steroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, 
or ingestion of large amounts of potassium salts.38 In other words the combination 
of multiple drugs increases the risk of hyperkalaemia compared to the use of an 
ACE-inhibitor alone in patients with renal impairment.
Another example is the use of rivaroxaban in patients with renal impairment. 
Approximately two-third of the rivaroxaban is hepatically metabolized through 
the liver via cytochrome P450 enzymes (both CYP3A4/3A5 and CYP2J2) and 
one third is renally excreted unchanged via P-gp-mediated and ABCG-2 mediated 
secretion.39,40 When rivaroxaban was used alone in patients with mild and moderate 
renal impairment the area under the curve (AUC) increased with approximately 15%. 
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When rivaroxaban was added to a treatment with erythromycin, a CYP3A4 and 
P-gp-inhibitor, the AUC of rivaroxaban increased with approximately 54% to 71% 
in patients with mild and moderate renal impairment, respectively, compared to 
rivaroxaban use alone.39 The combined drug-drug-disease interaction resulted in a 
clinically relevant increase in rivaroxaban exposure.39
The two examples illustrate which problems may occur in patients with renal 
impairment when different drugs for different indications are prescribed. To avoid 
these problems another drug may be chosen or the drug dose may be adapted. In 
a stable situation renally excreted drugs can be prescribed in patients with renal 
impairment. However, physicians should be aware of the fact that clinical situations 
may change over time. For example, declining of renal function over time, change 
of chronic nutritional status (defined as percentage of ideal body weight), serum 
potassium levels and age (individual patient characteristics) are all of influence on 
digoxin clearance (at least in hospitalized Korean patients, but probably also in other 
ethnic groups).32 Evaluating changes in patients’ situations over time, for example 
renal function, and the effects of adjustment of drug dose regimens on the clinical 
outcome should be subject to future research.
It is also possible that a clinical situation changes abruptly. For example in situations, 
such as diuretic therapy, vomiting, and diarrhoea, it can result in true volume depletion. 
Patients with CKD are then more vulnerable to toxic drug effects on the kidney.41 
Such an abrupt change may even lead to developing acute kidney injury (AKI) with 
increased risk of mortality.42 The best strategy is to avoid potentially nephrotoxic 
drugs and concomitant use of nephrotoxic drugs whenever possible.41 In Chapter 8 
we suggest to avoid renally cleared drugs in patients with renal impairment, but that 
is not always possible. Choosing a drug with a broad therapeutic window may also 
help to reduce future problems.
In summary, multiple drugs for multiple comorbidities is common in patients with 
renal impairment. Drug dosing in these patients is therefore often complex.
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Application of the guidelines ‘Drug dose advices in renal 
impairment’
Clinical decision support systems
CKD is a chronic disease that is frequently associated with comorbidities, making 
effective treatment difficult due to the complexity of care.43 Mistakes occurring 
during drug treatment are often related to an erroneous prescription, lack of time, 
missing information or lack of knowledge.44 The publication of guidelines is not 
enough by itself to change the prescribing behaviour of clinicians in this respect. 
Clinical decision support systems (CDSSs) may be helpful in the implementation 
of guidelines, such as ‘Drug dose advices in renal impairment’. CDSSs link patient 
characteristics with medical knowledge to generate recommendations for the 
clinician to improve PDTM.45
In Chapter 7 we demonstrated that an advanced pharmacotherapy-related CDSS 
leads to more relevant alerts compared to a basic pharmacotherapy-related CDSS. 
The impact of adding laboratory values and other patient characteristics resulted 
in a significantly higher positive predictive value (PPV) for the advanced CDSS 
compared to the basic CDSS (23.3% versus 12.2%; p < 0.05).46 However, the number 
of clinically irrelevant alerts remained high and continuous fine-tuning of these 
algorithms is necessary. Alerts related to recommendations in patients with renal 
impairment were not calculated separately. In our study alerts about drugs which 
were contraindicated in combination with a certain degree of renal impairment were 
classified as a ‘drug-disease interaction’. If alerts contained a drug dose advice at a 
certain degree of renal impairment they were classified as ‘dosing guidance’. The PPV 
for both categories increased substantially in the advanced CDSS: 24.5% versus 0% 
and 16.9% versus 5.6% for the category drug-disease interaction and dosing guidance, 
respectively.46 We know that these increases in PPVs in the advanced CDSS were at 
least partly due to algorithms using renal function laboratory values.
Although the PPV was increased in the advanced CDSS, the PPV could 
be increased further by combining algorithms. For example, one algorithm 
identified the combination of a renin-angiotensin-aldosteron-system (RAAS)-
inhibitor and potassium (-saving diuretics) and generated a medication alert with 
the recommendation to monitor the serum potassium level. Another algorithm 
checked if the serum potassium level was recently measured and within the range 
of 3.5-5.0 mmol/l. The first algorithm should be suppressed if the second algorithm 
does not generate a medication alert, because the potassium level is already monitored. 
Another step in improving a CDSS is adding more patient characteristics and
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 laboratory values. Seidling et al. identified potassium, leukocyte count, international 
normalized ratio (INR), therapeutic drug monitoring and eGFR as useful laboratory 
values to reduce the number of inappropriate signals. The identification of static as 
well as dynamic patient characteristics as modifiers is a promising strategy.44
In daily clinical practice alerts are often overridden by physicians and in half of the 
cases advices from CDSSs are ignored or not followed for several reasons.47-49 Reasons 
to ignore warnings were: irrelevant, not timely, already considered before, or simply 
because the expected benefit of the therapy outweighs the potential risks.44 Between 
physicians and pharmacists and among physicians approximately 50% agreed on the 
given advice or on turning the alert off because of the lack of clinical usefulness.50,51 
These results indicate that concordance in using guidelines is still lacking.
Another problem is that physicians experience the alerts as a disruption of their 
workflow. Reaching agreement on treatment and instructions on how to use 
medication often occurs before the prescription is entered into the computer.52 
Therefore current systems interrupt to correct decisions already made, rather 
than to assist earlier deliberations.52 Advices in an alert vary from discourage to 
prescribe a certain drug to monitoring renal function in time and over time.12 At 
the moment of prescription the first alert about not recommending a certain drug 
might be important and the physician may choose another drug. The second alert 
about monitoring renal function may not be important on that specific moment. The 
question is, is it possible to reduce the alerts at the moment of prescribing to alerts 
really necessary? And are physicians more prone to react on these selection of alerts? 
The next question is, who is responding to alerts turned off for the prescriber? To 
our opinion, pharmacists can play an important role here. Especially, when more 
prescribers are involved pharmacists have the overview of the combination of drugs 
for several comorbidities. Due to their education they are probably more capable 
of assessing the effects of a combination of drugs than physicians. In addition, 
pharmacists may handle specific alerts instead of the physician (see also the role of 
the pharmacist in PDTM described in the next section).
Many clinicians experience a CDSS as a tool to burden their work pressure. It 
is possible to reduce irrelevant alerts in current CDSS by using sophisticated 
algorithms, but these CDSSs also give more opportunities to increase the quality of 
PDTM. For example, an algorithm that checks if measurement of renal function is 
done timely. The possibilities for a CDSS are endless, but the number of alerts that 
can be evaluated by a clinician in daily practice is limited. In addition, daily clinical 
practice does not always correspond with the evidence published in guidelines. 
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Therefore continuous education of clinicians to improve their clinical judgment 
remains necessary. In the future CDSSs may also be used as a risk management tool 
to identify complex patients that need an integrated team-based evaluation.
In summary, CDSSs are an important element to solve some of the problems of 
implementing evidence into clinical practice, but not the only one.43 Current CDSSs 
generate too many irrelevant alerts, but more advanced CDSSs are promising to 
be more effective (generate more relevant alerts) and more efficient (generate less 
irrelevant alerts).
Role of the pharmacist in personalized drug therapy management
In the section above we mentioned the complexity of renal function and the 
excretion of drugs by the kidney. With information about pharmacodynamics 
and pharmacokinetics of a specific drug for each degree of renal impairment drug 
dose advices can be achieved. It might even be possible to predict certain unstable 
situations and their effect on the excretion of drugs. A CDSS might be supportive 
in the application of all the available knowledge, including the results presented in 
this thesis. The next question is, how can we realize PDTM in patients with renal 
impairment in daily clinical practice?.
Evidence based guidelines help to make the best scientific evidence accessible for 
decision makers.53 Simply making providers aware of clinical guidelines is often 
insufficient for inducing adherence with these clinical guidelines.53-56 Several 
implementation strategies can be applied, varying from education and support 
of health professionals to organisational change and financial incentives. These 
strategies can improve healthcare delivery, although the impact is mixed and overall 
moderate.53,56,57
We started this thesis with the six steps of good prescribing of drugs (see Table 9.1).58 
The responsibility for good prescribing is entirely allocated to the prescriber in 
the current document of the World Health Organization (WHO). The role of 
pharmacists is different across countries, but in The Netherlands pharmacists are 
drug specialists who can play an important role in the process of good prescribing 
of drugs and therefore be of added value in PDTM. Due to increased numbers 
of guidelines and standards and the growing empowerment of patients, good 
prescribing of drugs cannot rely on physicians solely. The key players in this process 
are: the patient, the physician(s) and the pharmacist. Below we suggest the added 
value of pharmacists in step 3, 4 and 6 of good drug prescribing in patients with 
renal impairment. In The Netherlands step 5 has already been implemented very 
well. Giving information, instructions and warnings when a drug is dispensed for 
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the first time is not any different for patients with or without renal impairment. 
Therefore we will not discuss this particular step.
Table 9.1 Six steps in good prescribing of drugs
Step 3: Verify the suitability of the personal-drug
Physicians have their personal preferred drug (P-drug) to prescribe when they 
suspect or diagnose a certain disease. A P-drug is based on four criteria: efficacy, 
safety, suitability and cost.58 The drug of first choice applies to the general population 
visiting the physician. When a patient with renal impairment represents himself/
herself the first choice P-drug might not be suitable. In Chapter 8 we presented 
considerations when prescribing drugs in patients with renal impairment. In 
summary, if the P-drug is renally excreted, the first consideration should be if a safer 
drug for patients with renal impairment is available which is equally effective. In 
addition, we presented a table with renally excreted drugs with a narrow therapeutic 
window (NTW) for which extra attention is necessary when prescribed in patients 
with renal impairment. The indication and thus the rate at which the therapeutic 
effect has to be achieved should also be taken into account. For example, when 
starting an antihypertensive drug, the starting dose might be low and the dose 
might be increased slowly depending on the effectiveness and ADRs. For treating an 
infection the approach might be better the other way around. Starting with a normal 
dose and if necessary decrease the dose depending on clinical response and ADRs.
The added value of pharmacists in this step of good prescribing is to be a sparring 
partner for the physician. Awareness about the suitability or unsuitability of 
P-drugs in patients with renal impairment might be increased by discussing 
guidelines in pharmacotherapeutic consults. For example, in primary care many 
general practitioners and community pharmacists discuss subjects on regular basis. 
P-drugs or adjusted dosage of P-drugs for patients with renal impairment can be 
determined and specified in protocols. When a prescription reaches the pharmacy, 
the pharmacist evaluates the drug and drug dose prescribed with regard to the 
patient’s renal function and, even more importantly, evaluates the prescription and 
Step Description Added value of pharmacist
1
2
3
4
5
6
Dene the patient’s problem
Specify the therapeutic objective
Verify the suitability of your P(ersonal)-drug
Write a prescription
Give information, instructions and warnings
Monitor (or stop?) the treatment
No
No
Yes
Yes
Yes
Yes
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renal function in the light of the co-medication already in use by the patient. This 
medication review may not only lead to a change in the new prescription but also to 
a change in the drugs already in use.
Step 4: Write a prescription
In the era of computerized physician order entry systems, prescriptions can be 
read properly by the pharmacy. The added value of the pharmacist in writing the 
prescription itself is nihil, but the added value must be found in the application of 
CDSSs in the prescribing process. In the section about CDSS above we described 
the advantage and disadvantage and challenges in using CDSSs.
We already mentioned that pharmacists can play an important role, because 
pharmacists have the overview of all drugs used by the patient, also those prescribed 
by different physicians. The added value of pharmacists may be increased by shifting 
the handling of alerts from the physician to the pharmacist. For example, a 68-year 
old man is prescribed naproxen 500 mg twice daily by the general practitioner 
(GP). He also uses a selective serotonin reuptake inhibitor (SSRI) prescribed by 
the psychiatrist and acetylsalicylic acid by the cardiologist. The addition of a proton 
pump inhibitor (PPI) is recommended due to the increased risk of gastrointestinal 
bleeding. In The Netherlands some pharmacists already have the agreement that 
they can add a PPI without contacting the GP, which is defined in a protocol. These 
initiatives should be encouraged and expanded. In case of alerts for patients with 
renal impairment one could choose to show only the drugs with a NTW to the 
physician to improve alert fatigue. Other alerts might be handled by the pharmacist, 
which mainly implies that sufficient instruction and warnings are needed when the 
drug is dispensed. In case of doubt and when an additional clinical view of the 
physician is needed, the pharmacist should contact the prescriber.
Step 6: Monitor (or stop?) the treatment
Numerous studies have shown that patients with chronic conditions adhere only to 
50-60% of their medications as prescribed.59 For example, in chronic heart failure 
and diabetes mellitus poor adherence to medications increases hospitalization and 
mortality.60,61 Patient adherence is greatest 5 days prior and 5 days post appointment 
with health care providers and usually tapers off significantly within 30 days.59 
Failure to identify and remediate poor adherence often results in intensified 
pharmacotherapy with increased doses of medication – thus increasing the overall 
cost of treatment, the risk of adverse effects, physician frustration, misdiagnoses, and 
in more extreme situations, unnecessary treatment and exacerbation of disease or 
even mortality.59 Reiterative, positive reinforcement, frequent feedback and regular 
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follow-up are essential to ensure adequate adherence over time.59,62 Discussing 
adherence to drug therapy is the first step in monitoring effectiveness and ADRs 
properly, both for patients with and without renal impairment. When it comes to 
monitoring effectiveness and/or ADRs the use of measurements, such as blood 
pressure, cholesterol level, therapeutic drug monitoring, serum creatinine level etc., 
become more important in patients with renal impairment. This is mainly due to 
the lack of evidence of the behaviour of a drug and therefore the prediction of the 
effects of a drug in patients with renal impairment seen in daily clinical practice, 
especially when multiple drugs are used simultaneously. In addition, the pharmacist 
should contact the patient more often to discuss the effectiveness and ADRs which 
cannot be measured. In Chapter 8 we described the importance of monitoring and 
recommended to monitor effectiveness and/or ADRs with laboratory measurements 
whenever possible. These laboratory values may vary between monitoring renal 
function itself, for example after starting an ACE-inhibitor, to therapeutic drug 
monitoring when carbamazepine or vancomycine is started, to measuring anti-Xa 
activity when dabigatran is used. Traditionally, requesting a laboratory value is the 
task of the physician. In both our cohort studies (Chapter 4 and 5) the percentage 
of patients with unknown renal function was high. In our diabetic population this 
percentage was approximately 30%. An even higher number was reported by van 
Blijderveen et al. in a dynamic population using a diuretic, ACE-inhibitor, and/
or angiotensin receptor blocker.63 Although physicians have a positive intention to 
monitor biochemical parameters, this is not always achieved in clinical practice.64 
Pharmacists can play a coordinating role. Along with the evaluation with the patient 
about the effectiveness and/or ADRs of a drug, pharmacists may contribute to the 
safe, effective, and efficient use of drugs, particularly when caring for people with 
multiple chronic conditions where multiple clinicians are involved.65
Implications for clinical practice
The eGFR reported by clinical laboratories should not be used naively. The implications 
for clinical practice are outlined in detail in Chapter 8. In summary, in patients with 
renal impairment the drug of choice is an effective drug that is not renally excreted. 
If a renally excreted drug is needed the reliability of the eGFR should be assessed 
more carefully for drugs with a NTW. After achieving the best approximation of the 
true GFR, we suggest a gradually drug dose adaptation according to renal function. 
Monitoring effectiveness and ADRs are the key component in PDTM and should 
be assessed with laboratory measurements whenever possible. PDTM should be 
based on an ongoing assessment of clinical status outweighing the risk versus the 
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benefit of the used drug regimen. In Chapter 9 we outlined the potential added 
value of pharmacists in coordinating the laboratory measurements and monitoring 
effectiveness and ADRs of drugs used in patients with renal impairment. The first 
step to achieve this changing role of pharmacists in PDTM is that physicians are 
aware of how important it is to share the eGFR value, especially in the ambulatory 
care setting where access to laboratory values is limited.
For some pharmacists their attitude to renal function should change as well. The 
eGFR value and the guidelines ‘Drug dose advices in renal impairment’ should 
not be applied strictly. Drugs with a broad therapeutic window may be dispensed 
without knowing renal function, except when a high dose is prescribed. For drugs 
with a NTW renal function should be assessed more carefully, but giving a normal 
dose instead of an adjusted dose on day 1 might even be more useful to achieve 
steady state levels more rapidly.
The first results of the study presented in Chapter 6 confirmed that awareness of 
the fluctuation of the renal function after discharge from the hospital is necessary. 
Community pharmacies and GPs should not rely on eGFR values measured around 
or during hospital admission only.
Specific implications for clinical practice followed from Chapter 4 and 5. Although 
we confirmed the advices for nitrofurantoin and metformin to not give these drugs 
when eGFR drops below 30 ml/min/1.73m2, additional information might be 
added to the existing advices in the Dutch guidelines ‘Drug dose advices in renal 
impairment’. In line with the Medicines and Healthcare products Regulatory 
Agency the advice for nitrofurantoin should be: “A short course (3 to 7 days) may 
be used with caution in certain patients with an eGFR between 30 and 44 ml/
min/1.73m2”.66 In Chapter 5 we found further evidence for the claim that the lower 
the renal function the higher the risk of lactic acidosis in metformin users. The 
risk was even higher when a high dose (> 2 g per day) of metformin was used. The 
current advice is to start with metformin 500 mg 2 times a day when renal function 
is between 30 and 50 ml/min/1.73m2.12 In daily clinical practice one should not only 
consider the starting dose of metformin, but also reconsider the metformin doses 
whenever a new eGFR value is reported, especially when eGFR drops below 60 ml/
min/1.73m2.
Implications for future research
The search for a formula ‘one size fits all’ to estimate GFR seems unrealistic. At 
least, it will take a long time to develop a formula with a better predictive value than 
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formulas involving serum creatinine and to validate it in diverse patient populations. 
Current clinical practice needs research that rather focuses on identifying variables 
or situations in which the currently known serum creatinine-based formulas should 
not be used for PDTM or used with extreme caution.
There are many studies about the potential effects on drug dose advices when 
using different serum creatinine-based formulas, but clinical consequences remain 
largely unclear.6,22,67,68 Future research should focus on the clinical relevance of 
these differences in drug dose recommendations. In addition, a gradual drug dose 
adaptation as described in Chapter 8 should be subject for future research as well. 
For example, in metformin users, does a gradual adjustment of the metformin dose 
in line with the decrease of renal function affects morbidity, mortality and/or risk of 
lactic acidosis?. 
In daily clinical practice patients often have multiple morbidities and therefore 
use multiple drugs, especially patients with CKD. Most of the studies underlying 
guidelines are based on one drug in patients with a certain degree of renal 
impairment. Comorbidities are often excluded. The question is, how important is 
the factor renal function in PDTM in complex patients were multiple morbidities 
are present? Perhaps other factors are more of influence on the clinical effect of 
drugs and therefore should (also) be considered in PDTM. A broad approach on 
how to apply PDTM in these complex patients should be subject for future research.
Especially, in the hospital care setting it is known that eGFR may fluctuate within 
a day. When the eGFR points to another drug dose category, drug dose advices may 
also change from one day to another. What is the clinical relevance of adjusting drug 
doses from one day to another based on eGFR values?
In Chapter 8 we presented a list of drugs with a NTW. Subject for future research 
is the clinical consequences of using this ‘short-list’ versus the current use of the 
guidelines ‘Drug dose advices in renal impairment’. The added value of pharmacists 
in PDTM should also be investigated. This can be done by monitoring clinical 
effectiveness and ADRs of a specific group of drugs, for example, antibiotics.
In this thesis special attention was paid to the drugs nitrofurantoin and metformin. 
Other drugs which are contraindicated in patients with renal impairment might 
also be of interest for future research. For future research a clear definition on 
how to validate formulas is recommended. This should be done before a formula 
is implemented worldwide. It seems logical, but variables should be measured with 
the same method and the same gold standard should be used as in the development 
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study. Of interest were also the statistical methods used to analyse the validity of, 
in our case, the MDRD formula. The most informative method to assess diagnostic 
tests is the Bland-Altman plot, as this identifies the direction and the magnitude of 
the bias. Agreement on this aspect for future research is recommended.
Conclusion
The researches presented in this thesis showed the complexity of PDTM in patients 
with renal impairment. The MDRD formula that is widely used in The Netherlands 
in drug dosing, appeared not to be valid or the validity was unclear in specific patient 
populations. In addition, the results in this thesis showed that database cohort studies 
are useful in confirming advices published by guidelines. Despite the uncertainties 
of the MDRD formula and the limited evidence underlying guidelines, the fact is 
that the eGFR is automatically reported by clinical laboratories and the guidelines 
are used in daily clinical practice. In Chapter 8 we discussed pragmatically how 
to use the eGFR values and the guidelines. We presented a list of drugs with a 
NTW that should be avoided or used with great caution in patients with renal 
impairment. In all cases, monitoring effectiveness and ADRs of drugs over time is 
an important key component in PDTM. Pharmacists may play an important role 
in improving PDTM by monitoring effectiveness and ADRs and coordinating the 
measurement of laboratory values whenever necessary. CDSS might be supportive 
in the application of all the available knowledge.
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Summary
An important challenge in the good prescribing of drugs for treatment or prevention 
of diseases is finding the suitable drug for the patient’s problem. The risk-benefit ratio 
in patients with renal impairment might be different from other patient populations 
without renal impairment. In addition, knowledge about the clinical effects, both 
effectiveness and adverse drug reactions (ADRs), of drugs used in patients with renal 
impairment is not fully understood. Therefore, monitoring of the treatment will be 
even more important. As renal function fluctuates over time, the right drug and right 
drug dose should be reconsidered when the renal function changes substantially. 
Additional advices about monitoring specific variables or additional instructions for 
the patient to recognize ADRs timely might also be necessary. Finding the suitable 
drug in the right dose for the patient’s problem and monitoring its effectiveness 
and adverse drug reactions (ADRs) over time, are defined as personalized drug 
therapy management (PDTM). This thesis focuses on PDTM in patients with renal 
impairment.
Over the past few years the focus on renal function and pharmacotherapy has 
increased. Studies showed that up to one third of the adverse drug reactions (ADRs) 
leading to hospital admission may be related to impaired renal function. After the 
introduction of the Modification of Diet in Renal Disease (MDRD) formula, which 
estimates the glomerular filtration rate (eGFR), the eGFR is reported by clinical 
laboratories whenever serum creatinine levels are ordered. This led to a better 
recognition of impaired renal function and therefore it became easier to follow the 
guidelines ‘Drug dose advices in renal impairment’ in daily clinical practice, in which 
drug dose advices are given categorically per renal function group. The application 
of these guidelines led to disagreement between pharmacists and physicians. 
Questions that physicians may ask were: “How strong is the evidence underlying the 
advice? What is the degree of the risk when my patient gets an inappropriate drug or 
drug dose?” These questions triggered that the evidence behind the guidelines was 
further examined. It appeared that the evidence was mainly based on case reports 
and pharmacokinetic studies in controlled environments. The lack of population-
based studies and/or translation of evidence to the population seen in daily clinical 
practice became the domain of this thesis. This thesis aims to give insight in: (1) the 
validity of the MDRD formula used in prescribing drugs in renal impairment, (2) to 
add new evidence to evaluate existing guidelines, and (3) to give practical approaches 
for handling renally excreted drugs in patients with renal impairment. 
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The validity of the Modification of Diet in Renal Disease Formula
The MDRD formula is widely used in clinical practice to assess the correct drug 
dose. This formula is based on serum creatinine levels, which is a by-product of 
muscle catabolism. There is a clear inverse correlation between serum creatinine 
levels and the true GFR. However, there are several factors which may influence 
serum creatinine levels without affecting GFR itself, which potentially distorts 
the interpretation of values for clinical use. Although the serum creatinine-based 
formulas provide a better estimation of the true GFR than serum creatinine 
concentrations in the general population, these have been poorly validated in specific 
patient populations. Chronic diseases themselves or the effects of chronic diseases 
may influence serum creatinine levels. Inaccuracy in eGFRs might lead either to 
overestimation of renal function, leading to administration of inappropriately 
large doses and therefore possible toxicity, or, conversely, underestimation of renal 
function, leading to subtherapeutic dosing and therefore treatment failure, and 
prolonged illness.
Chapter 2 presents a systematic review of the validity of the MDRD formula in 
patients infected with human immunodeficiency virus (HIV) over the full eGFR 
range. Renal dysfunction is highly prevalent in HIV-infected patients and may 
require dose adjustment of renally excreted antiretroviral drugs. We conducted a 
systematic search in Pubmed and EMBASE to identify studies which compared the 
MDRD formula with measured glomerular filtration rate (mGFR) in HIV-infected 
patients. Five studies were included, which provided data from 464 HIV-infected 
patients. We concluded that the MDRD formula was as valid in HIV-positive as 
in HIV-negative patients with good renal function to mild renal impairment. More 
research is still needed to validate the MDRD formula in HIV-infected patients 
with moderate to severe renal impairment. The MDRD formula was developed in 
patients with chronic kidney disease (CKD) and was therefore by definition not 
properly tested in patients with normal renal function. For a broader systematic 
review in Chapter 3 we therefore selected only patients with a(n) (e)GFR < 60 ml/
min/1.73m2. We examined the validity of the MDRD formula in the following 
specific patient populations: elderly, hospitalized and obese patients, patients with 
cardiovascular diseases, cancer, chronic respiratory diseases, diabetes mellitus, liver 
cirrhosis and human immunodeficiency virus (HIV). This selection was based on three 
general patient groups which were inadequately represented in the development of 
the MDRD formula, four common categories of chronic diseases, which are leading 
causes of death and other chronic diseases in which reduced muscle mass can be 
present. We searched for articles in Pubmed published from January 1999 through 
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January 2014. Other selection criteria we applied were a comparison of the MDRD 
formula with a gold standard, and statistical analysis focussed on bias, precision, and 
accuracy. A bias of 20% or less, a precision of 30% or less and an accuracy expressed 
as P30 of 80% or higher were indicators of the validity of the MDRD formula. 
In total we included 27 studies. The validity of the MDRD formula has not yet 
been tested properly in patients with cardiovascular diseases and chronic respiratory 
diseases. In obese patients, patients with cancer and HIV the validity of the MDRD 
formula has been insufficiently tested. For patients with diabetes mellitus and liver 
cirrhosis, hospitalized patients on the internal medicine and nephrology ward and 
elderly with moderate to severe renal impairment we concluded that the MDRD 
formula is not valid. 
In conclusion, the use of the MDRD formula in different specific patient populations 
for the fine-tuning of drug therapy management is not without limitations. There is 
no hard evidence that the MDRD formula is valid in patients with several chronic 
diseases combined with renal impairment, and in some cases there is evidence that 
the MDRD formula is not valid.
New evidence to evaluate existing guidelines
In the second part of this thesis we looked closer to the research evidence underlying 
the drug treatment recommendations in guidelines. We were especially interested 
in the frequently prescribed drugs nitrofurantoin and metformin. Both drugs are 
the drug of choice when, respectively urinary tract infection (UTI) in women or 
diabetes mellitus type 2 are diagnosed, but both drugs are also contraindicated 
when renal function drops below a specific level. Are patients with renal impairment 
falsely withheld from a first choice drug? It became evident that the contraindication 
of these drugs in renal impairment was based on pharmacokinetic studies and case 
reports.
According to the drug label, nitrofurantoin is contraindicated when the eGFR is less 
than 60 ml/min, because of ineffectiveness and safety problems. In Chapter 4 we 
present a cohort study in which we determined whether treatment with nitrofurantoin 
in women with UTI and renal impairment in primary care is associated with a higher 
risk of ineffectiveness and/or serious adverse events than in women without renal 
impairment. A cohort of 21,317 women treated with nitrofurantoin identified from 
the PHARMO Record Linkage System were analysed. Moderate renal impairment 
(30-50 ml/min/1.73m2) was not associated with ineffective treatment, but the risk of 
pulmonary adverse events leading to hospitalization was significantly 4 times higher 
in patients with renal impairment (< 50 ml/min/1.73m2).
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For the study in Chapter 5 about metformin we used the Clinical Practice Research 
Datalink (CPRD), in which the primary outcome lactic acidosis and plasma lactate 
levels of > 5 mmol/l could be identified. A cohort of 223,968 metformin users and 
34,571 diabetic patients who had never used metformin (non-users), were identified. 
Compared to non-users, the risk of lactic acidosis or elevated lactate levels in current 
metformin users was six times higher in patient with a renal function < 60 ml/
min/1.73m2. This risk was further increased to 12 times in users with ≥ 730 g of 
metformin in the preceding year and in users with a recent high daily dose (> 2 g) 
of metformin. Our study is consistent with current recommendations that the renal 
function of metformin users should be adequately monitored and that the dose level 
of metformin should be adjusted if necessary.
Since measurement of renal function is not frequently performed in the ambulatory 
care setting, changes in renal function may remain unnoticed. Informal clinical 
observations in the hospital care setting suggest that the renal function may fluctuate 
so much that the renal function group and therefore the recommended dose, can 
change within a few days. The magnitude of the fluctuation and its potential effect on 
appropriate prescribing of medications, for example after discharge from the hospital, 
is unknown. Chapter 6 presents a study protocol to describe these changes in eGFR 
in elderly patients 14 days and 2 months after discharge from hospital compared 
to the value at discharge. The first results showed that the proportion of patients 
in which a change occurred in renal function group is noteworthy, namely 39%. 
Further research is necessary to identify risk factors and the consequences for drug 
therapy management.
Both, retrospective cohort studies and prospective observational studies, are of added 
value for healthcare for the creation, adjustment or confirmation of recommendations 
for monitoring renal function and drug dose recommendations in patients with renal 
impairment.
Drug therapy management in patients with renal impairment in clinical 
practice
In the third and last section of this thesis, we focused on how the results of the previous 
sections can be applied in daily clinical practice. In Chapter 7 we demonstrate that 
an advanced pharmacotherapy-related clinical decision support system (CDSS) may 
lead to more relevant alerts compared to a basic pharmacotherapy-related CDSS. 
The impact of adding laboratory values and other patient characteristics resulted 
in a significantly higher positive predictive value (PPV) for the advanced CDSS 
compared to the basic CDSS (23.3% versus 12.2%; p < 0.05). However, the number 
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of clinically irrelevant alerts remained high and continuous fine-tuning of these 
algorithms is necessary. Alerts related to recommendations in patients with renal 
impairment were not calculated separately, but the increase in PPV for the advanced 
CDSS was at least partly due to algorithms using renal function as laboratory value. 
In conclusion, CDSSs may be helpful in the implementation of guidelines, such as 
‘Drug dose advices in renal impairment’.
In view of the uncertainties surrounding the prescribing of drugs in patients with 
renal impairment we give practical guidance in Chapter 8 on how to cope with 
these uncertainties in daily clinical practice. Before starting a renally excreted 
drug an equally effective drug which can be used more safely in patients with renal 
impairment should be considered. If a renally excreted drug is needed the reliability 
of the eGFR should be assessed and when necessary a 24-h urine creatinine 
clearance collection should be performed. After achieving the best approximation 
of the true GFR, we suggest a gradual drug dose adaptation according to renal 
function instead of using renal function groups. For drugs with a narrow therapeutic 
window (NTW) we recommend a more careful approach. For practical purposes a 
therapeutic window of 5 or less was defined as a NTW and a list of NTW-drugs 
is presented. Considerations about the drug dose may be different at the start of 
the therapy or during the therapy and depending on the indication. Considerations 
include the rate at which the intended therapeutic effect has to be achieved, the risk 
of therapeutic failure with a subtherapeutic dose, and the risk of toxicity in case the 
dose is too high. Monitoring effectiveness and adverse drug reactions are important, 
especially for NTW-drugs. 
Dose adjustment of a drug, suggested by a CDSS or not, should be based on an 
ongoing assessment of clinical status and risk versus the benefit of the used regimen 
for the patient with (or without) renal impairment.
Discussion and conclusion
Finally, the results of the studies are summarized and put into a broader perspective 
in Chapter 9. Three topics are addressed: (1) complexity of renal function in drug 
dosing, (2) application of the guidelines ‘Drug dose advices in renal impairment’, 
and (3) implications for clinical practice and future research.
Our systematic reviews showed that the MDRD formula is not valid in diverse 
patient populations. Newer formulas, such as the Chronic Kidney Disease 
EPIdemiology Collaboration (CKD-EPI) formulas, are not expected to perform 
better than the MDRD formula as long as they are serum creatinine-based. The CG 
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formula has historically been the method applied to determine drug dose regimens 
in patients with renal impairment. We discussed the differences between the CG 
and MDRD formula and concluded that there is little evidence on the clinical 
relevance of the differences for most of the drugs. The fact that renal impairment 
not only alters the renal excretion of unchanged drug and/or their metabolites, but 
it can also lead to modifications in plasma protein binding, distribution, transport 
and biotransformation of drug substances, makes it even more complicated. 
Integrated pharmacokinetic/pharmacodynamic studies are needed to evaluate the 
necessity of drug therapy adjustment in patients with renal impairment. For older 
drugs cohort studies as published in this thesis might be useful to confirm current 
recommendations, which are mainly based on case reports and/or pharmacokinetic 
studies. In daily clinical practice clinicians are confronted with patients with 
multiple comorbidities, such as renal impairment, using multiple drugs. Therefore 
the best strategy is to avoid potentially nephrotoxic drugs and renally excreted drugs 
whenever possible.
For the application of the guidelines ‘Drug dose advices in renal impairment’ we 
discussed technical support to identify patients at risk and the role of the pharmacist 
in PDTM. CDSSs link patient characteristics with medical knowledge to generate 
recommendations. In daily clinical practice alerts are often overridden by physicians 
and in half of the cases advices from CDSSs are ignored or not followed for several 
reasons. Due to increased numbers of guidelines and standards and the growing 
empowerment of patients, good prescribing of drugs cannot rely on physicians 
solely. Pharmacists can play an important role in suggesting a preferred drug in 
patients with renal impairment, handling specific medication alerts, coordinating 
measurements to assess effectiveness and/or ADRs, and evaluate effectiveness and/
or ADRs by contacting the patient. Pharmacists can thus contribute to the safe, 
effective, and efficient use of drugs, particularly when caring for people with multiple 
chronic conditions where multiple clinicians are involved.
More research is needed to identify variables or situations in which the currently 
known serum creatinine-based formulas should not be used for drug dosing. 
We suggested a gradual drug dose adaptation instead of categorical. The clinical 
relevance of this approach is of interest for future research. A broad approach on how 
to apply PDTM in complex patients with renal impairment, including the added 
value of pharmacists described in the general discussion, should also be subject for 
future research.
In conclusion, the results of the studies presented in this thesis demonstrate the 
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complexity of PDTM in patients with renal impairment. The MDRD formula 
appeared not to be valid or the validity was unclear in diverse patient populations. 
Cohort studies appeared to be useful in confirming guidelines concerning drug 
therapy management in renal impairment. We discussed how serum creatinine-based 
formulas can be handled in daily clinical practice, despite their uncertainties. CDSSs 
may be supportive in the application of all the available knowledge. Pharmacists 
can play an important role in improving PDTM by monitoring effectiveness and/or 
ADRs and coordinating the measurements of laboratory values whenever necessary.
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Samenvatting
Het vinden van een geschikt geneesmiddel is gegeven de diagnose van de patiënt 
een belangrijke uitdaging bij het voorschrijven van geneesmiddelen. De risico-
batenverhouding bij een patiënt met een verminderde nierfunctie is soms anders dan 
bij de patiëntenpopulatie zonder verminderde nierfunctie. Bovendien is de kennis over 
de klinische effecten, zowel de effectiviteit als de bijwerkingen, van geneesmiddelen 
bij patiënten met een verminderde nierfunctie niet volledig bekend. Daarom is het 
monitoren van de behandeling belangrijk. De nierfunctie fluctueert in de loop van 
de tijd. Het juiste geneesmiddel en de juiste dosering zouden heroverwogen moeten 
worden zodra de nierfunctie substantieel verandert. Daarnaast zijn adviezen over 
het monitoren van specifieke variabelen of aanvullende instructies aan de patiënt om 
bijwerkingen tijdig te herkennen wenselijk. Het vinden van het juiste geneesmiddel 
in de juiste dosering passend bij de diagnose van de patiënt en het monitoren van 
het effect en de bijwerkingen in de tijd is gedefinieerd als geïndividualiseerde 
medicamenteuze therapie management (GMTM). Dit proefschrift gaat over 
GMTM bij patiënten met een verminderde nierfunctie.
In de afgelopen paar jaar is de aandacht voor farmacotherapie in relatie tot de 
nierfunctie gegroeid. Onderzoeken laten zien dat tot één derde van de bijwerkingen, 
welke hebben geleid tot een ziekenhuisopname, mogelijk waren gerelateerd aan 
een verminderde nierfunctie. Na de introductie van de Modification of Diet in 
Renal Disease (MDRD) formule, welke een schatting geeft van de glomerulaire 
filtratie snelheid (eGFS), rapporteren klinisch chemische laboratoria de eGFS zodra 
een serumkreatinine bepaling wordt aangevraagd. Dit heeft geleid tot een betere 
herkenning van een verminderde nierfunctie en daarmee is het ook makkelijker 
geworden om de richtlijnen ‘Doseringsadviezen voor geneesmiddelen  bij een 
verminderde nierfunctie’ toe te passen in de dagelijkse klinische praktijk. In deze 
richtlijnen worden doseringsadviezen categorisch per nierfunctiegroep weergegeven. 
Het toepassen van deze richtlijnen leidde echter tot onenigheid tussen de apotheker 
en de arts. Vragen die artsen stelden waren: “Hoe sterk is het wetenschappelijk 
bewijs achter dit advies? Wat is de grootte van het risico wanneer mijn patiënt een 
onjuist geneesmiddel of een onjuiste dosering krijgt?” Deze vragen hebben geleid 
tot het nader bestuderen van het wetenschappelijk bewijs waarop de richtlijnen 
zijn gebaseerd. Het bleek dat het bewijs hoofdzakelijk bestond uit case reports en 
farmacokinetische studies in een gecontroleerde omgeving. Het ontbreken van 
onderzoeken gebaseerd op patiëntenpopulaties en/of de vertaling van de resultaten 
naar deze patiëntenpopulaties, welke gezien worden in de dagelijkse praktijk, is de 
basis van dit proefschrift. Dit proefschrift heeft als doel om inzicht te geven in: (1) 
 Samenvatting
189
de validiteit van de MDRD formule welke wordt toegepast bij het voorschrijven van 
geneesmiddelen aan patiënten met een verminderde nierfunctie, (2) de meerwaarde 
van nieuw wetenschappelijk bewijs om bestaande richtlijnen te evalueren en (3) 
praktische handvaten voor het omgaan met renaal geklaarde geneesmiddelen bij 
patiënten met een verminderde nierfunctie.
De validiteit van de Modification of Diet in Renal Disease formule
De MDRD formule wordt wereldwijd gebruikt in de klinische praktijk om de juiste 
geneesmiddeldosering vast te stellen. Deze formule is gebaseerd op serumkreatinine, 
wat een bijproduct is van spierafbraak. Er is een duidelijke omgekeerde correlatie 
tussen de serumkreatinine en de ware GFS. Er zijn echter verschillende factoren 
welke de uitslag van de serumkreatininebepaling mogelijk kunnen beïnvloeden 
zonder dat het effect heeft op de GFS zelf. Dit kan potentieel leiden tot verkeerde 
interpretatie bij de klinische toepassing van de eGFS. Ondanks dat de formules, 
welke zijn gebaseerd op serumkreatininewaarden, een betere schatting geven van 
de werkelijke GFS dan de serumkreatininewaarde zelf in de algemene populatie, 
zijn deze formules onvoldoende gevalideerd in specifieke patiëntenpopulaties. 
Chronische ziekten zelf of de effecten daarvan zijn mogelijk van invloed op de 
serumkreatininewaarde. Onnauwkeurigheid in de eGFS kan mogelijk leiden tot 
enerzijds een overschatting van de nierfunctie, resulterend in het geven van onjuiste 
hoge doseringen en daarmee mogelijk toxiciteit, of anderzijds tot een onderschatting 
van de nierfunctie, resulterend tot subtherapeutische doseringen en daarmee 
mogelijk het falen van de behandeling en verlenging van de ziekteduur.
Hoofdstuk 2 presenteert een systematisch literatuuroverzicht over de validiteit van 
de MDRD formule in patiënten met het human immunodeficiency virus (HIV) 
over het hele bereik van de eGFS. Nierfunctiestoornissen komen vaak voor bij HIV-
patiënten en kunnen leiden tot dosisaanpassingen van antiretrovirale geneesmiddelen 
welke renaal worden uitgescheiden. We voerden een systematische zoekopdracht uit 
in Pubmed en EMBASE naar onderzoeken waarin de MDRD formule vergeleken 
werd met een gemeten GFS (mGFS) in HIV-patiënten. Vijf onderzoeken werden 
geïncludeerd, welke data bevatten van 464 HIV-patiënten. We concludeerden dat 
de MDRD formule net zo valide was voor HIV-positieve als voor HIV-negatieve 
patiënten met een goede tot licht verminderde nierfunctie. Meer onderzoek is nodig 
om de MDRD formule te valideren in HIV-patiënten met matige tot ernstige 
verminderde nierfunctie. 
De MDRD formule is ontwikkeld in patiënten met een chronische nierinsufficiëntie 
(CNI) en was daarmee per definitie niet getest in patiënten met een goede nierfunctie. 
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In hoofdstuk 3 selecteerden we voor een bredere systematische zoekopdracht alleen 
patiënten met een (e)GFS < 60 ml/min/(1.73m2). We bestudeerden de validiteit 
van de MDRD formule in de volgende specifieke patiëntenpopulaties: ouderen, 
patiënten opgenomen in een ziekenhuis, patiënten met obesitas, cardiovasculaire 
ziekten, kanker, chronische longziekten, diabetes mellitus, levercirrose en HIV. 
Deze selectie was gebaseerd op drie algemene patiëntgroepen welke onvoldoende 
vertegenwoordigd waren bij de ontwikkeling van de MDRD formule, vier veel 
voorkomende categorieën van chronische ziekten, welke wereldwijd de belangrijkste 
doodsoorzaken zijn, en andere chronische ziekten waarbij er sprake kan zijn van 
verminderde spiermassa. We zochten in Pubmed naar studies welke gepubliceerd 
waren vanaf januari 1999 tot januari 2014. Andere selectiecriteria waren een 
vergelijking van de MDRD formule met een gouden standaard en een statistische 
analyse gebaseerd op bias, precisie en accuraatheid. Een bias van 20% of minder, 
een precisie van 30% of minder en een accuraatheid uitgedrukt als P30 van 80% 
of hoger waren indicatoren voor de validiteit van de MDRD formule. In totaal 
includeerden we 27 studies. De validiteit van de MDRD formule bleek nog niet 
goed getest in patiënten met cardiovasculaire ziekten en chronische longziekten. 
Voor patiënten met obesitas, kanker en HIV bleek de validiteit van de MDRD 
formule wel getest, maar onvoldoende goed om een uitspraak te kunnen doen. Voor 
patiënten met diabetes mellitus en levercirrose, patiënten opgenomen op de afdeling 
interne geneeskunde of nefrologie en ouderen met matige tot ernstige verminderde 
nierfunctie concludeerden we dat de MDRD formule niet valide is. 
Samenvattend, het gebruik van de MDRD formule in verschillende specifieke 
patiëntenpopulaties voor het verfijnen van de medicamenteuze therapie is niet zonder 
beperkingen. Er is geen hard wetenschappelijk bewijs dat de MDRD formule valide 
is in patiënten met verschillende chronische ziekten en een verminderde nierfunctie. 
In sommige gevallen is er bewijs dat de MDRD formule niet valide is.
Nieuw bewijs voor het evalueren van bestaande richtlijnen
In het tweede gedeelte van dit proefschrift hebben we de onderzoeken welke ten 
grondslag liggen aan de medicamenteuze behandeladviezen in de richtlijnen nader 
bekeken. We waren in het bijzonder geïnteresseerd in de frequent voorgeschreven 
geneesmiddelen nitrofurantoïne en metformine. Beide geneesmiddelen zijn eerste 
keus wanneer respectievelijk een urineweginfectie (UWI) of diabetes mellitus type 2 
worden gediagnosticeerd, maar beide geneesmiddelen zijn ook gecontraïndiceerd 
wanneer de nierfunctie onder een bepaalde waarde komt. Krijgen patiënten met 
een verminderde nierfunctie onterecht een eerste keus geneesmiddel niet? Uit nader 
 Samenvatting
191
onderzoek bleek dat het gecontraïndiceerd zijn van deze geneesmiddelen bij een 
verminderde nierfunctie was gebaseerd op farmacokinetische studies en case reports. 
Volgens de bijsluiter is nitrofurantoïne gecontraïndiceerd wanneer de eGFS 
< 60 ml/min is vanwege mogelijke ineffectiviteit en veiligheidsproblemen. In 
hoofdstuk 4 presenteren we een cohortstudie waarin we bekeken of de behandeling 
met nitrofurantoïne bij vrouwen met een UWI in de eerste lijn én een verminderde 
nierfunctie geassocieerd is met een hoger risico op ineffectiviteit en/of het optreden 
van bijwerkingen in vergelijking met vrouwen met een UWI zonder verminderde 
nierfunctie. Uit de PHARMO Record Linkage System was een cohort met 21.317 
vrouwen, die behandeld zijn met nitrofurantoïne, geïdentificeerd en geanalyseerd. 
Een matige verminderde nierfunctie (30-50 ml/min/1.73m2) was niet geassocieerd 
met een ineffectieve behandeling, maar het risico op pulmonaire bijwerkingen 
leidend tot een ziekenhuisopname was significant 4 keer hoger bij patiënten met een 
verminderde nierfunctie (< 50 ml/min/1.73m2). 
Voor de studie over metformine in hoofdstuk 5 gebruikten we de Clinical Practice 
Research Datalink (CPRD) met als primaire uitkomstmaat lactaatacidose en plasma 
lactaat spiegels van > 5 mmol/l. Een cohort van 223.968 metformine gebruikers 
en 34.571 diabetespatiënten die nog nooit metformine hadden gebruikt (niet-
gebruikers) werden geïdentificeerd. Vergeleken met niet-gebruikers was het risico 
op lactaatacidose of verhoogde lactaat spiegel in huidige metformine gebruikers 
met een nierfunctie < 60 ml/min/1.73m2 6 keer hoger. Het risico nam verder toe 
tot 12 keer in gebruikers met ≥ 730 g metformine in het voorgaande jaar en in 
gebruikers met een recent hoge dagdosering metformine (> 2 g). De resultaten van 
ons onderzoek komen overeen met de huidige aanbevelingen dat de nierfunctie van 
metformine gebruikers adequaat moet worden gecontroleerd en dat de metformine 
dosering wanneer nodig moet worden aangepast. 
In de ambulante zorg wordt de nierfunctie niet frequent gemeten, waardoor 
veranderingen onopgemerkt kunnen blijven. Informele klinische observatie in 
het ziekenhuis suggereerde dat de nierfunctie mogelijk in die mate kan fluctueren 
dat de nierfunctiegroep en daarmee de aanbevolen dosering binnen een paar 
dagen kan veranderen. De grootte van de fluctuatie en het potentiële effect op 
het juist voorschrijven van geneesmiddelen, bijvoorbeeld na ontslag, is onbekend. 
Hoofdstuk 6 presenteert een studieprotocol om deze veranderingen in de eGFS bij 
oudere patiënten 14 dagen en 2 maanden na ontslag uit het ziekenhuis in kaart te 
brengen en te vergelijken met de nierfunctie bij ontslag. De eerste resultaten laten 
zien dat het aantal patiënten waarbij een verandering op trad in de nierfunctiegroep 
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noemenswaardig was, namelijk 39%. Vervolgonderzoek is nodig om risicofactoren 
te identificeren en uit te zoeken wat de consequenties zijn voor medicamenteuze 
therapie management. 
Retrospectieve cohortstudies en prospectieve observationele studies zijn beiden van 
toegevoegde waarde voor de gezondheidszorg ten aanzien van het ontwikkelen, 
aanpassen of bevestigen van aanbevelingen voor de monitoring van de nierfunctie 
en doseringsadviezen bij patiënten met een verminderde nierfunctie.
Medicamenteuze therapie management bij patiënten met een verminderde 
nierfunctie in de klinische praktijk
In het derde en laatste deel van dit proefschrift, leggen we de nadruk op hoe de 
resultaten van de eerdere delen kunnen worden toegepast in de dagelijkse klinische 
praktijk. In hoofdstuk 7 laten we zien dat een geavanceerd medicatiebewakings-
systeem (MBS) mogelijk leidt tot meer relevante medicatiebewakingssignalen 
in vergelijking met een eenvoudig MBS. De impact van het toevoegen van 
laboratoriumwaarden en andere patiëntenkarakteristieken resulteerden in een 
significant hogere positief voorspellende waarde (PVW) voor het geavanceerde 
MBS in vergelijking met het eenvoudige MBS (23.3% versus 12.2%; p < 0.05). 
Echter bleef het aantal klinisch niet-relevante medicatiebewakingssignalen hoog 
en continue verfijning van deze algoritmen is daarom nodig. Er is geen subanalyse 
uitgevoerd voor de medicatiebewakingssignalen met betrekking tot aanbevelingen 
voor patiënten met een verminderde nierfunctie. Echter, de toename in PVW voor 
het geavanceerde MBS was tenminste gedeeltelijk toe te schrijven aan de algoritmen 
waarin de nierfunctie als laboratoriumwaarde werd gebruikt. Concluderend, 
MBSen kunnen ondersteunend zijn bij het implementeren van richtlijnen zoals 
‘Doseringsadviezen voor geneesmiddelen bij een verminderde nierfunctie’. 
In het licht van de onzekerheden rondom het voorschrijven van geneesmiddelen 
aan patiënten met een verminderde nierfunctie geven we in hoofdstuk 8 praktische 
handvaten hoe om te gaan met deze onzekerheden in de dagelijkse klinische 
praktijk. Voordat een renaal uitgescheiden geneesmiddel wordt gestart, dient een 
gelijkwaardig geneesmiddel, welke veiliger is voor patiënten met een verminderde 
nierfunctie, te worden overwogen. Wanneer een renaal uitgescheiden geneesmiddel 
toch nodig is, dient de betrouwbaarheid van de eGFS te worden vastgesteld en 
wanneer nodig een 24-uurs urine te worden verzameld voor de bepaling van een 
kreatinineklaring. Na het vaststellen van de beste schatting van de werkelijke GFS, 
stellen we een graduele dosisaanpassing voor op basis van de nierfunctie in plaats 
van het gebruik van nierfunctiegroepen. Voor geneesmiddelen met een nauwe 
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therapeutische breedte (NTB) wordt een voorzichtige aanpak aanbevolen. Voor 
praktische doeleinden was een therapeutische breedte van 5 of minder gedefinieerd 
als NTB en een lijst met NTB-geneesmiddelen is gepresenteerd. Overwegingen 
bij het bepalen van de geneesmiddeldosering is mogelijk anders aan het begin van 
de therapie dan tijdens de therapie en afhankelijk van de indicatie. Overwegingen 
bestaan uit de snelheid waarmee het beoogde therapeutische effect moet worden 
bereikt, de risico’s van therapeutisch falen bij een te lage dosering en de risico’s op 
toxiciteit bij een te hoge dosering. Het monitoren van effectiviteit en bijwerkingen 
zijn belangrijk, vooral bij NTB-geneesmiddelen.
Dosisaanpassingen van een geneesmiddel, voorgesteld door een MBS of niet, 
zouden gebaseerd moeten zijn op een continue beoordeling van de klinische status 
van de patiënt en het continu afwegen van het risico versus de baten van het gekozen 
behandelplan bij patiënten met (of zonder) een verminderde nierfunctie.
Discussie en conclusie
De resultaten van de onderzoeken zijn samengevat en in een breder perspectief 
geplaatst in hoofdstuk 9. Er worden drie onderwerpen behandeld: (1) de 
complexiteit van de nierfunctie bij het doseren van geneesmiddelen, (2) toepassing 
van de richtlijnen ‘Doseringsadviezen voor geneesmiddelen  bij een verminderde 
nierfunctie’ en (3) gevolgen voor de klinische praktijk en toekomstig onderzoek. 
Onze systematische literatuuronderzoeken lieten zien dat de MDRD formule niet 
valide is in diverse patiëntenpopulaties. Van nieuwere formules, zoals de Chronic 
Kidney Disease EPIdemiology Collaboration (CKD-EPI) formules, wordt niet 
verwacht dat ze beter zijn dan de MDRD formule zolang ze gebaseerd zijn op 
serumkreatininewaarden. Historisch gezien, is de CG formule de methode om de 
geneesmiddeldosering vast te stellen bij patiënten met een verminderde nierfunctie. We 
bediscussieerden de verschillen tussen de CG en MDRD formule en concludeerden 
dat er voor het merendeel van de geneesmiddelen weinig wetenschappelijk bewijs 
is over de klinische relevantie van de verschillen. Het feit dat een verminderde 
nierfunctie niet alleen de uitscheiding van geneesmiddelen en/of hun metabolieten 
verandert, maar ook kan leiden tot veranderingen in binding aan plasmaproteïne, 
distributie, transport en biotransformatie van geneesmiddelen, maakt het geheel nog 
complexer. Geïntegreerde farmacokinetische/farmacodynamische studies zijn nodig 
om het aanpassen van de medicamenteuze therapie bij patiënten met een verminderde 
nierfunctie te evalueren. Voor oudere geneesmiddelen kunnen cohortstudies, 
zoals gepresenteerd in dit proefschrift, nuttig zijn om huidige aanbevelingen, 
welke grotendeels gebaseerd zijn op case reports en/of farmacokinetische studies, 
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te onderbouwen. In de dagelijkse klinische praktijk worden artsen en apothekers 
geconfronteerd met patiënten met meerdere co-morbiditeiten, zoals een 
verminderde nierfunctie, en het gebruik van meerdere geneesmiddelen. De beste 
strategie is daarom om potentieel nefrotoxische geneesmiddelen en renaal geklaarde 
geneesmiddelen zoveel als mogelijk te vermijden. 
Voor de toepassing van de richtlijnen ‘Doseringsadviezen voor geneesmiddelen  bij 
een verminderde nierfunctie’ bediscussieerden we de mogelijkheid van technische 
ondersteuning om risicopatiënten te identificeren en de rol van de apotheker in 
GMTM. MBSen kunnen patiëntenkarakteristieken combineren met medische 
kennis om aanbevelingen te genereren. In de dagelijkse klinische praktijk worden 
deze medicatiebewakingssignalen vaak overschreven door artsen waarvan in de 
helft van de gevallen adviezen van MBSen worden genegeerd of niet opgevolgd om 
verschillende redenen. Vanwege het toenemende aantal richtlijnen en standaarden 
en toenemende patiëntparticipatie kan het correct voorschrijven van geneesmiddelen 
niet alleen bij de artsen liggen. Apothekers kunnen een belangrijke rol spelen in 
het adviseren van een voorkeursgeneesmiddel voor patiënten met een verminderde 
nierfunctie, het afhandelen van specifieke medicatiebewakingssignalen, het 
coördineren van bepalingen om de effectiviteit en/of bijwerkingen vast te stellen, en 
het evalueren van de effectiviteit en/of bijwerkingen door in gesprek te gaan met de 
patiënt. Apothekers kunnen dus een bijdrage leveren aan veilig, effectief en efficiënt 
geneesmiddelengebruik, juist wanneer het mensen met meerdere chronische ziekten 
betreft waar meerdere artsen bij betrokken zijn. Meer onderzoek is nodig om factoren 
of situaties te identificeren waarin de huidige formules gebaseerd op serumkreatinine 
niet gebruikt zouden moeten worden bij het doseren van geneesmiddelen bij een 
verminderde nierfunctie. We stelden voor om de geneesmiddeldosering gradueel 
aan te passen in plaats van categorisch. Een brede aanpak over hoe GMTM toe 
te passen bij complexe patiënten met een verminderde nierfunctie, waaronder ook 
de toegevoegde waarde van apothekers zoals beschreven in hoofdstuk 9, zou ook 
onderwerp moeten zijn voor toekomstig onderzoek.
Samenvattend, de resultaten van de onderzoeken gepresenteerd in dit proefschrift 
laten de complexiteit zien van GMTM bij patiënten met een verminderde nierfunctie. 
De MDRD formule bleek niet valide of de validiteit was onduidelijk in diverse 
patiëntenpopulaties. Cohort onderzoeken bleken toepasbaar om richtlijnen over 
medicamenteuze therapie management bij verminderde nierfunctie te bevestigen. 
We bediscussieerden hoe formules gebaseerd op serumkreatinine toch gebruikt 
kunnen worden in de dagelijkse klinische praktijk ondanks de onzekerheden. 
MBSen zouden ondersteuning kunnen bieden in het toepassen van alle beschikbare 
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kennis. Apothekers kunnen een belangrijke rol spelen in het verbeteren van GMTM 
door de effectiviteit en/of bijwerkingen van geneesmiddelen te monitoren en door 
bepalingen van laboratoriumwaarden te coördineren als dat nodig is.
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Dankwoord
Trots is het gevoel dat overheerst nu het proefschrift af is. 
Zoals elke promovendus kende ook ik mijn pieken en dalen. Na twee jaar tijd te 
hebben geïnvesteerd in het onderwerp ‘clinical rules’ switchten we naar de nierfunctie. 
Dit is niet een onderwerp waar mijn hart ligt. Toch won de nieuwsgierigheid naar de 
antwoorden op de vragen die gesteld zijn in dit proefschrift. Zonder enthousiasme van 
het promotieteam, interesse en steun van iedereen om me heen was dit proefschrift 
er niet geweest. Ik heb met veel verschillende mensen samen mogen werken, zowel 
wat betreft expertises als persoonlijkheden. Dit heeft mijn kennis verrijkt, maar 
bovenal maakten de onderlinge interacties dit promotietraject kleurrijk. Daarom een 
woord van dank aan iedereen die dit proefschrift mede mogelijk heeft gemaakt.
Allereerst natuurlijk dank aan mijn promotoren Peter de Smet en Michel Wensing. 
Jullie waren een mooi duo. Peter, je hebt goede ideeën die alle kanten op kunnen 
gaan. Onderzoeksprotocollen werden daardoor soms erg ingewikkeld. Michel, jij 
wist dat weer terug te brengen naar iets wat overzichtelijker was. Ik volgde niet 
altijd het geijkte pad. Ik combineerde verschillende functies in mijn werk en ging 
op wereldreis. Dat maakte het niet altijd even makkelijk. Dank voor het mij blijven 
motiveren, de levendige discussies en dat jullie zoveel geduld met mij hebben gehad.
Beste Jeroen, jij voegde je iets later bij het promotieteam toen onze wegen elkaar 
kruisten bij ZANOB. Enthousiast begonnen we aan het onderzoek over clinical 
rules. Ook jouw hart ligt niet bij fundamenteel onderzoek over validiteit van 
nierfunctie formules, maar door je contacten met de Universiteit Utrecht hebben we 
twee mooie epidemiologische onderzoeken kunnen doen, waar we allebei blij van 
werden. Bedankt voor je adviezen, tips en steun tijdens het traject.
Dank aan alle co-auteurs: Jean Conemans, Toine Egberts, Arjen Geerts, Rob 
Heerdink, Walter Hermens, Rein Hoedemakers, Kees Kramers, Arief Lalmohamed, 
Matthijs van Luin, Rob van Marum, Clemens Richter, Frank de Vries, Wietske 
Wester en Jack Wetzels. De één adviseerde me op afstand, met de ander heb ik 
intensief uren achter de computer doorgebracht om analyses uit te voeren. Jullie 
waren allemaal heel geduldig om mij dingen uit te leggen en behulpzaam in het mij 
de goede kant opsturen. Het was inspirerend om met jullie samen te mogen werken. 
Het combineren van al jullie expertises heeft dit mooie proefschrift opgeleverd met 
hele gevarieerde onderzoeken. Dank jullie wel!
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ZANOB is waar het allemaal begon. Jean en Tamara, jullie stonden aan de wieg 
van mijn interesse voor wetenschappelijk onderzoek toen ik mijn onderzoeksstage 
bij jullie deed in 2001. Ongeveer 8 jaar later creëerden jullie, Walter en Siebold, 
voor mij de mogelijkheid dat ik naast mijn opleiding tot ziekenhuisapotheker kon 
starten met het promotieonderzoek. Ondanks dat de SRC een ZAPIKO-traject 
niet goedkeurde, bleef ZANOB mij steunen. Daarvoor ben ik jullie zeer erkentelijk. 
Lieve (oud-)collega’s, uiteindelijk heb ik 8 jaar rondgewandeld bij ZANOB en veel 
met jullie beleefd. Bedankt voor jullie interesse in mijn proefschrift, bedankt voor 
jullie inzet bij het onderzoek in hoofdstuk 7, bedankt voor jullie flexibiliteit, maar 
bovenal bedankt voor de gezelligheid. Een speciaal woord van dank aan de CJG. 
Annemieke, Rianda en Reinier, bedankt voor de gezellige etentjes, de lach en de 
traan (meestal van het lachen)!
Beste Loes, je was de enige onderzoeksstagiaire die betrokken was bij één van mijn 
onderzoeken. Je hebt echt veel werk verzet en initiatief genomen op het moment dat 
ik het niet kon. Dank je wel en ik wens je alle goeds toe voor de toekomst.
Ka-Chun en Margreet wat had ik zonder jullie gemoeten? We deelden een knusse 
kamer in de barak. Naast de promotieperikelen doorstonden we de vrieskou, de 
tropische dagen en deelden we lief en leed. De barak is er niet meer, maar onze 
vriendschap nog wel en die koester ik.
Een woord van dank aan de afdeling IQ healthcare voor het faciliteren van zaken die 
ik nodig had. Een speciaal woord van dank voor Jolanda. Jij weet echt alles! Iedere 
praktische vraag over het promotietraject wist je te beantwoorden. Bedankt voor 
alles. Ik wil de afdeling klinische farmacie bedanken voor de medefinanciering van 
publicaties, congresbezoek en het drukken van dit proefschrift.
De laatste twee jaar heb ik op verschillende plekken gewerkt. Collega’s van de 
ziekenhuisapotheek van het Slingeland Ziekenhuis, Brocacef Ziekenhuisfarmacie 
en het Geneesmiddel Informatie Centrum, bedankt voor jullie interesse in 
mijn onderzoeken en de vorderingen met het boekje. Bedankt voor de prettige 
samenwerking en gezellige pauzes. Het maakte de laatste loodjes minder zwaar.
Lieve familie en vrienden. Ook al begreep niemand wat ik precies deed, jullie zagen 
mijn harde werken. En waar ik dacht dat niemand geïnteresseerd was in de inhoud 
kwam deze interesse steeds vaker. Ook uit onverwachte hoeken. Erg leuk! Het was 
en is fijn om elkaar te zien. In de afgelopen jaren waren dit voor mij hele fijne 
momenten, ook omdat ik dan even niet aan de promotie hoefde te denken. Voor 
mijn gevoel heb ik de afgelopen jaren steken laten vallen. Voor het eerst vergat ik 
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weleens een afspraak, kocht ik cadeautjes last-minute, desnoods bij de benzinepomp, 
zei ik verjaardagen af en belde ik zomaar een paar maanden niet. Toch kon en kan 
ik rekenen op jullie onvoorwaardelijke steun en liefde. Hartverwarmend! Bedankt! 
Een hele andere tak van sport is het ontwerpen van een proefschrift, zowel de kaft 
als de lay-out aan de binnenkant. Lieve Ruud, ik vroeg je om me te helpen met het 
ontwerp van de kaft, maar dat kon volgens jou niet los staan van de binnenzijde. Ik 
vond het erg leuk om met je samen te werken. Je laat je niet snel gek maken en zeker 
niet door mij, de perfectionist. Gelukkig maar, want wat een mooi resultaat!
Het is des Willemijns om de mensen die me het meest na staan op eigen wijze te 
bedanken. Ik heb jullie lief!
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